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I. Abstract 
Background 
Cystic Fibrosis (CF) is the most common inherited condition amongst people of European descent. It 
is caused by a mutation in the CFTR gene located on chromosome 7, and codes for the CFTR protein. 
Mutations in the CFTR gene lead to the characteristic features of CF, namely progressive and 
irreversible lung disease which is responsible for the majority of premature deaths in CF. Recently, 
research into the management of CF has shifted towards personalised genomic medicine. New 
classes of drugs called mutation-specific-therapies have been designed to target the mutation 
specific defects in CFTR protein synthesis or function. They have shown to restore the gating defect 
of class III mutations (CFTR potentiators) and intracellular processing defect of class II mutations 
(CFTR correctors) in cell studies. Both CFTR potentiators and CFTR correctors have progressed to 
human clinical trials. Cochrane systematic reviews are the gold standard for establishing the current 
evidence base for interventions.  
Objective  
To conduct two Cochrane systematic reviews to evaluate the benefits and harms of 1) CFTR 
potentiators (for class III-IV mutations) and 2) CFTR correctors (for class II mutations) on clinically 
important outcomes in children and adults with CF.  
Methods 
Systematic reviews were conducted according to peer assessed and published review protocol. 
Relevant studies were identified by searching the Cochrane Cystic Fibrosis Trials Register, compiled 
from electronic database searches and hand searching of journals and conference abstract books. 
We also searched the clinical trial registries maintained by the EMA, the US NIH and the WHO and 
contacted leading researches and industry for relevant trials. We included only RCTs of parallel 
design that met pre-defined eligibility criteria. Two authors independently extracted data and 
assessed the risk of bias in included trials. If appropriate, data were combined in a meta-analysis.  
Results  
Studies with patients with the G551D mutation demonstrated a clinically relevant impact of Ivacaftor 
on outcomes at 24 and 48 weeks providing evidence for the use of Ivacaftor (CFTR potentiator) in 
patients with G551D mutation (Class III). There is no evidence to support the short-term use of CFTR 
correctors, CFTR potentiators, or both as combination therapy in patients with the ΔF508 mutation 
(class II mutation). As patients with Class II mutations comprise a significant proportion of all CF 
patients, identifying an efficacious CFTR corrector (or CFTR corrector and CFTR potentiator 
combination) will have a profound impact on the field.   
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Chapter 1 
Introduction 
1.1 Cystic Fibrosis    
Cystic Fibrosis (CF) is the most common genetically inherited condition amongst individuals of 
European descent with a carrier status of 1 in 25 individuals (occurs in 1 in 2500 births). An 
estimated 28, 804 people in the US and 8284 people living in the UK are currently affected by this 
disorder.1, 2 It is caused by a mutation in the gene that codes for the CFTR protein. This protein is 
expressed throughout the body and when defective causes the characteristic phenotypic 
consequences of CF, namely an elevated sweat chloride concentration, recurrent lung infections and 
bronchiectasis. Despite outstanding advances in management of CF, patients with CF continue to die 
prematurely. In the majority of CF patients, chronic infection with P. aeruginosa leads to progressive 
and irreversible airway obstruction which, with time leads to the loss of lung function and 
respiratory failure.3 In the UK, CF has a mean life expectancy of 43.5 years.4 
1.1.1 Progression of research in CF 
Since the discovery of CF, advances in characterisation of its pathophysiology and in its management 
have been remarkable and this is demonstrated by the improved life expectancy of affected 
individuals. Statistics released by the Cystic Fibrosis Foundation show that since 2002 the median 
survival age of a patient with CF has increased by almost 10 years from age 31.3 in 2002 to 41.1 in 
2012.2  
The history of CF can be better discussed if divided into three eras; pre gene discovery, gene 
discovery and post gene discovery.5 
Pre gene discovery 
The pre gene discovery era spans half a century and begins in 1938 when Dorothy Anderson, a 
paediatric clinician working in New York, was the first to recognise the pathology and disease 
pattern of CF. She identified and described mucus plugging of glandular tissues in the pancreas and 
recognised this as a distinct pathological process to coeliac disease.6 Her pioneering work did not 
stop there. She then investigated the aetiology of CF and recognised it to be an autosomal recessive 
disorder .7 At this stage the prognosis of CF was extremely poor with many children dying in their 
first year of life. In 1949, Lowe postulated that because CF is inherited in an autosomal recessive 
pattern the defect must lie with a single gene.8 But before the putative gene was identified, the 
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molecular basis of the disease was characterised when high levels of salt were detected in the sweat 
of patients with CF, on a hot New York day.9 This discovery instigated development of the diagnostic 
sweat chloride test through pilocarpine iontophoresis by Gibson and Cooke and also helped 
distinguish milder CF phenotypes.10 Sweat salt concentration remains an important diagnostic test 
even today. In 1983, Quinton isolated sweat glands and demonstrated that chloride ion channels 
were unusually impermeable to chloride ions.11 Defective chloride conductance and increased 
sodium reabsorption were then identified at the apical membranes of epithelial cells lining the 
airways, characterising the molecular defect of CF.12, 13 At this point in the history of CF, the three 
pillars of CF management; nutritional repletion, relief of airway obstruction and antibiotic therapy of 
lung infection were established.14   
Gene discovery 
In 1989, the putative ‘Cystic Fibrosis Transmembrane Regulator’ gene (CFTR gene) was discovered 
through innovative chromosome identification techniques (chromosome ‘walking and jumping’).15-17 
It was located on chromosome 7 and coded for the CFTR protein; a cAMP-regulated chloride ion 
channel located at the apical surface of epithelial cells. Defects in the CFTR gene resulted in either 
insufficient amounts of CFTR protein within the cell membranes or in CFTR that embedded in the cell 
membrane but displayed defective ion conductance.15-17  
Post gene discovery and the era of personalised genomic medicine 
23 years post gene discovery, the mainstay of CF management is still focused on aggressive 
symptomatic management. However research into the putative gene has provided the CF 
community with a greater understanding into the how the gene influences CFTR production, 
expression and function. With this knowledge, new personalised therapies targeting the underlying 
defect of CF have started to emerge, igniting an exciting era of personalised genomics in CF.18  
Before we can understand how these therapies aim to work, we must appreciate how normal CFTR 
protein (also known as Wild-type (WT) CFTR) is synthesised and functions, how this is affected by 
mutations in the CFTR gene, and the impact of CFTR gene mutations on the body.  
1.1.2 CFTR synthesis, structure and function  
The production of CFTR from gene to protein  
The CFTR gene is located on the long arm of chromosome 7 at position q13.2. The process of CFTR 
synthesis and maturation is highly monitored as it is subject to many sites of quality control.19, 20 
Extracellular signals stimulate transcription of the CFTR gene into single stranded messenger RNA 
(mRNA) in the nucleus of epithelial cells located in sweat ducts, airways, pancreatic ducts, intestine, 
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biliary tree and vas deferens. Single stranded mRNA escapes the nuclear pores and is translated by 
ribosomes situated principally in the endoplasmic reticulum (ER) but also in the cell cytoplasm. With 
transfer RNA (tRNA) donating amino acids, a fully extended ‘nascent’ CFTR glycoprotein is produced. 
Further maturation involves a process of folding in the lipid bilayer of the ER. This process however is 
inefficient. Approximately 60-75% of CFTR are improperly folded and are subject to degradation via 
the ER-associated degradation (ERAD) system. This is a quality control system involving various 
molecular chaperones and ensures only properly folded CFTR progress.21 What specifically happens 
is that the misshapen CFTR are detected by the Ubiquitin Protease System (UPS) (part of the ERAD) 
which signals the 26S proteasome system to eliminate all defective CFTR. It is however possible for 
misshapen CFTR to escape this degradation process. Once nascent CFTR has successfully progressed 
(or escaped) beyond this stage, it undergoes further post-translational modification in the Golgi 
body before being trafficked to the cell membrane in vesicles. At the cell membrane, WT CFTR has a 
half-life of 12-24 hours and is subject to on-going quality control. The plasma membrane protease 
quality control system either recycles CFTR back to the plasma membrane or commits CFTR to 
degradation by lysosomes.19 Approximately 10-35% of CFTR cellular activity is required to prevent 
significant morbidity in CF.22 
Structure of CFTR  
CFTR is a member of a larger group of ATP-binding cassette transporters of which CFTR is the only to 
function as an ion transporter.23 It is composed of five domains comprising two homologous halves. 
There are two intracellular nucleotide binding domains (NBD1/NBD2) that each contribute an ATP-
binding sites, two membrane spanning domains (MSD1/MSD2) that form the channel pore and a 
central intracellular regulatory ‘R’ domain that is susceptible to phosphorylation (Figure 1)24. 
Phosphorylation of the ‘R’ domain by cAMP dependent protein kinases, principally protein kinase A 
induces further binding of ATP to both NBD sites. These sites therefore influence the activation state 
of the channel and ion gating through CFTR.19, 25 It remains unclear whether ATP hydrolysis is 
required at both sites (NBD1 and NBD2) for CFTR channel activation.26  
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Figure 1 Structure of CFTR 
 
Figure 1: A diagram of CFTR. Starting inside the cell, there are two nucleotide binding domains 
(NBD1/NBD2) with a centrally located ‘R’ domain between them. Within the cell membrane lies the 
membrane spanning domains (MSD1/MSD2). When the nucleotide binding domains and R domain 
are activated, the channel pore is activated. Dephosphorylation of the R domain causes subsequent 
closure of the channel.24 
Function of CFTR protein 
CFTR functions as a chloride ion transporter at the apical cell membrane of epithelial cells located in 
the airways, pancreas, liver, intestine, sweat glands and vas deferens (Figure 2).27, 28 Phosphorylation 
with cAMP and binding of ATP induces activation of the CFTR channel pore and results in the 
movement of chloride ions out of the epithelial cells.29 CFTR is also responsible for regulating ENaC; 
a sodium transporter channel and bicarbonate transporter channels. The functions of CFTR maintain 
salt, fluid and pH balance within the cell.30, 31 CFTR has also been shown to influence its host’s 
susceptibility to P. aeruginosa lung infection.31  
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Figure 2 Diagrammatic representation of CFTR Function   
 
Figure 2: A diagrammatic representation of normal CFTR function. Activation of the CFTR channel 
pore results in the movement of chloride ions out of the apical epithelial cells. CFTR also down 
regulates ENaC, a sodium transporter channel. Under normal circumstances, there is minimal 
transport of sodium ions into cells.27  
1.1.3 Classification of CFTR Gene mutations  
Mutations in the CFTR gene affect either the synthesis or function of CFTR (or both) and are 
responsible for initiating a cascade of events that ultimately leads to the morbidity and mortality 
associated with CF (Figure 3). To date, over 1500 variations of the CFTR gene have been identified. 
The majority (80%) of these are represented by six mutation classes which are based on whether the 
mutations in the CFTR gene impair 1) mRNA translation 2) CFTR processing and folding or 3) chloride 
channel gating (Figure 5).32, 33 Some mutations, for example the ΔF508 mutation, exhibit multiple 
defects and therefore can be characterised by more than one mutation class.  
Class I 
Class I mutations are characterised by nonsense, frameshift and splicing mutations that prevent 
CFTR biosynthesis. These mutations result in the presence of an early stop codon (UAG, UAA or UGA) 
within the mRNA nucleotide sequence which has one of two resultant consequences: either a 
truncated protein or mRNA that cannot be translated (unstable mRNA). The truncated proteins or 
unstable mRNA are degraded by the ERAD before they can be trafficked to the cell membrane. 
Therefore patients with only class I mutations do not express functional CFTR at cell membranes, 
and demonstrate the most severe CF phenotypes.32, 34  
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Class 1 mutations are designated an X (e.g. W1282X) and account for approximately 10% of loss-of-
function alleles worldwide.19 W1282X mutation accounts for slightly greater than 1% of CF cases 
worldwide but has a vastly increased frequency (greater than 50%) amongst Israeli Ashkenazi Jews.35  
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 Figure 3 Pathophysiologic cascade of CF Lung disease 
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Class II 
Class II mutations can be represented by the common ΔF508 -CFTR mutation. This loss-of-function 
mutation accounts for 70% of homozygous patients and at least one allele of 90% of heterozygotes, 
making it the most common loss of function allele in Caucasians.36, 37 The ΔF508 mutation causes 
deletion of three base pairs (T-A-G) that code for the amino acid Phenylalanine at position 508 of the 
CFTR glycoprotein (Figure 4). Loss of Phenylalanine generates a misfolded protein, which is mostly 
(99%) identified by the ER quality control system, tagged with Ubiquitin and degraded by protease.38 
This is known as the intracellular processing defect and is characteristic of class II mutations. With 
ΔF508-CFTR minute amounts of have been shown to escape the degradation system and are 
expressed on the apical cell membrane of epithelial cells.39 Here however, they display defective 
anion transport (like class III/IV mutations) and have been demonstrated to have reduced half-lives 
(<4hours) due to degradation by the plasma membrane protease quality control system.38, 40  
 Figure 4 Site of ΔF508 mutation  
 
Figure 4 demonstrates the structure of the CFTR protein, and the site of ΔF508 mutation within the 
nucleotide Binding Fold (also known at the nucleotide binding domain).37 
Class III  
Class III mutations are characterised by a disrupted pattern of channel gating. The CFTR protein 
products of class III mutations are synthesised, trafficked and embedded within the cell membrane 
normally, but fail to respond to normal intracellular cAMP stimulation. This prevents 
phosphorylation of the ‘R’ domain and binding of ATP to the NBDs, reducing activation of the 
channel pore.41 Therefore, Class III CFTR can only function minimally.   
The G551D mutation is the most common Class III mutation, and the third most common CFTR 
mutation, accounting for 4% of loss-of-function alleles worldwide.24 It is caused by the substitution 
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of glycine for aspartic acid at codon 551 found in NBD1 and results in the inability of NBD to utilize 
ATP.42 The G551D mutation is the first, and only current, allele that has a licensed mutation specific 
therapy in the UK.43  
Class IV 
Class IV mutations are characterised by compromised chloride ion conductance. The protein product 
of class IV mutations are embedded within the apical cell membrane of epithelial cells and respond 
normally to intracellular stimuli, however demonstrate either 1) reduced permeation to chloride 
ions or 2) reduced channel opening time, meaning chloride ion conductance is significantly 
reduced.44  
The R117H mutation is a class IV CFTR mutation. During protein synthesis, arginine is substituted for 
histidine at position 117 and this results in a reduced channel opening time. It has a worldwide 
frequency of approximately 2% amongst patients with CF.24  
Class V  
Class V mutations are characterised by errors in RNA splicing resulting in fewer mRNA transcripts 
and reduced quantity of functional CFTR.44 Gene splicing mutations accounts for 11.6% of known 
mutations in the CFTR mutation database but are rarely found in patients with CF (<1% of patients 
with CF).24  
Class VI 
The protein product of class IV mutations are truncated leading to increased cell surface turnover 
and degradation.45   
1.1.4 Summary   
Cystic Fibrosis is the most commonly inherited condition amongst people of European decent. It is 
caused by mutations in the CFTR gene, located on chromosome 7. Under normal circumstances the 
CFTR gene codes for a CFTR protein product responsible for maintaining ion, fluid and pH balance 
within the cell. Mutations of the CFTR gene lead to inadequate amounts of CFTR or defective CFTR 
function (Figure 5) and are therefore responsible for clinical features on CF (Figure 3). The mutation 
classes are summarised in Table 1.   
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Figure 5 A diagrammatic representation of how mutation classes affect CFTR protein synthesis or 
function. 
  
 
Figure 5: A diagrammatic representation of how CFTR mutation classes affect CFTR synthesis or 
function. Class I mutations are characterised by the presence of a premature stop codon in the 
mRNA sequence, coding for a truncated or unstable CFTR protein. Class II CFTR proteins are folded 
incorrectly whilst in the ER bilayer and subsequently degraded by ERAD.  Unlike Class I-II mutations, 
Class III-VI CFTR are synthesised and trafficked to the cell membrane normally. At the cell membrane 
however, Class III CFTR demonstrate defective response to normal stimuli and class IV CFTR 
demonstrate inactive chloride ion gating. Class V mutations are characterised by splicing mutations, 
whereby reduced functional CFTR is trafficked to the cell membrane. Class VI CFTR is subject to 
increased cell surface turnover and degradation at the cell membrane.33 
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Table 1 Summary of the CFTR gene mutations 
 Example 
mutation  
Mutation type  Pancreatic 
function and 
phenotype   
Worldwide 
frequency  
Nature of the 
defect 
Class 
1 
W1282X Nonsense  Insufficient  10% worldwide 
(>50% Ashkenazi 
Jews with CF 
possess W128X 
allele) 
Defect in 
Biosynthesis – no 
functional CFTR 
expression 
Class 
2  
ΔF508 Missense 
(amino acid 
deletion)  
Insufficient 70% homozygous 
and at least one 
allele in 90% of 
heterozygotes.  
Intracellular 
trafficking defect – 
minimal functional 
CFTR expression 
Class 
3 
G551D Missense 
(amino acid 
substitution)  
Insufficient 4% Defect in regulation 
by phosphorylation 
and ATP.  – minimal 
CFTR expression  
Class 
4  
R117H Missense 
(amino acid 
substitution) 
Sufficient  2% Defect in chloride 
ion conductance – 
residual CFTR 
function 
Class 
5 
3849+10kb C-
>T 
Missense 
(amino acid 
substitution) 
Sufficient  <1% Reduced synthesis 
of functional CFTR - 
variable CFTR 
function 
Class 
6  
Q1412X 
 
   Increased cell 
surface turnover 
and degradation of 
CFTR  
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1.2 Pathophysiology and clinical features of CF  
In CF, pathological changes are seen in all organs that express defective CFTR. The most profound 
impact of defective CFTR is demonstrated in the lungs, which are responsible for the majority of 
mortality associated with CF. The pathological process of airway disease starts with dehydration of 
the lining of the lungs (Figure 3).  
1.2.1 Airway disease  
Dehydration of ASL  
The airway surface liquid (ASL) lining the airways is composed of two layers; an inferiorly positioned 
pericilliary layer and a superiorly positioned hydrated mucus layer. The mucus layer is mainly 
composed of water (98%) and facilitates distal to proximal shifting of surface components by the 
action of cilia; a process known as the mucociliary clearance system. This system is dependent on 
the hydration status of the mucus layer and is crucial for eliminating invading pathogens.46 
In CF, there are two theories behind the progression of airway disease from defective CFTR to 
chronic infection and inflammation; the ‘low salt’ theory and the high salt theory.’ The ‘low salt’ 
theory is the most well established theory. Here, defective CFTR is unable to down regulate ENaC 
permitting the transepithelial movement of sodium ions from the ASL back into the cell. Water then 
follows by osmosis leaving the mucus layer dehydrated. This has a detrimental impact on mucociliary 
clearance. Thick viscous mucus, secreted by submucosol glands and goblet cells cannot be shifted 
and therefore remains stagnant in the airways. This obstructs the airways and makes them 
vulnerable to repeated infections and increased contact time with bacteria.47 
The 'high salt' theory suggests that defective CFTR creates a high concentration of salt in the ASL. 
This is proposed to predispose CF airways to infection by reducing the effectiveness of antimicrobial 
peptides within the ASL and disrupting mucociliary transport.47  
Infection - Airway microbiology  
Dehydration of ASL increases the propensity of the CF airways to be infected by bacteria. This is 
evident as early as infancy and early childhood when a large proportion of patients develop 
intermittent infections with P. aeruginosa and other bacteria such as Staphyloccocus aureus (S. 
aureus) and Haemophilus influenza (H. influenza). When treatment regimens fail to eradicate the 
infection, often following repeated intermittent infection, the patients are said to have developed 
chronic infection.  
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Chronic P. aeruginosa dominates the CF airways and is detected in more than 50% of UK CF patients 
by the age of 20-23 years. The change in prevalence of infective organisms identified from CF 
airways with increasing age is demonstrated in Figure 6.48  
The increased propensity of P. aeruginosa to chronically infect CF airways is multifactorial. P. 
aeruginosa has the ability to mutate in response to environmental stresses (for example hypoxia 
created by a mucus plug) into mucoid variants, during the years following initial colonisation. 
Mucoid variants produce alginate, which surrounds them and protects them from external 
challenges such as mucociliary clearance, host immune response and antibiotic agents. Therefore 
conversion to the mucoid phenotype allows for persistent infection that is difficult to eradicate.49 
The high prevalence of P. aeruginosa in CF lungs has also been associated with the lack of wild-type 
(normal) CFTR. Under normal circumstances wild-type CFTR receptors are thought to bind to P. 
aeruginosa antigens and stimulate internalisation of the pathogen by epithelial cells.50 Mutant CFTR 
is unable to bind to P. aeruginosa so it is allowed to freely reside within the CF airways. In addition to 
this, P. aeruginosa also forms biofilms, which make the prospect of its eradication even more 
challenging.51 Chronic infection with P. aeruginosa is associated with a faster decline in lung 
function, worse nutrition and ultimately reduced survival rates.52  
Figure 6 Prevalence of infective organisms  
 
Figure 6 demonstrates the change in prevalence of infective organisms identified from CF airways 
with increasing age. It is evident from this graph that from approximately 16-19 years of age, chronic 
infection with P. aeruginosa dominates the CF airways.48 
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Airway inflammation  
In chronically infected CF airways, the picture is that of a prolonged primary inflammatory 
response.53 Neutrophils predominate and are the principal inflammatory cells responsible for tissue 
damage and disease progression in CF.54 They secrete various pro-inflammatory cytokines (including 
interleukin (IL) -8, IL-6 and IL 1β), oxidants and proteases (such as neutrophil derived elastase (NE)) 
that damage the lungs. Neutrophil cytokines and oxidants injure the respiratory epithelium, and the 
former incite further neutrophil accumulation at the site of infection. Proteases also weaken airway 
structures by digesting structural proteins.55 The presence of NE in sputum or serum is associated 
with a faster lung function decline and onset of bronchiectasis.56 Under normal circumstances, 
antiprotease defences in the airways oppose the effects of proteases. Protective antioxidants 
prevent free radicals placing oxidative stress on airways and anti-inflammatory factors, such as IL-10, 
oppose the action of pro-inflammatory factors. In the CF airways however, the effect of these 
protective factors are overwhelmed, leading to the excessive and continuous inflammatory response 
seen in patients with CF.54, 55  
Chronic infection by bacteria is the leading trigger of lung inflammation in CF and as the bacterial 
burden increases the inflammatory response intensifies. Chronic infection with P. aeruginosa in 
particular elicits an aggressive inflammatory response; upon infection with P. aeruginosa cells 
lacking functional CFTR secrete higher amounts of IL-1, IL-8, tumour necrosis factor (TNF)-a and 
macrophage inflammatory protein (Mip)-2.57 Viruses also contribute to airway inflammation. They 
pre-dispose the airways to bacterial infection and change the antibiotic resistance pattern which 
incites a greater inflammatory response.58  
It is well recognised that lung inflammation starts early and that CF airways deficient of WT CFTR 
exhibit a pro-inflammatory state and over-respond to infectious agents.59 The relationship between 
infection and inflammation however is hazy. It was previously considered that airway infection 
initiated the process of inflammation but there is emerging evidence demonstrating dissociation 
between infection and inflammation.60  
Lung damage 
As a consequence of chronic infection and inflammation, patients with CF may develop 
bronchiectasis and episodes of pulmonary exacerbations.  
Bronchiectasis  
Patients with cystic Fibrosis develop bronchiectasis, defined as the abnormal dilation of the bronchi 
due to the loss of elastic and muscular components of the wall. It is considered to be a result of 
destruction of elastin, muscle and cartilage by proteases from neutrophils during inflammation. 
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Patients with bronchiectasis develop increased mucus production and persistent lower respiratory 
tract infection.61  
Pulmonary exacerbations  
CF patients with chronic airway infection and inflammation usually exhibit on-going symptoms such 
as cough and sputum production, but some may be symptom free. Episodes of worsening symptoms 
or new symptoms that require additional antibiotic therapy are termed ‘exacerbations.’ These 
episodes are intermittent and unpredictable and occur due to the presence of chronic lower 
respiratory infection, usually P. aeruginosa. In many cases they are triggered by additional factors, 
for example non adherence to maintenance treatment or viral infection (RSV, Influenza).62 
Pulmonary exacerbations are associated with worse pulmonary function and a more rapid rate of 
lung function decline and also have a significant detrimental impact on psychological health of the 
patient.63-65  
Other complications  
In addition, patients can develop other life threatening airway complications that must be 
recognised early and appropriately management. These include: haemoptysis, pneumothorax and 
respiratory failure.66 
1.2.2 Pancreatic, hepatobiliary and GI tract manifestations   
CFTR is also expressed throughout the entire GI system, including the pancreatic (exocrine and 
endocrine) and the hepatobiliary systems. In these systems, the picture is similar to that of the CF 
airways whereby thick, viscous mucus obstructs lumen lined by epithelial cells possessing defective 
CFTR. The most pronounced effects of defective CFTR occur in the intestines, pancreas and 
hepatobiliary system which carry their own risks and also contribute to the poor nutritional status 
seen in patients with CF.  
CF Intestine 
Meconium ileus (MI), Distil Intestinal Obstruction Syndrome (DIOS) and constipation form the 
obstruction syndromes that burden the CF intestines. They are all consequences of increased 
viscosity of luminal mucus and reduced transit time.67 MI is characterised by thick, adhesive and 
dehydrated meconium that completely obstructs the intestinal lumen and fails to pass. It occurs in 
20% of CF infants, with the majority of cases (13-17% of CF infants) present at birth. Once diagnosed, 
prompt management is required to reduce the risk of bowel perforation and sepsis.68 After 
neonatal/infancy period, DIOS emerges as the major cause of obstruction. It can be either complete 
or incomplete faecal obstruction of the ileocecum and occurs more commonly in adults than 
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children.67 In the long term, thick viscous mucus within the lumen of the intestines contributes to 
development of constipation and contributes to malabsorption of nutrients.  
CF Exocrine and Endocrine Pancreas 
Pancreatic exocrine insufficiency (PEI) is responsible for the majority of malnutrition in people with 
CF. It affects 85-90% of the CF population and is characterised by inadequate secretion of digestive 
enzymes and alkaline fluid.69 Consequently, people with PEI are burdened by maldigestion, 
malabsorption and increased energy loss, in particular of fats, which clinically manifests as 
steatorrhoea in the short term and the consequences of malnutrition in the long term long term.  
The pathophysiology EPI relates to the short and long term effects of defective CFTR. Within the 
pancreatic ducts, mucus containing a high concentration of digestive enzymes is created.70 This 
obstructs the ductal lumen and prevents digestive enzymes and alkaline fluid from being secreted. 
After prolonged stagnation of mucus within the ducts, the digestive enzymes (present in high 
concentrations) start to degrade secretory acinar cells and lead to fibrosis of the pancreas (hence 
“cystic fibrosis of the pancreas”) and fatty infiltration.71   
When progressive acinar fibrosis and fatty infiltration progress to the islet of Langerhans cells, 
patients with PEI develop  CF related diabetes (CFRD).72 The diagnosis of CF is commonly made 
around 20 years of age and population studies have demonstrated that 76% of CF patients have 
CFRD by the age of 30.72  
CF Hepatobiliary system  
CFTR is expressed at the apical membrane of cholangiocytes and gall bladder epithelial cells but not 
hepatocytes. Therefore hepatic damage in CF is a consequence of pathological processes occurring 
in the biliary system.73 Mucous that obstructs the biliary lumen leads to 1) injury of bile duct cells 2) 
bile duct plugging making the bile duct epithelium susceptible to destruction by cytotoxic agents 
secreted in bile and 3) malabsorption of fats. After long-standing biliary obstruction and progressive 
fibrosis, focal biliary cirrhosis develops. This process burdens a third of patients with CF and is 
becoming more prevalent as patients with CF live longer.74 CF hepatobiliary disease has a negative 
impact on nutritional status through malabsorption, has a detrimental impact on long term lung 
function and carries its own risk for mortality.74   
Nutritional status  
Reduced nutrient intake, malabsorption, increased loss of nutrients and increased energy 
expenditure all contribute to worsen nutritional status in patients with CF.75 Poor nutritional status 
during childhood is associated with a failure to grow, developmental delay, reduced quality of life 
and reduced pulmonary function when older.76   
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1.2.3 Other clinical manifestations of Cystic Fibrosis  
Sweat Glands  
In the CF sweat glands, there is reduced re-absorption of sodium, chloride and potassium ions due to 
the absence or dysfunction in CFTR. The resultant salty skin is characteristic of CF and sweat chloride 
levels exceeding 60 mmol/L is diagnostic of CF.77  
Reproductive System  
The majority of males with CF have congenital bilateral absence of the vas deferens (CBAVD). This is 
a developmental defect whereby transport of spermatozoa from the testes or epididymis to the vas 
deferens is blocked. The resultant azoospermia means that 99% of males are impotent.78 Women on 
the other hand with CF have structurally normal reproductive systems. With aggressive nutritional 
and airway management and normal hormonal levels, CF women should develop into sexually 
mature adults. The only possible obstacle to successful fertilisation is thickened cervical mucus.79  
CFTR-related disease  
Single organ conditions that have been related to CFTR mutations are called CFTR-related diseases. 
They have been given a separate classification to typical and atypical CF as patients do not show the 
classic or mild phenotypes of CF, yet are single organ disorders caused by CFTR related mutations. 
Disorders include bilateral absence of the vas deferens, idiopathic pancreatitis and allergic bronch0-
pulmonary aspergillosis.46 
1.2.4 Genotype – phenotype correlation 
There is an association between different mutation classes and phenotype.80 These phenotypes are 
based on individuals who possess the most common mutations; ΔF508 mutation, present in 90% of 
individuals; G551D, W1282X, G542X and N1303K present in 1-4% of CF individuals and 
approximately 20 more that have a frequency of >0.1%.81 The clinical consequences of specific well 
characterised mutations are outlined on the Clinical and Functional Translation of CFTR (CFTR2) 
website (www.cftr2.org).82 It is difficult to characterise phenotypes for the remaining genotypes that 
have the propensity to cause disease because of their relatively low frequency, however emerging 
studies seek to explore these mutations by sourcing data directly from well phenotyped subjects.83  
CFTR mutations can be categorised into mild or severe depending on disease severity (Table 2).80, 84 
The main differences in phenotype between patients with mild and severe genotypes appears to be 
linked to pancreatic status, as pancreatic function has been shown to correlate well with CFTR 
genotype, unlike pulmonary function.80 Mild genotypes correspond to pancreatic exocrine 
sufficiency and more severe phenotypes, such as being homozygous for the ΔF508-CFTR mutation, 
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correspond to PEI.80 This difference in severity between genotypes correlates with the amount of 
functional CFTR expressed in the cell membrane (Table 1, Table 2).34  
Despite this, CFTR genotypes alone cannot be used to determine phenotypes which are subject to 
much heterogeneity. Patients with identical genotypes have been shown to display variable 
phenotypes, suggests that the influence of CF phenotypes is most likely multifactorial.85 
Environmental factors (bacterial infection, pollution) and/or modifier genes have been proposed to 
have a role.85, 86  
Table 2 Phenotypic characteristics of mild and severe CFTR genotypes 
1.2.5 Summary  
CF airways are obstructed by thick, viscous mucus that cannot be cleared due to defective 
mucociliary clearance. This creates an ideal environment for infective agents, namely bacteria to 
reside and chronically infect the airways. One pathogen in particular, P. aeruginosa has an increased 
propensity to chronically infect the CF airways. This chronic infection of the CF airways is dominated 
by neutrophil inflammation typically seen in an acute infection. Neutrophil inflammation is 
progressive and irreversible and ultimately manifests as bronchiectasis and recurrent episodes of 
pulmonary exacerbations.   
Malabsorption of nutrients occurs in a large proportion of the CF population (90%) and is mainly due 
to pancreatic exocrine insufficiency, but also due to obstruction within the intestines and biliary 
system. Disease processes in these systems also pose their own risk on the survival of patients with 
CF.  
Certain genotypes have been associated with more severe clinical manifestations (www.cftr2.org), 
and this is probably due to the amount of functional CFTR that is expressed. Despite this, patients 
Severe CFTR mutations (classes 1-3) Mild CFTR mutation (classes 4-6) 
Pancreatic insufficiency (>95% of cases) Pancreatic sufficiency  
Liver disease (3-5% of patients)   
Previously young age of diagnosis (Early onset of 
clinical manifestations)  
Later age of diagnosis (>10 years of age) (Late 
onset of clinical manifestations) 
High sweat chloride concentration (>80 mmol/L) Lower sweat chloride levels  
Meconium ileus (approximately 20% of cases) No meconium ileus  
 Milder pulmonary disease  
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with the same genotypes often demonstrate different disease severities, suggesting the influences 
of CF phenotypes are most likely multifactorial.  
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1.3 Management of Cystic Fibrosis   
The management of CF involves a multidisciplinary approach from a specialist CF team, usually at a 
specialist CF centre. This consists of specialist CF clinicians, nurses, dieticians, physiotherapists, 
pharmacists, clinical psychologists and microbiologists all working together to promote CF health.68 
The management of CF involves aggressive treatment of airway disease and poor nutrition status 
and can be very burdensome to the lives of patients.  
1.3.1 Airway management  
In order to limit the progression of CF airway disease, current therapies target steps in the 
pathogenesis demonstrated in Figure 3. This includes; restoration of the hydration status of ASL, 
promotion of airway clearance, eradication of infections and limiting progression of airway 
inflammation.  
Restoration of hydration status of ASL  
Restoration of hydration status has been targeted via three angles: therapeutic osmolytes, ion 
transport regulators and ENaC inhibitors.87 The strongest evidence lies with hypertonic saline (HS, 
7% NaCl), a therapeutic osmolyte. Studies have demonstrated it can reduce pulmonary 
exacerbations, increased quality of life and improve lung function in the short term. 88, 89 However, a 
Cochrane review called for additional long term studies to demonstrate its long term effectiveness.90  
Promotion of airway clearance  
Therapies or practices that target increased airway secretions include mucolytics and chest 
physiotherapy. Mucolytics reduce mucus viscosity facilitating easier clearance of airway secretions. 
To date, inhaled Dornase alpha (Pulmozyme®) is the only mucolytic for which there is evidence 
demonstrating improved long term lung function and is recommended in CF airway management.91 
This therapy specifically targets the DNA released by dead neutrophils which contributes to the 
increased viscosity of mucus in patients with CF.  
The principal of chest physiotherapy is to promote expectoration of airway secretions and has been 
demonstrated to improve mucus clearance in the short term.92 A specialist CF physiotherapist is 
required to tailor the technique (chest percussion with postural drainage or high frequency chest 
wall oscillation) towards the patient’s age, preference and adverse events, but the practice itself can 
be self-administered.93, 94  
Eradication of Infections  
Aggressive antibiotic treatment is a cornerstone of CF airway management. Intermittent infections 
should be treated promptly (< 4weeks) with a suitable antibiotic regimen. Options include 28 days of 
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tobramycin solution for inhalation (TIS) and up to 3 months of a combination of nebulised colistin 
and oral ciprofloxacin.93  Patients who are chronically infected with P. aeruginosa are indefinitely 
managed with daily antipseudomonals such as inhaled tobramycin (TOBI®) and Colomycin. Inhaled 
tobramycin is associated with improved lung function and reduced exacerbation rates.93, 95   
Limiting the progression of airway inflammation  
Anti-inflammatory drugs have a role in reducing neutrophil dominated airway inflammation. 
Corticosteroids have limited the progression of lung disease in several clinical trials in patients with 
CF.96 However, due to their significant adverse effects such as glucose intolerance and growth 
retardation, they are not recommended in patients with CF unless there is concomitant asthma.93 
Another anti-inflammatory drug, Ibuprofen, has also slowed the long term progression of CF lung 
disease in one trial.97 However, this evidence is insufficient to guide recommendations. Therefore at 
present, anti-inflammatory drugs are not recommended for routine management in patients with 
CF.  
Treatment of Pulmonary exacerbations 
The treatment of patients with CF should focus on limiting and preventing pulmonary exacerbations. 
However, when they do occur they should be treated promptly and aggressively to maintain lung 
function, improve QoL and prolong survival. For upper respiratory tract infections with more than 3-
5 days of cough or other lower respiratory tract symptoms, a minimum of 10 days of oral antibiotics 
that cover both H. influenza and S. aureus are required. If symptoms do not resolve, or worsen on 
oral antibiotics, a course of intravenous antibiotics is indicated. Patients chronically infected with P. 
aeruginosa who develop new symptoms are treated with oral antibiotics in conjunction with regular 
inhaled anti-pseudomonal therapy. If this therapy fails to resolve symptoms, a combination of 2 
intravenous antibiotics is recommended for 14 days. This may change depending on individual 
patient requirements and local guidelines. Patients who require intravenous antibiotics also require 
the following: more intense, supervised chest physiotherapy and airway clearance, increased 
nutritional supplementation and closer monitoring of other CF related issues.98 
1.3.2 Nutritional repletion  
Nutritional management  
CF patients with good nutritional status have been demonstrated to have better pulmonary function 
and survival.99 In order to achieve proper nutritional status CF patients need to follow an 
unrestricted diet that is high in calories (30%-40% of the calories from fat), have optimal pancreatic 
replacement enzyme therapy and use supplemental nutrition (orally or enterally) when 
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appropriate. Bicarbonate supplementation and acid suppressants may also be used to neutralise the 
acidic duodenal pH of CF patients.100  
1.3.3 Summary  
The mainstay of CF airway management is symptomatic and targets the different stages of events in 
the cascade of events leading to progressive airway disease (Figure 3). The most important emphasis 
is placed on prompt and aggressive antibiotic management during intermittent infections to limit the 
onset of chronic infection. When patients are chronically infected particularly with P. aeruginosa, 
they require daily inhaled antibiotic therapy and regular physiotherapy to increase mucus clearance. 
Therapies that aim to hydrate the ASL (hypertonic saline) and reduce viscosity of secretions (Dornase 
alpha) are also recommended for routine airway management. In addition to achieving good 
nutrition this forms a pivotal part of CF management and has a significantly beneficial impact on long 
term prognosis of patients with CF. 
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1.4 New approaches to management   
It is clear that to date, the focus of treatment has been aimed at resolving the consequences of 
defective CFTR through aggressive symptomatic management. This has been very efficacious, and 
has drastically improved survival of patients with CF over the past decades.2 However it would be 
preferable for CF therapies to target the underlying CFTR defect itself and this feat has been made 
possible with the knowledge attained from discovery of the putative gene in 1989.  
First efforts at targeting the gene defect aimed to replace the mutated CFTR gene with correct CFTR 
DNA through CFTR gene transfer therapy. More recent efforts in this field have focused on restoring 
mutation specific defects in CFTR synthesis or function (Table 1) and are called mutation specific 
therapies.  
1.4.1 CFTR Gene Transfer Therapy  
CFTR gene therapy aims to deliver correct CFTR DNA into CF airway cells. Theoretically this methods 
of treatment is relevant to CF patients as 1) CF is monogenic 2) heterozygotes are phenotypically 
normal therefore DNA levels do not need to match that of non-CF people 3) therapy targeting the 
lungs can be administered topically and 4) normal lungs at birth offer a therapeutic window.101 If 
effective, gene transfer therapy could be used to treat patients with all types of gene mutations. 
CFTR DNA can be delivered through viral or non-viral mediums. Viral gene transfer therapy involves 
using a viral vector for example an adenovirus to introduce the coding sequence to the target cell so 
it can be transcribed into mRNA or even insert it into the cell genome. Non-viral methods of delivery 
involve using non-viral vectors such as liposome-based vectors to introduce the coding sequence to 
the cell. Laboratory studies have demonstrated successful transfer of correct CFTR DNA to airway 
cells in cell and animal models.102 Despite this, CFTR Gene Transfer therapy through both viral and 
non-viral mediums has not yet demonstrated clinical benefit to humans, owing to difficulties in 
overcoming host immune responses and physical barriers.103, 104 Research into the development of a 
clinically effective gene transferring therapy is on-going and is being led by the UK Cystic Fibrosis 
gene therapy consortium.105 
1.4.2 Mutation-specific therapies  
CFTR Potentiators  
The first strategy, particularly related to mutation classes III-V, but potentially important to mutation 
class II, was to augment the function of defective CFTR successfully embedded within the cell 
membrane. Drugs that successfully augment membrane bound CFTR were called CFTR potentiators. 
Genistein, present in tofu and soy, demonstrated increased chloride channel activity in both 
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defective and WT CFTR.106 More recently, a small 
molecule called Ivacaftor (also called VX-770 and 
Kalydeco®) was identified through high throughput 
screening by Vertex Pharmaceuticals.107 The exact 
mechanism of action of Ivacaftor is not completely 
understood but has been demonstrated to increase the 
open time of activated CFTR channel pores located at the 
epical cell membrane, in a phosphorylation dependent 
but ATP independent pattern.108 Ivacaftor has successfully 
corrected abnormal salt transport in cell models of both 
ΔF508 (Class II) and G551D (Class III) CFTR.109 It has 
progressed to human clinical trials in patients with both 
the G551D mutation and ΔF508 mutation and is a 
licensed therapy for children (6-11 years old) and adults 
with the G551D mutation in the UK.43  
CFTR Correctors  
In addition to CFTR potentiators, other drugs that aim to 
correct the underlying defect of mutation classes have 
been developed. CFTR correctors aim to correct the 
intracellular processing defect of class II mutations so CFTR can be trafficked to the cell surface. As 
the ΔF508 mutation (class II) accounts for 90% of alleles in the CF population, these therapies could 
represent a significant healthcare resource and have received much attention. However, due to the 
complexity of the trafficking process, identifying effective therapeutics has proved challenging.  
Early studies demonstrated that low temperature could increase protein trafficking and function.110 
Following this, therapies that targeted molecular chaperones or therapies approved for other 
conditions demonstrated ΔF508-CFTR rescue activity.107 In vitro Studies of glycerol (chemical 
chaperone) demonstrated increased CFTR expression at the cell membrane and increased function 
of chloride transport.111, 112 Subsequently, studies of 4-phenylbutyrate (4PBA), a compound approved 
for an inherited of urea metabolism, demonstrated increased trafficking of mature ΔF508 CFTR to 
the cell surface.113 Miglustat, a drug approved for the treatment of Gaucher disease, has recently 
been shown to promote ΔF508 CFTR trafficking to the cell membrane and augment chloride 
conductance and sodium reabsorption.114 In vitro studies of CPX (8-cyclopentyl-1, 3-
dipropylxanthine), an A1 adenosine receptor antagonist, demonstrated increased WT and ΔF508-
CFTR potentiator  
A drug that aims to increase the 
amount of functional CFTR expressed 
at the epithelial cell apical membrane 
by enhancing defective CFTR already 
embedded within the cell membrane. 
CFTR corrector    
A CFTR corrector is defined as a drug 
which aims to increase the amount of 
CFTR expressed at the epithelial cell 
apical membrane, by reducing or 
preventing degradation of CFTR by 
normal intracellular mechanisms seen 
in Class II mutations.  
Stop codon therapies  
Therapies that ‘skip’ premature stop 
codons found in mRNA of Class I 
mutations.  
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CFTR channel activity. 115 Following the positive results achieved with these therapies in vitro, they 
have all progressed to human clinical trials.116-120  
Additionally, small molecules with ΔF508 corrector ability, namely Lumacaftor (VX-809) and VX-661, 
have recently been identified by Vertex Pharmaceuticals through high throughput screening (HTS). 
So far Lumacaftor has demonstrated the most progress. In vitro studies demonstrated significantly 
improved chloride transport in ΔF508 CFTR cells to that of 14% of non-CF individuals.121 Its 
mechanism of action is not fully understood, but it is proposed to suppress the folding defect of 
ΔF508- CFTR by modulating the shape of MSD1.122 Developments of both Lumacaftor and VX-661 
have progressed into human clinical trials.123-125  
In vitro studies have demonstrated that CFTR correctors successfully increase ΔF508-CFTR trafficking 
and expression within the apical cell membrane. However, this does not resolve the issue of 
compromised chloride conductance of ΔF508-CFTR when embedded within the cell membrane. 
Restoration of ΔF508 CFTR is therefore likely to require the addition of CFTR potentiators to 
augment CFTR function at the cell membrane. In vitro studies have demonstrated almost doubled 
effect of Lumacaftor on ΔF508 human bronchial epithelial cells when used in combination with 
Ivacaftor.126 Studies examining the impact of CFTR corrector and CFTR potentiator combination 
therapy have progressed to human clinical trials.127-130   
Stop Codon Therapies  
The mRNA product of Class I mutation possess a premature termination codon (PTC) that codes for a 
truncated, unstable protein (Table 1). Stop codon therapies ‘force’ read-through of the PTC during 
translation and aim to produce a full length polypeptide chain. In vitro studies of Gentamicin (an 
aminoglycoside) demonstrated that two loss of function class I CFTR mutations could be suppressed, 
which resulted in a fully synthesised CFTR polypeptide chain that restored CFTR function up to 35% 
of WT levels at the cell membrane. 131, 132 Research into Gentamicin has progressed to human clinical 
trials but there are concerns about regular and high doses of this therapy given its adverse effects 
profile includes ototoxicity and nephrotoxicity.133  
More recently, another stop codon therapy called Ataluren (PTC124), developed by PTC therapies, 
has made significant progress. It allows the ribosome to read through the PTC but unlike Gentamicin, 
it does not allow read through of the correct PTC at the end of the mRNA chain.134 Research into 
Ataluren has progressed to testing in humans.133, 135  
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Summary  
Gene transfer therapy and mutation-specific-therapies are the first therapies to be created in the 
field of personalised genomics in CF. They have both demonstrated efficacy in vitro, have progressed 
to human clinical trials and could represent significant healthcare resources for patients with CF. 
Recommendations for the use of these therapies in humans however must be guided by high quality 
evidence.  
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1.5: Cochrane Systematic Reviews  
1.5.1 Cochrane Systematic reviews  
Cochrane Systematic reviews are the most comprehensive and valid form of establishing the current 
evidence base.136, 137 They seek to answer a specific healthcare question in ways that limit bias to 
selection, critical appraisal and synthesis of studies, and are widely seen at the gold standard 
resource for up-to-date evidence. In comparison to narrative reviews where the author is able to 
select the studies to include, systematic reviews involve a more objective assessment of the 
literature. This is through robust and transparent methodology.138, 139 All Cochrane systematic 
reviews start with a protocol stage outlining the proposed methodology for the inclusion, 
methodological assessment and synthesis of studies. This is peer-assessed and published prior to the 
literature search being conducted, to minimise risk of bias in the selection of studies. The literature 
search process involves a thorough search of published and unpublished trials to ensure that the 
evidence is based on all relevant literature. In Cochrane systematic reviews this is done through a 
specific Cochrane Registry for example the Cochrane CF registry and by contacting leaders in the 
field. The identified studies are then screened and assessed for eligibility with pre-specified eligibility 
criteria. The eligible studies are critically appraised to highlight any systematic error in the included 
studies that could potentially limit the internal validity of the evidence. Conclusions are formed from 
results of synthesised data and take into account systematic error within the included studies. This 
robust and transparent methodological approach, employed by systematic reviews and in particular 
Cochrane systematic reviews, ensures that bias is kept to a minimum. Cochrane systematic reviews 
are regularly updated to ensure the evidence base is kept up to date.   
Systematic reviews include a meta-analysis. Meta-analysis is the statistical technique used to 
synthesise data from eligible studies that demonstrate homogeneity, thereby increasing the number 
of participants that the data were obtained from and thus increasing the sample size. Synthesis of 
data in a meta-analysis can therefore increase the precision of the overall treatment effect estimate, 
if trials demonstrate consistency.140  
Cochrane systematic reviews provide a unique resource for clinicians. They provide a concise 
summary of large bodies of evidence, which would have otherwise taken an extended period of time 
to assess. In addition to this they also provide a thorough and methodologically transparent 
appraisal of the evidence for authors who wish to determine how conclusions were formed, so they 
can form their own judgments on the validity of the evidence. Cochrane systematic reviews are also 
a unique resource for patients and their families. They report results in a way that is both relevant 
and interpretable to lay people, empowering patients and their families to make informed decisions 
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about treatment plans. They are also readily accessible for free on the Cochrane Library, which is 
particularly important for patients and their families given they may not have access to medical 
journals.  
1.5.2 Quality of the evidence  
In order to provide the strongest current evidence base, studies considered eligible for inclusion in 
systematic reviews must demonstrate sufficient methodological quality. In Cochrane systematic 
reviews of interventions, included studies are usually limited to randomised controlled trials (RCTs). 
RCTs represent the most rigorous way of determining whether a cause-effect relationship exists 
between treatment and outcomes and are therefore considered the best from of clinical trial with 
regards to clinical trial methodology. Meta-analysis of homogenous RCTs therefore provide the 
highest quality of evidence (Figure 7).136     
The validity of evidence can still be limited by flaws in the conduct, analysis and reporting of 
included studies. In Cochrane systematic reviews, studies are critically appraised using the Cochrane 
risk of bias tool to determine the effect of these flaws on the treatment effect estimate.   
1.5.3 Summary  
Cochrane systemic reviews are the gold standard for establishing the current evidence base for 
interventions. They aim to reduce bias in the review process, and also identify flaws in included 
studies that can limit the validity of the evidence. This is done through robust, transparent and 
reproducible methodology.  
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Figure 7 Hierarchy of evidence with regards to treatment interventions provided by the Oxford centre for Evidence base medicine.  
 
x   
Figure 7 demonstrates a hierarchy of evidence for healthcare interventions. At the top of the hierarchy lies systematic reviews (SR) based on homogenous 
RCTs.136  
1a - SR (with 
homogeneity) 
of RCTs
1b - Individual RCT 
(with narrow 
Confidence 
Interval)
2a - SR (with homogeneity) of 
cohort studies
2b - Individual cohort study (including 
low quality RCT; e.g., <80% follow-up)
2c - “Outcomes” Research; Ecological studies
3a - SR (with homogeneity) of case-control studies
3b - Individual Case-Control Study
4 - Case-series (and poor quality cohort and case-control studies)
Expert opinion without explicit critical appraisal, or based on physiology, bench research or 
“first principles”
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1.6 Objective this MPhil    
Since CFTR potentiators and CFTR correctors are novel therapies, it is important that randomised 
controlled trials (RCTs) testing these chemicals are critically appraised. This will enable examination 
of the evidence relating to their benefits and harms. It is also important for funding bodies such as 
NHS to have a clear evidence-base on which to assess new therapies for CF that aim to correct the 
basic defect as it is likely that these therapies will represent a significant healthcare resource and 
cost in the future. It is also important for healthcare practitioners and patients to have a clear 
evidence base to inform clinical decision making.  
The objective of this MPhil is:  
To conduct two Cochrane systematic reviews to evaluate the benefits and harms of 1) CFTR 
potentiators (for class III-IV mutations) and 2) CFTR correctors (for class II mutations) on clinically 
important outcomes in children and adults with CF.  
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Chapter 2  
Methods 
Evidence for the impact of CFTR potentiators and CFTR correctors on clinically important outcomes 
in CF was assessed by conducting two systematic reviews of published and unpublished research 
evidence. These reviews adhered to guidelines published in the Cochrane Handbook of systematic 
reviews on interventions.138  
2.1 Development of the review questions and review protocol 
2.1.1 Development and defining the research questions  
The PICO tables clearly define the components of the research question.  
Table 3 PICO table for development of review question for CFTR potentiators  
Review Question  Potentiators (specific therapies for Class III and 
IV mutations) for cystic fibrosis 
Population  Patients with Cystic Fibrosis with class III-IV 
mutation.  
Intervention  CFTR potentiators  
Not alongside other mutation specific therapies 
Comparator  Placebo 
Outcomes  Figure 10 
 
Table 4 PICO table for development of review question for CFTR correctors  
Review Question  Correctors (specific therapies for class II CFTR 
mutations) for cystic fibrosis 
Population  Patients with Cystic Fibrosis with class II 
mutations.  
Intervention  CFTR correctors  
Comparator  Placebo 
Outcomes  Figure 10 
 
To assess CFTR potentiators, we created the title: Potentiators (specific therapies for Class III and IV 
mutations) for cystic fibrosis. To assess CFTR correctors we created the title: Correctors (specific 
therapies for class II CFTR mutations) for cystic fibrosis. In both reviews, we did not limit the studies 
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to participants with mutation classes highlighted in the title if it was clinically relevant to include 
patients with other mutation classes.  
2.1.2 Development of the Review protocol  
These systematic reviews were conducted in accordance with peer assessed and published 
protocols.141, 142 The author of this thesis was involved in producing the protocol for the CFTR 
correctors review; the protocol for the CFTR potentiators review had been published by the other 
review authors prior to commencement of this MPhil. The purpose of the protocol stage was to 
introduce the reviews, and demonstrate the planned review methodology. We first set out a clear 
description of Cystic Fibrosis, the interventions to be assessed, and the objectives. We then outlined 
the proposed review methodology through pre-defined selection criteria, planned search strategies, 
planned data extractions and proposed methods of quality assessment and synthesis of results. The 
published protocols are attached.  
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2.2 Criteria for considering studies for this review  
2.2.1 Types of studies  
We only included RCTs of parallel design (published or unpublished). Cross-over trials were 
considered inappropriate given the potential longer term impact of these therapies on outcomes.  
2.2.2 Types of participants  
In both systematic reviews, we included trials involving children and adults with CF. CF was 
confirmed by the presence of two disease causing mutations, or a combination of positive sweat test 
and recognised clinical features of CF.   
In both reviews, we included trials of patients with relevant mutation classes. For example, CFTR 
potentiators aim to enhance the function of compromised CFTR already embedded in the cell 
membrane. This is classically seen in class III and IV mutations (Table 1), but also in minute amounts 
in patients with class II mutations, namely the ΔF508 mutation. We therefore did not exclude studies 
where CFTR potentiators were examined in participants with class II mutations, as it was important 
to demonstrate the impact of CFTR potentiators on the minimal amounts CFTR that reaches the cell 
membrane. We also included participants with all levels of disease severity.  
2.2.3 Types of Interventions 
CFTR potentiators review:  
We included studies comparing CFTR potentiators to either placebo or another intervention. Studies 
that compared a CFTR potentiator with another mutation specific therapy (for example a CFTR 
corrector) were excluded given their principal purpose was to potentiate and not correct the defect. 
We deemed it more appropriate for these studies to be included in a review of CFTR correctors.  
CFTR correctors review:  
We included studies that compared CFTR correctors either as monotherapy or as combination 
therapy with other mutation specific therapies (for example a CFTR potentiator), to either placebo or 
another intervention.  
2.2.4 Types of outcomes measures  
To date, a core outcome set for systematic reviews in Cystic Fibrosis has not been established. The 
Core Outcome Measures in Effectiveness Trials (COMET) initiative aims to create a COS for CF but for 
now the selection of outcomes in this review was created by the review authors.143 We included 
clinically meaningful outcomes relevant to patients, clinicians, consumers, the general public, 
administrators and policy makers. We included all relevant outcomes, even if they were not 
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reported in the included clinical trials. This ensured that all clinically important data was included 
and highlighted any gaps in the reporting of outcome measures by trialists.  
Outcome measures fall into three classes; 1) clinical end-points 2) surrogate endpoints and 3) 
biomarkers. Clinical outcomes indicate how the patient feels, functions or survives and include the 
resolution or removal of symptoms (e.g. QoL). A surrogate endpoint is a laboratory measurement 
used as a substitute for clinical endpoint to determine adverse effects of the therapy or to predict its 
efficacy (for example FEV1). It must be associated with a clinical outcome to be clinically meaningful 
and have a link to survival, long term prognosis or be an accepted measure of treatment effect. The 
definition of a biomarker is “a characteristic that is objectively measured and evaluated as an 
indicator of normal biologic processes, pathogenic processes, or pharmacologic response to a 
therapeutic intervention.” In CF, biomarkers are not yet recognised as surrogate outcome measures, 
but have become more relevant as with the emergence of personalised therapies..144  
Primary outcome measures  
Survival 
The ultimate goal of clinical trials in CF is to increase survival, as despite recent advances, CF remains 
a life-limiting disease. Therefore, the impact of the intervention on survival is the gold standard 
efficacy measure in CF clinical trials and systematic reviews.145 Longer survival rates amongst CF 
patients has meant that this outcome is having a more limited role in short clinical trials, particularly 
in children, but It is crucial for all parties whom this review is aimed at, to understand how the 
intervention may impact survival (Figure 8).146  
Figure 8  Examples of outcomes most important to patients provided by the Cochrane Handbook  
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Quality of life (QoL) 
Health related quality of life (HRQoL) is a patient reported outcome (PRO). In interventional studies, 
PROs provide a unique insight the patient’s perspective on the benefit or harms of treatment by 
scoring how patients feel and function with respect to their health.147 They are essential because 
they are the only outcome to gather this information. PROs are particularly valuable in CF clinical 
trials and systematic reviews as patients with CF have to endure aggressive and time consuming 
treatment on a daily basis.148  
In CF, there are two disease specific HRQoL instruments; the Cystic Fibrosis Questionnaire – Revised 
(CFQ-R) and the Cystic Fibrosis Quality of Life Questionnaires (CFQoL). 149, 150 To date, the CFQ-R scale 
is the most well recognised validated measure of HRQoL in CF with an established minimal clinically 
important difference (MCID) score of 4.151 As a test, it has demonstrated reliability and consistent 
associations with other health outcomes (e.g. FEV1) in large samples.152 It is also a feasible test; 
available for both adults (>14 years of age) and children (6-13 years of age) and can be completed 
relatively quickly (15 minutes). This QoL score consists of 9 QoL domains; physical functioning, 
vitality emotional state, social limitations, role limitations/school performance, embarrassment, 
body image, eating constraints; 3 symptom scales; respiratory, digestive, weight and 1 health 
perception scale; health status.   
Incorporating PROs into Cochrane systematic reviews of interventions for CF is highly valuable for 
patients and clinicians. PROs directly reflect how the participants of trials felt under the intervention; 
therefore any concerns highlighted by participants in the trials can be interpreted by patients as 
issues directly relating to them. This has a number of advantages. It empowers the patient to make 
informed decisions about personalised treatment plans, maintains the clinical relevance of Cochrane 
Systematic reviews to patients and provides a unique insight into how interventions can affect the 
lives of patients for healthcare professionals. 
In our systematic reviews we reported on total QoL scores and individual scores for different QoL 
domains. We reported results on HRQoL scores measured using any validated instrument (e.g. CFQ-
R). Both individual and pooled scores for adults and children were included.    
Physiological measures of lung function (litres or per cent predicted for age, sex and height) 
In our reviews we included the following physiological measures of lung function (litres or percent 
predicted for age, sex and height) 
1. Forced expiratory flow rate at one second (FEV1) (relative change from baseline) 
2. FEV1 absolute values (rather than change from baseline) 
48 
 
3. Forced vital capacity (FVC) (absolute values and change from baseline) 
Forced expiratory flow rate at one second (FEV1)  
FEV1 (% predicted) is a non-invasive test that measures the maximum amount of air that can be 
expelled in 1 second. It is then calculated as a percentage of normal, based on age, gender and 
height. The resultant Figure is used to reflect the degree of airway obstruction within the airways. In 
CF, the change in FEV1 is in line with the progression of obstructive airway disease (figure 9). 153 
Therefore in clinical trials and systematic reviews, the change in FEV1 is used to reflect the change in 
airway obstruction over time and is considered the best possible available method for linking airway 
disease to survival in patients with moderate to severe lung disease.153-155 Data for FEV1 is also used 
to determine and define disease severity, to inform clinical decisions about changing or intensifying 
treatment and to form recommendations on new therapies.156, 157, 158 This outcome is therefore 
relevant to patients, healthcare professionals and policy makers and is an important outcome in CF 
systematic reviews.  
In both reviews, the relative change from baseline in FEV1 was a primary outcome of interest. We 
also reported on the absolute change from baseline in FEV1.  
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Figure 9 A bar chart demonstrating the negative correlation between FEV1 and age in patients with 
Cystic Fibrosis  
 
Figure 9 demonstrates the association between increasing age and mean FEV1 % predicted in 
patients with CF. The bars represent the number of patients of a particular age group enrolled in the 
study and the dots represent the mean FEV1 % predicted for that age. The dots demonstrate the 
negative correlation between increasing age and FEV1 in patients with Cystic Fibrosis. This is in line 
with the progression of obstructive airway disease in CF.153 
Forced Vital Capacity (FVC)  
FVC is the maximum amount of air a person can breathe out after maximum inspiration. As the rate 
of FVC decline is also related to survival age, it is important to report on this outcome as a reflection 
of changes in airway disease.154 We reported on the relative and absolute change from baseline in 
FVC values.  
Secondary outcomes  
Adverse effects of therapy 
In systematic reviews there should be a balance between the reporting of beneficial and harmful 
effects of the interventions. This is particularly relevant in systematic reviews of novel therapies, as 
before an intervention can be recommended its benefits must outweigh potential harms.  
We classified adverse effects into three groups by severity:  
 Mild: Therapy does not need to be discontinued  
 Moderate: Therapy is discontinued and the adverse effect ceases (require study drug 
interruption)  
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 Severe: Life threatening or debilitating or which persists even after treatment is 
discontinued (require study drug discontinuation)  
This classification of reporting adverse effects was outlined in the Cochrane Handbook of systematic 
reviews.159  
Pulmonary exacerbations  
Pulmonary exacerbations and their management are described in the Introduction. To date, there 
are several definitions of pulmonary exacerbation but there is no consensus regarding its diagnostic 
criteria. Therefore, trialists can employ different definitions when reporting pulmonary 
exacerbations. There are two commonly used definitions: physician defined exacerbations and 
protocol-defined exacerbations. Physician defined exacerbations are based on episodes of 
worsening symptoms for which the attending physician decides that extra antibiotic are required. 
Protocol-defined exacerbations are defined on a specified cluster of symptoms and signs to define 
the clinical need for additional treatment with antibiotics.98 As there is not yet a set diagnostic 
criterion or definition for pulmonary exacerbations, they are not considered a standardised outcome 
in CF systematic reviews. Therefore it was not an individual outcome in these reviews. Data for 
pulmonary exacerbations were reported under other adverse effects, hospitalisations and extra 
courses of antibiotics. We stated whether they were physician-defined or protocol-defined.  
It is important to report on pulmonary exacerbations because they are associated with worse long 
term prognosis, reduced QoL and are an important clinical outcome for patients and clinicians.63-65 
Studies have also demonstrated that the rate at which pulmonary exacerbations occurs contribute 
to lung function decline.160 Therefore, we also reported on the time to next exacerbation to 
demonstrate what effect the intervention can have on lung function decline.  
Hospitalisation 
This clinical outcome was mainly included to account for data on pulmonary exacerbation. We 
reported on the number of days of hospitalisation and the number of subjects who required 
hospitalisations. It is important to report on hospitalisations because they represent a chaotic and 
stressful time for both patients and their families. Patients and family members may have to take 
extended periods of time off school or work and this can significantly burden social and family life. 
Studies of the impact of hospitalisations for exacerbations on QoL have demonstrated a decreased 
QoL amongst inpatients.161  
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School or work attendance (i.e. number of days missed) 
Whilst at school, children develop cognitive skills and develop their sense of identity through 
comparison with their peers. School attendance (lack of) highlights CF-related differences and can 
impacts the ability of children to form intimate relationships.162 School and work attendances are 
particularly important clinical outcomes for patients and their families, as they directly relate to 
functional ability.  
Extra courses of antibiotics (measured as time-to the next course of antibiotics and the total 
number of courses of antibiotics) 
This outcome was included to account for the data on pulmonary exacerbation. We reported on 
oral, intravenous and inhaled antibiotics.  
Radiological measures of lung disease (assessed using any scoring system) 
The use of surrogate end-points in clinical trials is particularly limited in young children (less than six 
years of age). This is because young children do not always co-operate with lung function tests and 
cannot expectorate sputum. Computerised Tomogram (CT) scan be performed across all ages, 
assesses structure and is the most sensitive tool for detecting early disease.163 Chest x-rays are 
insensitive to the early changes of CF, but can be used to identify later changes such as 
bronchiectasis and hyperinflation. We therefore included measures of lung disease using 1) chest 
radiograph scores and 2) computerised tomogram (CT) scores. 
Acquisition of respiratory pathogens 
In CF, there is much emphasis on preventing/postponing bacterial infection, colonisation and chronic 
infection because chronic infection with respiratory pathogens, especially P. aeruginosa, is 
associated with significantly poorer long term-prognosis.52 Therefore in CF systematic reviews it is 
important to demonstrate how new interventions can affect the rate at which respiratory pathogens 
are acquired.  
Infection with a respiratory pathogen is identified by sputum culture. The procedure of obtaining 
sputum (expectorated or induced) is standardised and can be conducted in all age groups, except 
young children, with minimal risk. We reported on the acquisition of pathogens under the following 
sub-headings: i) P. aeruginosa, ii) S. aureus, iii) H. influenza and iv) any other significant pathogens.  
Eradication of respiratory pathogens (as defined by trial authors) 
We included this outcome to demonstrate the ability of interventions to help eradicate pathogens. 
We reported on the eradication of pathogens under the following sub-headings: i) P. aeruginosa, ii) 
S. aureus, iii) H. influenza and iv) other significant pathogens.  
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Nutrition and Growth growth (measured as relative change from baseline) (including z scores 
or centiles) 
Poor nutritional status worsens long-term prognosis in CF as outlined in the Introduction.76 It is 
therefore important to demonstrate, particularly in children, how a novel therapeutic can impact 
weight and growth. We reported on i) weight ii) BMI and iii) height.  
Sweat chloride (change from baseline) as a measure of CFTR function 
Sweat chloride concentration is well-recognised diagnostic test in CF but in CF clinical trials, it is a 
biomarker; a direct representation of CFTR activity in sweats glands. Although its relevance may not 
be apparent to patients, it is important in CF clinical trials and systematic reviews to demonstrate 
changes in CFTR function. The concentration of chloride ions has a number of strengths as an 
outcome. It can detect rapid changes in CFTR activity, can be measured consistently in patients of 
young age (non-invasive) and sweat glands do not appear to be susceptible to secondary damage 
from the disease process (unlike lungs and GI tract).164 Although sweat chloride concentration is 
derived from CFTR activity in the sweat glands, results from clinical trials have demonstrate that 
sweat chloride concentration may be representative of CFTR function expressed elsewhere.164  
Cost of treatment  
This outcome was not part of the original set out outcomes defined in the protocol for the 
potentiators review. It was added in the review stage because it is likely that the investigated 
therapies (CFTR potentiators and CFTR correctors) will represent a significant healthcare resource in 
the future and therefore represents a significant healthcare cost.  
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2.2.5 Summary of criteria for considering studies for each review 
 
Table 5 Summary of Inclusion/exclusion criteria for the CFTR potentiators review  
 
CFTR Potentiators review 
 Inclusion criteria   Exclusion criteria   
Studies  Only RCTs of parallel design  1. RCTs of cross over design  
2. Studies that are not RCTs 
Participants  1. Children or adults with CF  
2. Patients with any clinically relevant class 
mutation (II-IV)  
3. Patients with any disease severity 
 
Interventions  CFTR potentiator versus placebo or another 
intervention.  
1. Studies where CFTR 
potentiators are used 
alongside other mutation 
specific therapies e.g. (CFTR 
correctors) 
2. Interventions that aim to 
correct the underlying 
defect (CFTR correctors) 
3. Studies assessing stop-
codon-therapies 
Outcomes  Studies assessing outcomes relevant to this 
review as detailed in Figure 10 
Studies assessing only 
outcomes not relevant to this 
review e.g. NPD and LCI 
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Table 6 Summary of Inclusion/exclusion criteria for the CFTR correctors review  
CFTR Correctors Review 
 Inclusion criteria   Exclusion criteria   
Studies  RCTs of parallel design  1. RCTs of cross over design 
2. Studies that are not RCTs 
Participants  1. Children or adults with CF  
2. Patients with any clinically 
relevant class mutation (II)  
3. Patients with any disease 
severity  
 
Interventions  1. CFTR corrector versus 
placebo or another 
intervention.  
2. CFTR corrector are used 
alongside other mutation 
specific therapies e.g. (CFTR 
potentiator) versus placebo 
or another intervention 
1. Studies examining stop-
codon-therapies.  
Outcomes  Studies assessing outcomes 
relevant to this review as 
detailed in Figure 10 
Studies only assessing 
outcomes not relevant to this 
review e.g. NPD and LCI  
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Figure 10 Summary of outcomes measures in our systematic reviews  
  
CFTR potentiators review  
Primary outcomes 
1. Survival  
2. Quality of life (QoL) (measured using validated quantitative 
scales or scores (e.g. Cystic Fibrosis Questionnaire-Revised) 
a. Total QoL score 
b. Different sub-domains which may be reported 
3. Forced expiratory flow rate at one second (FEV1) (relative 
change from baseline) 
Secondary outcomes 
1. Adverse effects 
a. Graded by review authors as mild (therapy does 
not need to be discontinued) 
b. Graded by review authors as moderate (therapy 
is discontinued, and the adverse effect ceases) 
c. Graded by review authors as severe (life-
threatening or debilitating, or which persists 
even after treatment is discontinued) 
d. Other adverse effects of therapy (of any 
severity) that are not classifiable according to 
these categories 
2. Hospitalization 
a. Number of days 
b. Number of episodes 
3. School or work attendance (i.e. number of days missed)  
4. Other physiological measures of lung function (litres or per 
cent (%) predicted for age, sex and height) 
a. FEV1 absolute values (rather than "relative 
change from baseline", which is specified as 
primary outcome) 
b. Forced vital capacity (FVC) (absolute values and 
change from baseline) 
5. Extra courses of antibiotics (measured as time-to the next 
course of antibiotics and the total number of courses of 
antibiotics) 
a. oral 
b. intravenous 
c. inhaled 
6. Radiological measures of lung disease (assessed using any 
scoring system) 
a. chest radiograph scores 
b. computerised tomogram (CT) score 
7. Acquisition of respiratory pathogens 
a. Pseudomonas aeruginosa (P. aeruginosa) 
b. Staphylococcus aureus (S. aureus) 
c. Haemophilus influenzae (H. influenzae) 
d. Other significant pathogen 
8. Eradication of respiratory pathogens (as defined by trial 
authors) 
a. Pseudomonas aeruginosa (P. aeruginosa) 
b. Staphylococcus aureus (S. aureus) 
c. Haemophilus influenzae (H. influenzae) 
d. Other significant pathogen 
9. Nutrition and growth (measured as relative change from 
baseline) (including z scores or centiles) 
a. Weight 
b. Body mass index (BMI) 
c. Height 
10. Sweat chloride (change from baseline) as a measure of 
CFTR function 
11. Cost of treatment 
 
CFTR correctors review  
Primary outcomes 
1. Survival  
2. Quality of life (QoL) (measured using validated quantitative 
scales or scores (e.g. Cystic Fibrosis Questionnaire-Revised) 
a. Total QoL score 
b. Different sub-domains which may be reported 
3. Physiological measures of lung function  
a. Forced expiratory flow rate at one second 
(FEV1) (relative change from baseline) 
b. FEV1 absolute values  
c. Forced vital capacity (FVC) (absolute values and 
change from baseline) 
Secondary outcomes 
1. Adverse effects 
a. Graded by review authors as mild (therapy does 
not need to be discontinued) 
b. Graded by review authors as moderate (therapy 
is discontinued, and the adverse effect ceases) 
c. Graded by review authors as severe (life-
threatening or debilitating, or which persists 
even after treatment is discontinued) 
d. Other adverse effects of therapy (of any 
severity) that are not classifiable according to 
these categories 
2. Hospitalization 
a. Number of days 
b. Number of episodes 
3. School or work attendance (i.e. number of days missed)  
4. Extra courses of antibiotics (measured as time-to the next 
course of antibiotics and the total number of courses of 
antibiotics) 
a. oral 
b. intravenous 
c. inhaled 
5. Radiological measures of lung disease (assessed using any 
scoring system) 
a. chest radiograph scores 
b. computerised tomogram (CT) score 
6. Acquisition of respiratory pathogens 
a. Pseudomonas aeruginosa (P. aeruginosa) 
b. Staphylococcus aureus (S. aureus) 
c. Haemophilus influenzae (H. influenzae) 
d. Other significant pathogen 
7. Eradication of respiratory pathogens (as defined by trial 
authors) 
a. Pseudomonas aeruginosa (P. aeruginosa) 
b. Staphylococcus aureus (S. aureus) 
c. Haemophilus influenzae (H. influenzae) 
d. Other significant pathogen 
8. Nutrition and growth (measured as relative change from 
baseline) (including z scores or centiles) 
a. Weight 
b. Body mass index (BMI) 
c. Height 
9. Sweat chloride (change from baseline) as a measure of 
CFTR function 
10. Cost of treatment 
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2.3 Search Methods for identification of studies  
2.3.1 Electronic Searches  
A literature search was conducted with help from the Trials Search Co-ordinator from the Cochrane 
Cystic Fibrosis and Genetic Disorders Group (CFGD). To identify relevant trials, we conducted a 
search of the group’s Cystic Fibrosis trials register. This register is compiled from electronic searches 
of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of The 
Cochrane Library), MEDLINE (quarterly searches), EMBASE to 1995 and hand searching two journals - 
Pediatric Pulmonology and the Journal of Cystic Fibrosis. Studies were also identified by searching 
through the abstract books of three major cystic fibrosis conferences: the International Cystic 
Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis 
Conference.  
 
After each search of these databases and journals, all relevant trials were tagged with keywords and 
key terms developed by the CFGD. For the CFTR potentiators review, the keywords were; 
‘potentiator’, ‘VX-770’ and ‘genistein.’ Trials relating to one of these keywords were tagged with the 
appropriate keyword and all trials relating to these keywords were tagged with the key term; ‘drugs 
that augment function of abnormal CFTR protein in the cell membrane.’ For example, if a study on 
VX-770 was identified, it would be tagged with keyword ‘VX-770’ and also key term ‘drugs that 
augment function of abnormal CFTR protein in the cell membrane.’  
 
To identify all relevant studies for the CFTR potentiators review, we searched the Cystic Fibrosis 
trials register with the term; ‘drugs that augment function of abnormal CFTR protein in the cell 
membrane.’ An Example of the search strategy is demonstrated in Figure 11.  
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Figure 11 Example of search strategy for trials in the CFTR potentiators review  
 
 
The date of the last search of the Cystic Fibrosis trials register for studies to include in the CFTR 
potentiators review was the 13th February 2014. We also searched clinical trial registries maintained 
by the European Medicines Agency, the US National Institute of Health (clinicaltrials.gov) and the 
World health organisation (WHO). We identified on-going studies by using the terms ‘Cystic Fibrosis 
AND Ivacaftor OR VX-770’ and ‘Cystic Fibrosis AND genestein.’ The date of the last search of the 
trials registries maintained by these organisations was the 6th February 2014.  
The same search strategy was employed to search for eligible RCTs of CFTR correctors. For CFTR 
corrector therapies, studies relevant to the keywords; “corrector”, “CPX”, “VX-661”, “VX-809”, 
“phenylbutyrate”, “glycerol” and “miglustat” were identified and tagged and all relevant studies 
were tagged with the key term ; ‘drugs that correct defects in CFTR transcription, translation or 
processing.’ So on conducting the review, we entered the term; ‘drugs that augment function of 
abnormal CFTR protein in the cell membrane’ into the Cystic Fibrosis trials register to identify 
relevant trials.  
 
  
Figure 11 demonstrates the search strategy used for identifying trials for the CFTR potentiators 
review. All relevant trials had been tagged with the key term ‘drugs that augment function of 
abnormal CFTR protein in the cell membrane.’ 
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Figure 12 Example of search strategy for trials in the CFTR correctors review  
 
 
The date of the last search of the Cystic Fibrosis trials register for studies to include in the CFTR 
correctors review was the 13th February 2014. We also searched clinical trial registries maintained by 
the European Medicines Agency, the US National Institute of Health (clinicaltrials.gov) and the WHO 
for additional studies using CFTR correctors. We identified relevant on-going studies by using the 
terms “Cystic Fibrosis and corrector”, “Cystic Fibrosis and CPX”, “Cystic Fibrosis and VX-661”, “Cystic 
Fibrosis and VX-809”, “Cystic Fibrosis and phenylbutyrate”, “Cystic Fibrosis and glycerol” and “Cystic 
Fibrosis and miglustat.” The date of the last search of the trials registries maintained by these 
organisations was the 13th February 2014.  
2.3.2 Searching other resources  
We also screened references of included trials and contacted the authors of included trials, leaders 
in the field and pharmaceutical companies to identify any published and unpublished studies that 
may have been missed by these searches.  
  
Figure 12 demonstrates the search strategy used for identifying trials for the CFTR potentiators 
review. All relevant trials had been tagged with the key term ‘drugs that correct defects in CFTR 
transcription, translation or processing.’ 
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2.4 Data collection, risk of bias assessment and statistical analysis  
2.4.1 Selection of studies  
Two authors (IS and SP) independently assessed the suitability of each trial for inclusion into the 
review using the pre-defined eligibility criteria. If disagreements arose on the suitability of a trial for 
inclusion, we attempted to reach a consensus by discussion, failing which a third author arbitrated. 
Trials were included, excluded or considered on-going.  
2.4.2 Data extraction and management  
Once we had agreed on eligible studies, we independently extracted relevant data from each 
included trial using a standardised data extraction form. If disagreement arose on data extraction, 
we attempted to reach a consensus by discussion, failing which a third author arbitrated.  
We reported on our primary outcome 'survival' as a binary outcome as time-to-event data was not 
available. Where possible, we reported the relative change from baseline in FEV1, since this way of 
presenting FEV1 accounts for variance in baseline characteristics between groups and is very 
important in clinical practice. If this was not possible, we reported absolute change from baseline in 
FEV1 as a secondary outcome. We planned to report on QoL as the relative change from baseline in 
QoL but it was not possible to do this and insert the result in the analysis. We therefore extracted 
QoL as the absolute change from baseline.  
With regards to the secondary outcome 'adverse effects' we extracted the total number of 
participants who experienced adverse effects and the total number of participants who required 
trial drug interruption or termination (Table 7)  
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Table 7 Example of a data extraction table for moderate and severe adverse effects of therapy 
   Study ID  Study ID  
Number of 
participants that 
required study drug 
Interruption 
(moderate) 
Intervention group       
Placebo group       
Total number of 
participants that 
required study drug 
Interruption 
Intervention group + 
placebo group 
     
Number of 
participants that 
require study drug 
discontinuation 
(severe) 
Intervention group       
Placebo group       
Total number of 
participants that 
require study drug 
discontinuation 
Intervention group + 
placebo group 
     
 
When extracting data on pulmonary exacerbations, we noted whether they were protocol-defined 
or physician-defined. We reported the number of participants who experienced episodes of 
pulmonary exacerbation and reported time-to-exacerbation data if possible. We extracted the 
number of participants who required hospitalisations, the average number of days hospitalised, and 
the number of participants who required extra courses of antibiotics.  
For the secondary outcomes 'change from baseline in weight' and 'change from baseline in sweat 
chloride concentration', we extracted the absolute change from baseline results. Where data were 
provided on acquisition or eradication of respiratory pathogens, or radiological measures of lung 
disease, we reported data using the scoring system employed by the trialists. If data were reported 
on school or work attendance, we planned to report on the number of days missed.  
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For continuous outcomes, we extracted means and standard deviations (SDs). Where SDs were not 
provided, we calculated the standard error of the mean (SEM) from the 95% confidence intervals 
(CIs) and inserted the results into a generic inverse variance (GIV) analysis. Where outcomes were 
reported as dichotomous data, we compared the results in the intervention group to the results in 
the placebo group in the analysis. Where trials with multiple intervention groups reported 
dichotomous data i.e. adverse effects, we pooled the data to form one intervention group and 
compared data to the placebo group as recommended by the Cochrane Handbook (section 
16.5.4).165 Where multiple intervention groups were present, and it was not appropriate to combine 
the data from treatment groups, we presented the data in a table in the text. If the trial author 
presented non-parametric data, we reported results in the written text and not in the analysis. 
For the potentiators review, we reported data at 4 weeks, 16 weeks, 24 weeks and 48 weeks. In the 
correctors review, we reported results as short term (less than one month), long term (less than six 
months) and longer term (greater than six months).  
2.4.3 Risk of bias assessment (methodological quality) 
Bias is defined as systematic error, or deviation in truth in results that can lead to underestimation or 
overestimation in the true effect of the intervention.166 It is ascribed to flaws in design, conduct or 
analysis. In systematic reviews, risk of bias (RoB) influences the internal validity of the review, and 
thus the conclusions that can be drawn from it. Therefore, it is imperative that RoB assessment is 
part of critical appraisal process.   
In Cochrane systematic reviews, bias is assessed using the Cochrane Risk of Bias Tool (Table 8).167 
This tool involves assessment of following six RoB domains; 1) selection bias 2) performance bias 3) 
attrition bias 4) detection bias 5) reporting bias and 6) other sources of bias. Trials are judged as 
having either low risk, unclear risk or low risk of bias.167 The advantage of the Cochrane risk of bias 
tool over scales or category tools is that the judgements (high risk, low risk or unclear risk) are 
supported by a narrative explanation so readers can clearly see what methodological features 
influenced the decision on risk of bias. Also, with this tool, figures can be created to demonstrate 
graphically the risk of bias across the included trials. The disadvantage of this tool is that the 
assessments are subjective and therefore are dependent on the skill and experience of the 
assessors.168 For this reason, the Cochrane handbook provides examples of methodological features 
that should influence judgement, and for each review at least two authors are required to carry out 
the assessment. In these systematic reviews, two authors (IS and SP) assessed the risk of bias for 
each trial and If disagreement arose, attempts were made to reach a consensus by discussion, failing 
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which a third author (KWS or MS) arbitrated. Further description of the risk of bias domains is 
provided.  
Table 8 Cochrane Risk of Bias Tool  
 
Table 8 demonstrates the different risk of bias domains included in the Cochrane Risk of bias too, 
factors for review authors to consider when assessing these domains and the bias they can 
introduce.168  
Selection bias  
Selection bias refers to systematic differences in baseline characteristics in enrolled participants. 169 
Baseline characteristics in clinical trials of CF include demographic variables (age, gender, race, 
genotype) and prognostic variables (FEV1, BMI, sweat chloride concentration) that act as potentially 
confounding factors.170 If participants with particular baseline characteristics are deemed likely to 
benefit from the intervention, and subsequently assigned to the intervention group, this can lead to 
an over-estimation of the treatment effect. Assessment of selection bias has two parts; 1) random 
sequence generation and 2) allocation concealment (random sequence implementation). Random 
sequence generation refers to the generation of a random sequence to assign participants to either 
intervention or control group. When steps are taken to secure implementation of the random 
allocation sequence without foreknowledge of treatment assignments allocation is said to be 
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concealed.171 Inadequate randomisation and or allocation concealment have been demonstrated to 
over-estimate the treatment effect.172  
Random sequence generation  
Proper randomisation ensures that each participant enrolled into the study has an equal chance of 
being allocated to either the control or the intervention group. Improper randomisation over-
estimate the treatment effect and type 1 error (falsely rejecting the null hypothesis).173 We assessed 
what methods trialists employed to generate a random sequence and judged the method as either 
posing a high, low or unclear risk of bias. If, for example, a computer generated a list of random 
assignments, this would have been deemed low risk of bias. Trials that simply stated that they were 
‘randomised’ and did not provide a method of randomisation were judged to have an unclear risk of 
bias.   
Allocation concealment 
Allocation concealment ensures that neither participants nor study personnel are aware of which 
groups participants will be assigned to. It occurs before the intervention is administered and 
therefore can always be implemented (unlike blinding).174 Improper allocation concealment can 
undermine the effects of random assignment as trialists, who are aware of assignment, can exclude 
participants based on allocation to the ‘inappropriate’ group. Results from clinical trials have 
demonstrated that improper allocation concealment can affect the estimated treatment effect by up 
to 40%.171 In these systematic reviews, we assessed what methods trialists employed to conceal 
allocation and judged the method as posing either a high, low or unclear risk of bias. If for example, 
participants were allocated through a secure computerised voice system, we considered this method 
of having a low risk of bias.  
Blinding of study personnel and outcome assessors (performance bias and detection bias) 
Performance bias relates to differences in the way participants are treated with regards to care 
and/or exposure to other factors by study personnel.169 It is minimised by blinding (masking) 
personal involved with the conduct of the study; for example clinicians after allocation. Detection 
bias refers to differences in how outcomes are assessed.169 It is minimised by blinding outcome 
assessors to treatment assignment. Blinding of study personnel prevents knowledge of treatment 
assignment and thus favourable care towards participants in a particular group. We assessed 
whether study personnel and outcome assessors were blinded, and the methods employed to 
maintain blinding.   
Blinding of study participants (Performance bias)  
Inadequate blinding of study personnel also makes the trial vulnerable to performance bias.169 It is 
particularly important when considering PROs, which are vulnerable to being influenced by patient’s 
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pre-existing beliefs regarding the benefits or harms of the intervention. In addition, surrogate 
outcomes, for example FEV1, can differ due to the participant’s enthusiasm, driven by their 
allocation to a particular group.  
In both reviews we assessed whether trialists blinded participants to treatment assignments and the 
methods used to maintain the blind. We specifically assessed for reports on matching of the 
intervention and placebo for example in taste, colour, size, shape of oral tablet to and searched the 
trial report for evidence of similar treatment schedules between groups. Any evidence to suggest 
the possibility of participants finding out about treatment assignment, for example different 
coloured tablets between groups, was judged to have a high risk of bias.   
Attrition bias  
Attrition bias refers to systematic differences in withdrawals from the study.169 It has two 
components; 1) withdrawals - referring the proportion of participants who withdrew from the study 
and 2) missing data - referring to whether an intention to treat analysis (ITT) was employed in the 
analysis. Participants can withdraw from the trial due to various reasons; adverse effects, loss to 
follow up and by patient’s request. If the differences in characteristics between groups created by 
withdrawals relates to outcome measures, this can introduce attrition bias.175 There is no specific 
proportion of withdrawal at which attrition bias is considered a problem. However, if a high 
proportion of participants (approximately >20%) withdraw from the study, authors should be 
concerned about the possibility of attrition bias.176 In an ITT analysis, data from all randomised 
participants is used in the analysis, ignoring withdrawals, protocol deviations and noncompliance 
occurring after randomisation. This approach prevents exclusion of withdrawn participants with 
poor prognostic characteristics from being omitted from the analysis and thus over-estimation of 
treatment effect.177  
In order to assess the impact of withdrawals on attrition bias, we calculated the percentage of 
participants who withdrew. If <15% of overall participants withdrew, the trials were judged to be of 
low risk of attrition bias in relation to withdrawals. In order to assess whether an intention-to-treat 
analysis was conducted, we extracted data on the number of participants with each outcome event, 
by allocated treated group, irrespective of compliance and whether or not the participant was later 
thought to be ineligible or otherwise excluded from treatment or follow-up. We also checked to see 
whether this information was consistent with the data presented on the US online trials registry 
(ClinicalTrials.gov). If data were missing or unclear, we sought why these participant’s data had been 
excluded, either by scanning the text or by contacting the primary investigators for clarification. If 
participant data had been excluded from the analysis for reasons that could introduce bias, it was 
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considered to have a high risk of attrition bias in relation to missing data. For example, if 
intervention assigned participant data were excluded because they withdrew due to adverse effects, 
this could have led to an over-estimation of the treatment effect because these participants may 
have had unfavourable measurements. If the trial was deemed to have a high risk of attrition bias 
with relation to either withdrawals or missing data, it was judged to be of a high risk of overall 
attrition bias.   
Outcome reporting bias  
Outcome reporting bias refers to selective reporting of some outcomes but not others.178 It is found 
in a large proportion of published trials and therefore represents a significant problem that affects 
the conclusions of systematic reviews.179 The different factors involved in assessment of a trial for 
selective outcome reporting are shown in table 9.180, 181 
Table 9 Factors to consider when assessing a trial for selective outcome reporting  
1. Selective omission of outcomes: outcomes present in review protocol or the methods of the 
full report are not reported in the results.  
2. Incomplete reporting of outcome data: outcome data is not reported in sufficient detail for 
inclusion in meta-analysis (e.g. only reporting P values and not 95%CIs) 
3. Selective choice of measurement for assessing an outcome: reporting on outcomes using a 
form of measurement that was not pre-specified  
4. Selective reporting of analysis using the same data: reporting on outcomes using a form of 
analysis that was not pre-specified  
5. Selective reporting of subsets of the data: reporting on outcomes on a subset of 
participants that was not pre-specified  
6. Selective reporting of data for outcomes not pre-specified in trial protocol: reporting on an 
outcome that was not included in the protocol.  
7. Omission of key outcomes: omission of outcomes considered key and expected to have 
been reported in such clinical trial.  
 
In these reviews, in order to identify selective outcome reporting, we compared outcomes described 
in the trial protocol with those reported in the publications. We requested protocols for specific 
trials from the primary investigators when they were not available. We have recorded the 
proportion of protocols that were available to us. If the protocol was not available or provided, we 
checked available information on the trial registry databases (e.g. clinicaltrials.gov). We also 
compared outcomes listed in the 'Methods' section of the final paper with those presented in the 
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'Results' section. If the published papers reported negative findings either only partially, or not at all, 
we contacted primary investigators for these data. If discrepancies in outcome reporting were found 
we judged the trials to have a high risk of outcome reporting bias because of the association this has 
with over-estimation of the treatment effect.182 We also assessed the publications for points 2-7 
from table 9, and where potential sources of selective outcome reporting were identified; we 
contacted the trial authors for clarification. Whether selective reporting in points 2-7 were judged 
sufficient reason to judge the trial as having a high risk of selecting outcome reporting bias, was 
based on the subjective assessments of the authors.  
We planned to assess publication bias by constructing and assessing the symmetry of a funnel plot. 
This would have been possible if we had included more than 10 trials in the review. 
Other sources of bias  
This section is for all other potential sources of bias.168 The review authors assessed for differences 
in baseline characteristics.  
Overall methodological quality  
For each review, we assessed the overall methodological quality of the included studies from the 
assessments of the risk of bias in each domain for each study.  
2.4.4 Statistical analysis  
Measurement of treatment effect  
Meta-analysis was conducted with RevMan 5.  
For binary outcomes, we calculated a pooled estimate of the treatment effect for each outcome 
using the pooled odds ratio (OR) and 95% CIs. If calculating a pooled OR was not appropriate, we 
calculated an estimate of the treatment effect for each outcome using the OR and 95% CIs. 
For continuous outcomes, we calculated the mean change from baseline for each group or the mean 
post-intervention values and 95% CIs for each group. We produced a pooled estimate of treatment 
effect by calculating the mean difference (MD) and 95% CIs. For QoL, CFQ-R was the most frequently 
used questionnaire and so we calculated the MD and 95% CIs. No other questionnaire was used. 
For time-to-event outcomes, such as 'time to first pulmonary exacerbation', we used measures of 
survival analysis, and calculated hazard ratios (HR) and 95% CIs between different arms of the trial. 
Where included trials did not report change data, but instead presented absolute post-treatment 
data without baseline data so it was not possible to calculate change data, we planned to use 
absolute post-treatment data instead of change from baseline. However, if the report presented 
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baseline and post-treatment data for any outcome, we calculated SDs for the change from baseline, 
for example if the CI was available. If there was not enough information available to calculate the 
SDs for the changes, we planned to impute them from other trials in the review, where data were 
available and trials were similar (i.e. when they used the same measurement scale, had the same 
degree of measurement error and had the same time periods between baseline and final value 
measurement). If neither of these methods were possible, we planned to calculate a change-from-
baseline SD, making use of an imputed correlation coefficient (methods described in section 16.1.3.2 
in the Cochrane Handbook of Systematic Reviews of Interventions).165 
Unit of analysis issues 
Within these reviews, we only included results from RCTs of parallel design in which individual trial 
participants were randomised. We excluded cross-over trials, because they are not appropriate for 
evaluating therapies that potentially correct the underlying defect.  
Heterogeneity  
In systematic reviews, data from several trials are synthesised to create an overall pooled estimate. 
One can expect there to be differences in results between included trials. However it is important to 
determine whether this variability (heterogeneity) is due to either ‘random play of events’ (chance), 
in which case synthesis of data is appropriate, or other factors that further require investigation.183 
Heterogeneity requiring further investigation can be categorised into three types: clinical, 
methodological and statistical. Clinical heterogeneity refers to differences in the participants, 
interventions and outcomes between each trial. When there is variability in study design and or risk 
of bias, it is known as methodological heterogeneity. Statistical heterogeneity considers both clinical 
and methodological heterogeneity and refers to differences in results being more different than 
expected if simply due to random chance.184 In this review, statistical heterogeneity is referred to 
simply as heterogeneity.  
We planned to assess heterogeneity through a visual examination of the forest plots.185 If the results 
of studies ‘lined up’ on the forest plot, we assumed little heterogeneity. We also considered the I2 
statistic together with chi2 values and their CIs.184 This reflects the likelihood that the variation of 
results across trials was due to heterogeneity rather than chance, and we interpreted the I2 statistic 
using the following classification: 
 0% to 40%: might not be important; 
 30% to 60%: may represent moderate heterogeneity; 
 50% to 90%: may represent substantial heterogeneity; 
 75% to 100%: considerable heterogeneity. 
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This test was designed for analysis of heterogeneity in meta-analysis including large number of trials. 
Therefore we interpreted these test results with caution when only a small number of included trails 
were included.184 
Data synthesis 
Meta-analysis can use either a fixed effect or a random effects statistical model. A fixed effect model 
is used when there is no heterogeneity between included studies so the effect estimate of the 
treatment is the same between including trials and any variability is due to chance alone. A random 
effects model assumes that estimates of treatment effect vary between included trials due to both 
real differences in treatment effect and chance.186 In the potentiators review, we used a fixed-effect 
model to analyse data from trials that we did not consider to be heterogeneous. When substantial or 
considerable heterogeneity was present (I2 greater than 50%), we used a random-effects model to 
analyse data.  
In the correctors review, different interventions were being assessed (clinical heterogeneity) and so 
we always employed random effects model.  
Subgroup analysis and investigation of heterogeneity 
We planned to investigate any heterogeneity that we identified using subgroup analyses of potential 
confounding factors, if sufficient numbers (at least 10 trials) were available. For this review, we 
planned that these confounding factors would be: 
 age (children (defined as younger than 18 years of age) versus adults); 
 gender; 
 different mutation classes (Table 1)  
As we did not seek individual patient data from trial investigators, we did not undertake a subgroup 
analysis on the basis of disease severity.  
Sensitivity analysis 
If we had been able to combine a sufficient number of trials (at least 10), we planned to examine the 
impact of risk of bias on the results examined by comparing meta-analyses including and excluding 
trials with concerns of high risk of selection or reporting bias due to issues relating to randomisation, 
allocation concealment, or masking of interventions from participants or trial personnel. 
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Chapter 3 
Results 
In this section, I have highlighted the main findings of the reviews that are attached to this thesis. I 
have also report the results of the discussions held between the Cochrane Cystic Fibrosis Systematic 
Reviews team whilst conducting the reviews. For a more detailed report of the results please refer to 
result section of the completed reviews, attached in the appendix.   
3.1 Summary of findings from the CFTR potentiators review  
3.1.1 Results of the literature search  
We identified a total of 90 publications representing 21 trials.117-120, 123, 125, 127, 133, 135, 187-197 All 
publications were identified from searches of electronic databases and hand searching of conference 
abstracts. No additional studies were identified by contacting the pharmaceutical company 
responsible for conducting clinical trials investigating Ivacaftor (E-mail 1). After application of the 
eligibility criteria to the 21 trials, four trials (42 references) were included198-201, 16 trials (47 
references) were excluded117-120, 123, 125, 127, 133, 135, 187-192, 197 and four were ongoing193-196. Results of the 
search are displayed in a PRISMA flow diagram (Figure 13). Relevant data were extracted from each 
of the four eligible trials by two authors (SP and IS) independently and when comparing the two data 
exertion forms, no disagreements arose. The data extraction forms for each of the 4 studies are 
included in the appendix (Data extraction Tables 1-4).   
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Figure 13 A PRISMA flow diagram demonstrating the results of the literature search. 
90 publications (abstracts and full 
papers) representing 21 trials were 
identified through database 
searching. 
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90 publications (abstracts and full papers) 
representing 21 trials and 3 trials identified 
from the on-going trials database remained 
after duplicates were removed 
All 24 trials were 
screened 
16 trials (47 references) 
were excluded and 4 trials 
were on-going. 
Full-text articles of 4 trials 
(42 references) were 
assessed for eligibility 
0 trials were excluded. 
 
All 4 were trials included 
in qualitative synthesis 
 
4 studies were included in 
quantitative synthesis 
(meta-analysis) 
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3.1.2 Characteristics of included studies  
Four trials with 378 participants met the inclusion criteria for this review.198-201 All included trials 
were multicentre RCTs of parallel design, sponsored primarily by Vertex Pharmaceuticals 
Incorporated and examined the impact of Ivacaftor. In three of the four trials, possessing at least 
one G551D allele (Class III) was an important eligibility criterion. The first G551D trial was a phase 2 
trial enrolling patients 18 years and over (n=19) and measuring a number of outcomes at 14 and 28 
days. We called this study the Phase 2 G551D study.201 This was followed by two phase 3 G551D 
trials, the first enrolling patients ages 12 years and older (n = 167) (child phase 3 G551D study) and 
the second enrolled patients aged 6 to 11 years (n = 52) (adult phase 3 G551D study). These trials 
reported outcomes at 24 and 48 weeks.198, 200 The remaining trial examined Ivacaftor for patients 
with ΔF508 and enrolled participants aged 12 years or over (n = 140) for a duration of 16 weeks 
(Flume 2011). We called this trial the ΔF508 trial.199 The primary end-points for these studies were 
safety201 or change in FEV1198, 200 or both.199 A summary of the characteristics of the included studies 
(Table 10), on-going studies (Table 11) and reasons for exclusions (table 12) are provided.  
We approached all the trial authors of the included studies for data on outcomes reported in our 
systematic review, but not reported in the published trials (E-mail 1, 4, 7 and 11). Two out of the 
four authors responded, with no additional data to add (E-mail 2 and 4). In light of the response 
from Vertex in E-mail 1 we did not approach the authors of the three on-going studies (DeBoeck 
2014, Moss 2013, Nick 2014) also sponsored by Vertex for unpublished data. The remaining on-going 
study had only recently begun and was still recruiting patients.196 
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Table 10 Characteristics of studies included in the CFTR potentiators review   
 Study design Participants Interventions Outcomes 
Study  Study 
design  
Commercial 
research 
support 
Treatment 
period 
(weeks) 
Number 
of sites   
Number of 
participants  
Age 
group 
(years 
of 
age) 
Genotype  Intervention Control  Primary 
outcome 
Secondary 
outcomes 
Accurso 
2010201 
RCT of 
parallel 
design  
Vertex 
Pharmaceuticals 
Incorporated 
4  13 sites in 
North 
America 
and 
Europe 
19 > 18 ≥ 1 G551D  150mg and 
250 mg 
Ivacaftor BD 
Placebo  Safety  NPD. Δ BL 
QoL, 
Spirometry, 
sweat cl 
Ramsey 
2011198 
(adult 
G551D) 
RCT of 
parallel 
design 
Vertex 
Pharmaceuticals 
Incorporated 
48 29 sites in 
North 
America, 
Europe 
and 
Australia 
167 > 12 ≥ 1 G551D  150mg 
Ivacaftor BD 
Placebo  absolute 
change in 
FEV1 
Δ BL 
spirometry, 
weight, 
sweat cl,  
CFQR score 
& safety  
Davies 
2013200 
(child 
G551D) 
RCT of 
parallel 
design 
Vertex 
Pharmaceuticals 
Incorporated 
48 65 sites in 
North 
America, 
Europe 
and 
Australia 
52 6-11 
years 
≥ 1 G551D  150mg 
Ivacaftor BD 
Placebo  absolute 
change in 
FEV1 
Δ BL 
spirometry, 
weight, 
sweat cl 
CFQR score 
& safety 
Flume 
2011199 
(ΔF508 
study) 
RCT of 
parallel 
design 
Vertex 
Pharmaceuticals 
Incorporated 
16 34 sites in 
North 
America 
140 > 12 Homozygous 
ΔF508 
150mg 
Ivacaftor BD 
Placebo  Safety 
and 
absolute 
change in 
FEV1 
Δ BL sweat 
cl, weight, 
CFQR score 
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Table 11 Characteristics on-going of studies examining CFTR potentiators   
Study and title Sponsor Methods Participants. 
Confirmed 
diagnosis of CF +: 
Interventions Outcomes 
(NB  Δ BL indicates 
change from 
baseline) 
Status  at 
literature search 
De Boeck 2013 193 
“Ivacaftor in Subjects With 
Cystic Fibrosis Who Have a 
Non-G551D CFTR 
Gating Mutation 
(KONNECTION).” 
(NCT01614470) 
Vertex 
Pharmaceuticals 
Incorporated 
A phase 3, double-
blind, RCT of cross-
over design. 
1. At least 1 allele 
of pre-specified 
gating mutations. 
5. ≥ 6 years old 
Ivacaftor 150 mg 
orally 2x daily. 
Primary; Δ BL FEV1. 
Secondary: 
Δ BL in BMI, Sweat 
chloride and CRQ-R 
score 
No data available  
 
Moss 2013194 
“Study of Ivacaftor in 
Subjects With Cystic Fibrosis 
Who Have the R117H-CFTR 
Mutation (KONDUCT)” 
NCT01614457 
Vertex 
Pharmaceuticals 
Incorporated 
Phase 3, double-
blind, RCT of 
parallel design 
with outcomes 
measured at 24 
weeks  
1. At least 1 allele 
of the R117H-CFTR 
mutation. 
3. ≥ 6 years old 
Ivacaftor 150 mg 
orally 2x daily for 
24 weeks. 
Primary: Δ BL FEV1. 
Secondary: Δ BL 
BMI , Sweat 
chloride, CRQ-R 
score and time to 
first pulmonary 
exacerbation 
No data available  
 
Nick 2014 195 
“Study Testing the Effect of 
Ivacaftor on Lung Function in 
Subjects With Cystic Fibrosis 
and Residual CFTR Function” 
(NCT01685801) 
Vertex 
Pharmaceuticals 
Incorporated 
Phase 2, double-
blind RCT of 
crossover design 
with 4 treatment 
arms. 
1. Clinical evidence 
of residual CFTR 
function 
4. ≥ 12 years old 
Ivacaftor 150mg 
orally 2x daily. 
Primary:  Δ BL FEV1 
(4 weeks) 
Secondary: LCI (4 
and 8 weeks), Δ BL 
FEV1, sweat 
chloride, weight (8 
weeks) and Safety.  
On-going, no data 
available  
Nielson 2014 196 
“Short-Term Effects of 
Ivacaftor in Non-G551D 
Cystic Fibrosis 
Patients”(NCT01784419) 
University of 
California, San 
Francisco 
Double-blind RCT 
of cross-over 
design. 
1. Signs of residual 
CF channel 
function. 
Ivacaftor 150 mg 
2x daily. 
 
Primary: Δ BL 
Sweat chloride. 
Secondary: 
spirometry and 
multi-breath 
washout testing. 
Still recruiting 
patients  
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Table 12 Studies excluded from the CFTR potentiators review    
Study ID Reason for exclusion  
Accurso 2013187 Cross-over trial. 
Donaldson 2013123 
 
Compared CFTR potentiators with another 
mutation-specific therapy and not placebo. 
Clancy 2012125 
 
Intervention to correct molecular defect, not 
potentiate. 
Davies 2012189 Cross-over design. 
Altes 2011188 Cross-over design. 
Boyle 2011127 Compared CFTR potentiators alongside another 
mutation-specific therapy.  
Sermet-Gaudelus 2010135 Intervention for stop codon mutations. 
Wilschanski 2008197 Intervention for stop codon mutations. 
Rubenstein 2006192 
 
Intervention to correct molecular defect, not 
potentiate. 
Wilschanski 2003133 Intervention for stop codon mutations. 
Zeitlin 2002119 Intervention to correct molecular defect, not 
potentiate. 
McCarty 2002120 
 
Intervention to correct molecular defect, not 
potentiate. 
Pradal 2002190 Intervention for stop codon mutations 
Romano 2000191 Intervention for stop codon  mutations 
Chadwick 1998117 
 
Intervention to correct molecular defect, not 
potentiate. 
Rubenstein 1998192 
 
Intervention to correct molecular defect, not 
potentiate. 
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3.1.3 Risk of bias in included studies  
Two authors (myself and IS) individually assessed each of the four included trials for risk of bias. We 
found the risk of selection bias amongst the included studies to be low as three of four included 
studies sufficiently demonstrated how random sequences were generated and how participant 
allocations were concealed.198, 199, 201 The same three studies also demonstrated that necessary 
measures had been taken to blind site personnel and outcome assessors.198, 199, 201 However, we 
found that none of the included studies sufficiently demonstrated how participants were blinded. In 
each study, there was a lack of description on the details of the orally administered Ivacaftor tablet 
i.e. taste, colour and how it compared to placebo.198-201  
To assess for attrition bias we calculated the percentage of withdrawals in each trial and determined 
whether an intention-to-treat (ITT) approach had been employed. In all four studies there was low 
attrition (less than 15%).198-201 However, three studies were found to have excluded relevant data 
from the analysis (not ITT).198-200 We approached primary authors of these trials for additional 
information about missing data (E-mail 2, 4, 8). Only study personnel from the sponsoring body 
involved with the child phase 3 G551D study responded. They stated that an ITT approach had not 
been employed and instead a modified ITT approach had been employed (not per-protocol) 
whereby only participant data that were available were included in the analysis (E-mail 5). As 
withdrawals from this study were due to reasons that could have potentially lead to patients with 
unfavourable or favourable characteristics from being excluded, (e.g. adverse events, withdrawal of 
consent), attrition bias remained high in this study.200 The remaining two studies were also judged to 
have a high risk of attrition bias because participant data were excluded for no apparent reason.198, 
199, 201  
With regards to selective outcome reporting bias, a high risk was identified in all four trials.198-201 This 
was due to either not reporting outcomes pre-defined in the protocol or failure to report key 
outcomes that would be expected to have been reported. Initially, there was disagreement between 
the authors in whether failure to report a key CF outcome, that was measured during the trial but 
not pre-specified in the trial protocol, should be enough reason to judge a trial as having a high risk 
of selective outcome reporting bias. To resolve this, we first consulted the Cochrane handbook, 
which included the following statement as a criteria for the judgement of ‘high risk’ of bias; “the 
study report fails to include results for key outcomes that would be expected to have been reported 
for such a study.” We then discussed this issue with another author (KWS) and considered this to be 
enough reason to judge a trial as having a high risk of selective outcome reporting bias.  We 
approached all trial authors requesting 1) trial protocol if they were not already available 2) data for 
outcomes that were pre-defined in the protocol but not reported in the full report and 3) data for 
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key outcomes that were measured during the trial but not reported (E-mail 1, 3, 4, 6, 7, 9, 11) but no 
additional study protocols or data were provided.  
We did not find any other sources of bias amongst the included trials.  
Overall, we judged the methodological quality (risks of bias) in the included studies to be moderate. 
It was downgraded from high to moderate because of the high risk of attrition and selective 
outcome reporting bias across included studies (Figures 14 and 15). For more detail on the individual 
risk of bias assessments for each domain for each study, refer to the characteristics of studies 
section of the full review (attached). 
Figure 14 Risk of bias assessment for each included trial in CFTR potentiators review 
 
Risk of bias was based on author’s judgements. The symbols represent different risk of bias:  
represents low risk of bias, represents a high risk of bias and  indicates an unclear risk of 
bias.  
  
Figure 14 provides a summary of the 
individual risks of bias assessments 
for each study included in the CFTR 
potentiators review.  
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Figure 15 Summary of risk of bias for each included trial using Cochrane Risk of Bias Tool  
 
3.1.4 Effects of the intervention  
This summary of the effect of the Ivacaftor on clinically important outcomes in patients with CF has 
been extracted from the discussion section of the CFTR potentiators review and highlights all the 
pertinent results.  
With respect to this review's primary outcomes for this review, there were no deaths reported in 
any of the trials and the length and size of the trials precluded valid assessment of the impact of 
Ivacaftor on survival. For CFQ-R scores, the adults randomised to Ivacaftor in the phase 2 Accurso 
trial did not report significantly higher CFQ-R respiratory domain scores 28 days.201 However, adults 
in the phase 3 Ramsey trial reported significantly higher CFQ-R respiratory scores at 24 weeks, MD 
8.10 (95% CI 4.63 to 11.57) and at 48 weeks, MD 8.60 (95% CI 5.27 to 11.93) (Figure 16).  
Figure 16 Forest plot demonstrating the change from baseline in CFQ-R respiratory domain scores 
at 24 and 48 weeks in the adult phase 3 G551D study 
 
Figure 15 
demonstrates the 
high risks of attrition 
bias (incomplete 
outcome data 
addressed) and 
selective outcome 
reporting bias across 
the included studies.  
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This finding was not reproduced in the paediatric participants200 or the homozygous ΔF508 
participants199. Again, for relative change in FEV1, the phase 2 trial in G551D patients did not report 
treatment with Ivacaftor resulting in a significant improvement201. However, in the adult G551D 
phase 3 study, significant improvements in relative change in FEV1 were seen early (after 15 days) 
and maintained through to 48 weeks, MD 16.80% (95% CI 13.50 to 20.10) (Figure 17).198 
Figure 17 Forest plot demonstrating the relative change from baseline in FEV1 at 24 and 48 weeks 
in the adult phase 3 G551D study 
 
  
Significant improvements were also seen at 24 weeks in the paediatric trial, MD 17.4% (P <0.0001), 
but results at 48 weeks were not published.200 No significant improvements in relative change in 
FEV1 were reported in the ΔF508 trial.199  
Combined data from the two G551D phase 3 trials demonstrated a reduced reporting of cough, OR 
0.57 (95% CI 0.33 to 1.00) and reduced episodes of decreased pulmonary function, OR 0.29 (95% CI 
0.10 to 0.82) in the Ivacaftor group. Increased reports of dizziness were recorded in patients 
The plot in Figure 16 shows the advantage for treatment with Ivacaftor over placebo in CFQ-R 
respiratory domain scores, in adults with the G551D mutation. The point estimates at 24 weeks 
and 48 weeks demonstrate that participants reported higher CFQ-R when treated with 
Ivacaftor. The advantage can also be seen in the mean difference values and the 95%CIs suggest 
statistically significant advantage of Ivacaftor over placebo.  
The plot in Figure 17 shows the advantage for treatment with Ivacaftor over placebo in relative 
change from baseline in FEV1, in adults with the G551D mutation. The point estimates at 24 
weeks and 48 weeks indicate that improvements in FEV1 were reported in participants treated 
with Ivacaftor. The advantage can also be seen in the mean difference values and the 95%CI s 
suggest statistically significant advantage of Ivacaftor over placebo.  
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receiving Ivacaftor in the adult G551D trial,198 but this adverse effect was not reported by any other 
trial.199-201 No trial reported a significant increase in adverse effects leading to study drug 
interruption or study drug termination.198-201 Combined data from the phase 3 G551D trials 
demonstrate significantly fewer 'serious' cases of pulmonary exacerbation in the Ivacaftor group, OR 
0.34 (95% CI 0.17 to 0.70). When considering all data for exacerbations, fewer episodes were 
reported in adults in the Ivacaftor group by the phase 3 G551D trial, OR 0.54 (95% CI 0.29 to 1.01),198 
but this was not reported by the other trials.199-201 Ramsey reported that more participants in the 
placebo group required hospitalisation and IV antibiotics for pulmonary exacerbations and a greater 
proportion of participants in the Ivacaftor group were exacerbation-free at the 24 and 48 week time-
points (Figure 18).198 
Figure 18 Forest plot demonstrating hazard ratios for the time to next pulmonary exacerbation in 
adults with the G551D mutation treated with Ivacaftor.  
 
 
Both children and adults in the phase 3 G551D trials demonstrated significant weight gain on 
Ivacaftor at 24 weeks, MD 2.37kg (95% CI 1.68 to 3.06) and 48 weeks, MD 2.75 kg (95% CI 1.74 to 
3.75) (Figure 19).  
  
The plot in figure 18 shows the advantage for treatment with Ivacaftor over placebo in 
exacerbation-free time, in adults with the G551D mutation. The point estimates at 24 weeks 
and 48 weeks indicate that improvements in exacerbation free time were seen in participants 
treated with Ivacaftor. The advantage can also be seen in the hazard ratio values and the 
95%CIs suggest a statistically significant advantage of Ivacaftor over placebo.  
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Figure 19 Forest plot demonstrating the change from baseline in weight in participants with G551D 
treated with Ivacaftor compared to placebo.  
 
 
These two trials also reported that significantly higher BMI scores were achieved in the Ivacaftor 
group; for children, MD 1.09 kg/m2 (P = 0.0003) and for adults, MD 0.93 kg/m2 (P < 0.0001). 
Significantly higher BMI-for-age z scores were reported in the phase 3 G551D paediatric trial in the 
Ivacaftor group at 24 weeks, MD 0.34 (P ≤ 0.001) and at 48 weeks, MD 0.45 (P < 0.001).200 In a subset 
of participants aged 12 to 20 years old from the phase 3 G551D adult trial, a higher BMI-for-age Z 
score was reported at 48 weeks, MD 0.33 (P = 0.0490).198 No significant weight gain or change in BMI 
scores were reported in ΔF508 trial.199 
In the phase 2 G551D trial, Accurso reported significant reductions in sweat chloride concentration 
at 28 days in the 150 mg Ivacaftor group (median -64.5 mmol/L; P = 0.02) and 250 mg Ivacaftor 
group (median -43.0 mmol/L; P = 0.03)201. Combined data from the phase 3 G551D trials 
demonstrated significant reductions in sweat chloride concentration in participants on Ivacaftor at 
24 weeks, MD -48.98 mmol/L (95% CI -52.07 to -45.89) and 48 weeks, MD -49.03 mmol/L (95% CI -
52.11 to -45.94) (Figure 20).198, 200  
  
The plot in Figure 19 shows the advantage for treatment with Ivacaftor over placebo in the 
change from baseline in weight, in adults and children with the G551D mutation. The mean 
differences and point estimates at 24 weeks and 48 weeks both indicate that improvements in 
weight gain were reported in participants treated with Ivacaftor. The pooled mean difference 
values reinforce this and the 95% CIs suggest statistically significant advantage of Ivacaftor over 
placebo. There was no heterogeneity between trials.  
 
  
81 
 
Figure 20 Forest plot demonstrating the change from baseline in in sweat chloride concentration in 
participants with G551D treated with Ivacaftor compared to placebo. 
 
 
The ΔF508 study, also reported a significant reduction in sweat chloride concentration, MD -2.9 
mmol/L (95% CI -5.6 to -0.2). 
3.1.5 Conclusion  
The G551D phase 3 trials demonstrated a clinically relevant impact of Ivacaftor on outcomes at 24 
and 48 weeks, providing evidence for the use of Ivacaftor in children (over six years of age) and 
adults with CF and the G551D mutation. There is no evidence to support the use of Ivacaftor in 
ΔF508 patients. This evidence is based on trials of moderate methodological quality and readers 
should be aware of the high risks of attrition and selective outcome reporting bias found across 
studies.    
The plot in Figure 20 shows the advantage for treatment with Ivacaftor over placebo in the 
change from baseline in sweat chloride concentration, in adults and children with the G551D 
mutation. The point estimates at 24 weeks and 48 weeks indicate reductions in sweat chloride 
concentration in participants treated with Ivacaftor. The advantage can also be seen in the 
mean difference values. The pooled mean difference values reinforce this and the 95%CIs 
suggest statistically significant advantage of Ivacaftor over placebo. There was no heterogeneity 
between trials. 
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3.2: Summary of findings from the CFTR correctors review  
3.2.1 Results of the literature search  
We identified a total of 25 publications representing 16 trials were identified from searches of 
electronic databases and hand searching of conference abstracts.117-120, 123-125, 127-130, 192, 202-205 One 
additional reference (full report), for a study already identified, was found whilst scanning recently 
published literature.127 The literature search was assessed as up-to-date on the 14th July 2014. No 
additional studies were identified by contacting primary authors or screening relevant references. 
After application of the eligibility criteria to the 16 trials, five trials (15 references) were included,118-
120, 125, 127, 6 trials were excluded117, 192, 202-205 and five trials were on-going123, 124, 128-130. Results of the 
search are displayed in a PRISMA flow diagram (Figure 21). Relevant data were extracted from each 
of the five eligible trials by two authors (SP and IS) independently. When comparing the two data 
exertion forms, no disagreements arose. The data extraction forms for each of the 5 studies are 
included in the appendix.   
Figure 21 PRISMA flow diagram demonstrating the results of the literature search 
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9 trials (9 references) were 
identified from on-going trials 
databases. 
 
No duplicates were found. 
 
All 16 trials (26 
references) were 
screened 
 
 
6 trials were 
excluded and 5 trials 
were on-going. 
 
5 trials full-text articles 
were assessed for 
eligibility 
 
0 trials were excluded. 
5 trials were included in 
qualitative synthesis 
 
5 studies were included 
in quantitative synthesis 
(meta-analysis) 
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3.2.2 Characteristics of included studies  
Five trials with 225 participants met the inclusion criteria for this review; and compared 4-
Phenylbutyrate (4PBA)118, 119, 8-cyclopentyl-1, 3-dipropylxanthine (CPX),120 Lumacaftor monotherapy 
125, 127 and Lumacaftor and Ivacaftor combination therapy to placebo.127 All studies examined the 
impact of CFTR correctors in patients homozygous for the ΔF508 mutation (class II mutation on both 
alleles).118-120, 125, 127  
The first trial by Rubenstein was a pilot trial (n=18) comparing 19g of 4PBA daily to placebo in 
patients aged 14 years and older.118 We called this trial the pilot 4PBA study. This was followed by a 
phase 2 trial by Zeitlin (n=19) comparing escalating doses of 4PBA (20g, 30g and 40g daily) to 
placebo in patients 18 years and older (mean age 28.5 years).119 We called this study the phase 2 
4PBA study. Both 4PBA studies reported on safety and change in sweat chloride concentration at 1 
week.118, 119 The CPX study by McCarty was a phase 1 study (n=37) that examined escalating doses of 
CPX (1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300mg, 1000mg) in patients aged 18 years of age and older. 
Sweat chloride concentration values were reported at day 1 and adverse effects were monitored for 
1 week.120 Two trials compared escalating doses of Lumacaftor to placebo.125, 127 The first of these 
studies by Clancy (n = 89) examined escalating doses of Lumacaftor (25mg, 50mg, 100mg and 
200mg) in participants 18 years of age and older (median age 26 years) and reported on QoL, FEV1, 
adverse effects and sweat chloride concentration at 28 days.125 We called this study the Lumacaftor 
study. The remaining study by Boyle compared 1) Lumacaftor monotherapy and 2) Lumacaftor and 
Ivacaftor combination therapy to placebo; we called it the Lumacaftor-Ivacaftor study.127 This study 
was composed of 3 cohorts, but we only included data for participants randomised in cohort 1 (n = 
62). This is because data for placebo participants in cohorts 2 and 3 were combined in the analysis 
although randomisations in these cohorts were conducted separately. This invalidated the effects of 
randomisation and the review authors judged it inappropriate to include this data. In this review, the 
Lumacaftor-Ivacaftor study refers to cohort 1 of the study only. This study recruited patients 18 
years and older (mean 29.1 years of age) and reported on FEV1, adverse effects and sweat chloride 
concentration at day 14 (Lumacaftor monotherapy) and day 21 (Lumacaftor and Ivacaftor 
combination therapy)125. A summary of the characteristics of the included studies on-going studies 
and reasons for exclusions are provided (Tables 13, 14 and 15) 
We approached all the trial authors of the included studies for additional data on outcomes reported 
in our systematic review, but not reported in the published trials (E-mail 12-17). We also contacted 
the primary author of the Lumacaftor-Ivacaftor study for separate data for placebo participants in 
these cohorts 2 and 3 (E-mail 17). Four out five authors responded; two authors had no additional 
data to contribute (12 and 14) and the remaining two authors have not yet provided any additional 
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data (E-mail 13 and 15). Therefore, all data included data in this review is from published reports. 
We also approached the primary author of one of the on-going studies to illicit any preliminary data, 
but we did not receive a response (E-mail 18). We could not request additional data for the 
remaining on-going trials because contact information was not provided.  
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Table 13 Characteristics of studies included in the CFTR correctors review   
 Study design Participants Interventions Outcomes 
Study  Study 
design  
Commercial 
research 
support 
Treatment 
period 
(weeks) 
Number of 
sites  
Number of 
participants  
Age 
group 
(years 
of 
age) 
Genotype  Intervention Control  Primary 
outcome 
Secondary 
outcomes 
Rubenstein 
1998118 (pilot 
4PBA study)  
RCT of 
parallel 
design  
NIH, CF 
Foundation 
7 days Single site 
in USA 
18 > 14 Homozygous 
ΔF508 
19g 4PBA Placebo  NPD Safety, 
Sweat cl 
values 
 
Zeitlin 2002119 
(phase 2 4PBA 
study) 
RCT of 
parallel 
design 
CF Foundation  7 days  Single site 
in USA 
22 > 18 Homozygous 
ΔF508 
20g 30g and 
40g 4PBA 
Placebo  NPD Safety, 
sweat cl 
values, FEV1, 
sputum 
microbiology 
McCarty 2002120 
(CPX study) 
RCT of 
parallel 
design 
FDA office of 
orphan 
products 
development  
1 day 
(single dose 
assessment) 
4 sites in 
the USA 
37 > 18 Homozygous 
ΔF508 
1 mg CPX 
3 mg, 10 mg, 
30 mg 100 mg, 
300 mg, 1000 
mg CPX  
Placebo  Safety NPD, sweat 
cl values  
Clancy125 
(Lumacaftor 
study) 
RCT of 
parallel 
design 
Vertex 
Pharmaceuticals 
Incorporated 
28 days  25 sites N. 
America & 
Europe  
89 > 18 Homozygous 
ΔF508 
25mg, 50mg 
100mg & 
200mg of 
Lumacaftor 
Placebo  Safety  Δ BL sweat 
cl, NPD, lung 
function, 
CFQ-R score 
Boyle 2014127 
(Lumacaftor-
Ivacaftor study) 
 
Cohort 1 only  
RCT of 
parallel 
design 
Vertex 
Pharmaceuticals 
Incorporated 
21 days  90 sites in 
N.America, 
Europe & 
Australia 
62 > 18 Homozygous 
ΔF508 
200mg 
Lumacaftor (D 
1-21) and 
150mg/250mg 
Ivacaftor (D 
14-21) 
Placebo Δ BL sweat  
cl(Lumacaftor 
and Ivacaftor 
therapy)& 
safety 
Δ BL FEV1, 
sweat cl 
(Lumacaftor 
only) 
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Table 14 Characteristics on-going of studies examining CFTR correctors     
*not all outcomes presented, refer to characteristics of included studies in the full review for more detail
Study and title Sponsor Methods Participants. 
Confirmed diagnosis 
of CF +: 
Interventions Outcomes 
(Δ BL - change from 
baseline)* 
Status  at literature 
search 
Donaldson 2013123  
( NCT01531673) 
Vertex  Phase 2, double-blind, 
placebo-controlled, 3-part RCT 
of parallel design. Expected to 
enrol 130. Duration: 28 days. 
1. Homozygous or 
heterozygous for 
the ΔF508 
mutation. 
2. ≥ 18 years  
10mg, 30mg 100mg 
and 150mg VX-661 
OD +/- 150mg 
Ivacaftor BD   
Primary: Safety + : 
Δ BL in sweat cl  
Secondary: Absol + 
rel  Δ BL FEV1,  
Study recently 
complete, no data 
published to date.   
 
NCT02070744 2014124 
 
 
Vertex  Phase 2, double-blind, placebo 
controlled RCT of parallel 
design with outcomes 
measured at 12 weeks  
1. homozygous for 
the  ΔF508 
mutation.  
3. ≥ 18 years old 
VX-661 + Ivacaftor 
(doses unknown)  
compared to 
placebo 
Primary: Safety 
Secondary: Absol  Δ 
BL FEV1, Rel  Δ BL 
FEV1,  Δ BL weight,   
Recruiting 
participants  
 
NCT01807923 2013 or 
TRAFFIC or study  VX12-
809-103.128 
 
 
 
Vertex  Phase 3 double-blind, placebo-
controlled study RCT of 
Parallel design. 90 sites 
Worldwide Est to enrol 559 for 
24 weeks. 
1.  homozygous for 
the ΔF508 mutation 
2. 12-65 years old 
600mg Lumacaftor 
OD or 400mg 
Lumacaftor BD  + 
250mg Ivacaftor BD 
compared to 
placebo 
Primary:   Absol Δ 
BL FEV1 (Secondary:  
Rel  Δ BL FEV1, No of 
PEx,   Δ BL BMI,  Δ 
BL weight,  
On-going, no data 
available  
NCT01807949 or  
TRANSPORT or study 
VX12-809-104.129 
 
Vertex Phase 3 double-blind, placebo-
controlled study RCT of 
Parallel design. 82 sites 
Worldwide Est to enrol 563 for 
24 weeks.  
1.  homozygous for 
the ΔF508 mutation 
2. 12-65 years old 
600mg Lumacaftor 
OD or 400mg 
Lumacaftor BD  + 
250mg Ivacaftor BD  
Primary:   Absol Δ 
BL FEV1 (Secondary:  
Rel  Δ BL FEV1, No of 
PEx,   Δ BL BMI 
On-going, no data 
available 
NCT01931839  (Rollover 
study from TRAFFIC and 
TRANSPORT)130 
 
Vertex Phase 3, double-blinded 
rollover study of parallel 
design. 211 Worldwide. 
Estimated to enrol: 1122 for 
100 weeks. 
Participants from 
TRAFFIC and 
TRANSPORT 
600mg Lumacaftor 
OD or 400mg 
Lumacaftor BD  + 
250mg Ivacaftor BD  
Absol Δ BL FEV1,  Rel  
Δ BL FEV1, Safety,   Δ 
BL BMI,  Δ BL 
weight, 
On-going  
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Table 15 Studies excluded from the CFTR potentiators review    
Study ID Reason for exclusion  
NCT01897233 2013203 Single group assignment  
NCT01899105 2013202 Cross-over design  
Leonard 2012205 Cross-over design 
Lebecque 2011204 Cross-over design  
Rubenstein 2006192 Cross-over design  
Chadwick 1998117  No relevant outcome measures 
3.2.3 Risk of bias in included studies  
Two authors (myself and IS) individually assessed each of the four included trials for risk of bias. The 
Lumacaftor-Ivacaftor study by Boyle sufficiently described methods to account for selection bias, 
detection bias and performance bias, however in the remaining studies, it was less clear; none 
reported on random sequence generation, allocation concealment or blinding. These studies were 
therefore judged to have an unclear risk of selection bias, detection bias and performance bias 
except the phase 2 4PBA study which was judged to have a high risk of performance bias because 
intervention assigned participants, assigned to different doses of 4PBA (20g, 30g and 40g), followed 
different daily schedules and were given different quantities of tablets.   
We assessed for attrition bias in the same way we did for the studies included in the CFTR 
potentiators review. With regards to withdrawals; all randomised participants completed the final 
study visit or the percentages of withdrawals were low (all less than 15%). With regards to missing 
participant data, in the Lumacaftor study by Clancy, data was excluded from the analysis for no 
apparent reason and in the phase 2 4PBA study by Zeitlin, the number of participants included in the 
analysis was unclear.119, 125 We approached the primary authors of these trials for clarification, but 
no additional information was provided (E-mail 13 and 15). In Lumacaftor-Ivacaftor study (cohort 1), 
participants were excluded from the analysis due to insufficient data from the patient. For example, 
data were excluded for the analysis of change from baseline in sweat chloride concentration 
because insufficient sweat was gathered for analysis. Although this reason does not specifically lead 
to participants with unfavourable characteristics being excluded from the analysis (unlike for 
example withdrawals due to adverse events), the review authors judged attrition bias in this review 
to be unclear because we could not determine the effects of these exclusions on the balance 
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between groups in baseline characteristics.127 In the remaining two trials, all participant data was 
included in the analysis.118, 120   
Zero trial protocols were available online or were provided after approaching the trialists. We 
assessed selective outcome reporting by comparing outcomes reported on online trials registries or 
in the methods section to the outcomes reported in the results. Both review authors identified a 
high risk of selective outcome reporting in the phase 2 4PBA study and the Lumacaftor study 
because trialists failed to report data for pre-defined outcomes.119, 125 We approached the primary 
authors of both trials for missing outcome data. The remaining three trials reported all pre-defined 
outcomes.118, 120, 127 
We did not find any other sources of bias amongst the included trials and no disagreements arose 
whilst comparing the risk of bias assessments.  
Overall, we judged the methodological quality (risks of bias) in the included studies to be moderate, 
because most of the data in this trial was judged to be of unclear risk of bias. A summary of the risk 
of bias judgements is demonstrated in the Figures 22 and 23. For more detail on the individual risk of 
bias assessments for each domain for each study, refer to the characteristics of studies section of 
the full review.  
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Figure 22 Summary of risk of bias for each included trial using Cochrane Risk of Bias Tool in the 
CFTR correctors review  
 
Risk of bias was based on author’s judgements. The symbols represent different risk of bias:  
represents low risk of bias, represents a high risk of bias and  indicates an unclear risk of 
bias.  
Figure 23 Summary of risk of bias for each included trial using Cochrane Risk of Bias Tool in the 
CFTR correctors review.  
 
 
Figure 23 shows a large proportion of domains were judged to have an unclear risk of 
bias in the CFTR correctors review.  
 
Figure 22 provides a summary of the 
individual risks of bias assessments 
for each study included in the CFTR 
potentiators review.  
 
  
90 
 
3.2.4 Effects of the intervention  
This summary of the effect of the Ivacaftor has been extracted from the discussion section of the 
CFTR correctors review and highlights all pertinent results.  
With respect to the primary outcomes for this review (survival, QoL, relative and absolute change in 
FEV1 from baseline and the change from baseline in FVC) the evidence was limited. No deaths 
reported in any of the trials and size and length of trials precluded valid assessment of CFTR 
correctors on survival. The Lumacaftor study by Clancy measured QoL; where lower QoL 
(demonstrated by lower CFQ-R domain scores) was reported by participants taking 25 mg, 50 mg 
and 200 mg of Lumacaftor at 28 days.125 With regards to lung function, patients treated with 
Lumacaftor monotherapy and Lumacaftor and Ivacaftor combination therapy did not demonstrate 
short term improvements in FEV1.125, 127  
There was no difference between the CPX treatment groups and the placebo group in the frequency 
of mild adverse effects.120 Participants assigned to 20 g of 4PBA in the phase 2 4PBA study by Zeitlin 
reported episodes of transient nausea, headache, sleepiness after the initial dose (relieved by an 
acetaminophen) and body odour, but this was not reported by participants taking 19 g 4PBA in the 
pilot trial by Rubenstein.119 We considered 30 g and 40 g doses of 4PBA, examined in the phase 2 
4PBA study by Zeitlin, to be unsafe. All participants in the 30 g 4PBA group reported episodes of 
transient nausea, headache, sleepiness and transient visual disturbances after the initial dose and 
two out of six participants in the 30 mg group either discontinued the study drug or reduced the 
dose. All three participants receiving 40 g 4PBA developed episodes of nausea, headache and visual 
disturbances and one participant reported cramp in hands and fingers. One participant withdrew 
from the study and one participant was assigned to a reduced study dose. All participants were 
eventually terminated from the 40 g group after it was considered unsafe by the safety monitoring 
committee.119 In participants assigned 100 mg and 200 mg of Lumacaftor (combined data), in the 
Lumacaftor study by Clancy, there was no significant difference in the frequency of mild adverse 
effects when compared to participants randomised to placebo.125 This was consistent with findings 
in the Lumacaftor-Ivacaftor study, which demonstrated no difference between patients treated with 
1) Lumacaftor monotherapy and placebo and 2) Lumacaftor and Ivacaftor combination therapy and 
placebo (combined data), in the number of participants experiencing mild adverse effects. Four 
participants, one from each of the Lumacaftor dosage groups, withdrew from the Lumacaftor study 
due to respiratory adverse effects,125 which was also in line Lumacaftor-Ivacaftor study where one 
participant withdrew during the 200mg Lumacaftor monotherapy period due to chest tightness.127 
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Treatment with CPX or 4PBA did not improve CFTR function in sweat glands.118-120 Data at 28 days in 
the Lumacaftor study demonstrated significant reductions in sweat chloride concentration in 
participants assigned to 100 mg of Lumacaftor once daily, MD -6.13 mmol/L (95% CI -12.25 to -0.01) 
and 200 mg Lumacaftor once daily, MD -8.21mmol/L (95% CI -14.33 to -2.09) (Figure 24).125 
Figure 24 Forest plot demonstrating the change from baseline in sweat chloride concentration in 
homozygous ΔF508 participants treated with Lumacaftor at 28 day.  
 
 
Data at 21 days, for patients treated with 200mg Lumacaftor once daily (day 1-21) and 250mg of 
Ivacaftor twice daily (day 15-21) in the Lumacaftor-Ivacaftor study, demonstrated the greatest 
reduction in sweat chloride concentration compared to placebo in patients with the ΔF508 
mutation, MD -10.90 mmol/L (95% CI -17.60 to -4.20) (figure 25).127  
  
The plot in figure 24 shows the advantage for treatment with Lumacaftor over placebo in the 
change from baseline in sweat chloride concentration, in adults homozygous for the ΔF508 
mutation. The point estimates at 28 days indicate reductions in sweat chloride concentration in 
participants treated with 100mg and 200mg of Lumacaftor. The advantage can also be seen in 
the mean difference values and the 95%CIs suggest statistically significant advantage of 
Lumacaftor over placebo for both dose groups.  
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Figure 25 Forest plot demonstrating the change from baseline in sweat chloride concentration in 
homozygous ΔF508 participants treated with Lumacaftor and Ivacaftor at day 21.  
 
 
3.2.5 Conclusion    
The CFTR correctors review examined the impact of 4PBA, CPX and Lumacaftor (monotherapy and 
combination therapy with Ivacaftor). Short-term treatment with Lumacaftor demonstrated 
statistically significant but clinically minimal reduction in sweat chloride concentration when used as 
monotherapy (28 days) and when used as combination therapy with Ivacaftor (21 days) in 
homozygous ΔF508 patients. Lumacaftor monotherapy and combination therapy with Ivacaftor did 
not demonstrate a statistically significant impact on any other clinically relevant outcomes in 
patients with ΔF508. Neither 4PBA nor CPX demonstrated a clinically relevant impact on outcomes in 
patients with ΔF508. In light of the results presented in this review, there is no current evidence to 
support the short-term use of CFTR correctors (as monotherapy or combination therapy) for patients 
with class II mutations. This evidence is based on studies with an overall moderate methodological 
quality. It was downgraded from high to moderate because of the large proportion of domains with 
an unclear risk of bias (Figure 23).  
  
The plot in figure 25 shows the advantage for treatment with Lumacaftor + Ivacaftor over 
placebo in the change from baseline in sweat chloride concentration, in adults homozygous for 
the ΔF508 mutation. The point estimates and mean differences at 21 days indicate reductions in 
sweat chloride concentration in participants treated with Lumacaftor and Ivacaftor. Only the 
95%CI for the participants treated with 200mg Lumacaftor and 250mg Ivacaftor suggest a 
statistically significant advantage of Lumacaftor and Ivacaftor combination therapy over 
placebo.  
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Chapter 4 
Discussion 
The protein products of Class II mutations are mainly degraded within the cell, but minimal amounts 
of CFTR reach the cell membrane where they demonstrate defective function. The protein products 
of Class III mutations are transported normally to the cell membrane but display defective function. 
In both cases, inadequate or compromised CFTR at the cell membrane leads to compromised ion 
transport and a severe CF phenotype characterised by chronic infection and inflammation and lung 
damage. New therapies that target the underling defect of class II (CFTR correctors) and III mutations 
(CFTR potentiators) aim to restore normal ion conductance and are likely to represent a significant 
healthcare resource in patients with Cystic Fibrosis.  
We conducted two systematic reviews to examine the impact of 1) CFTR potentiators and 2) CFTR 
correctors on clinically important outcomes in patients with Cystic Fibrosis. The reviews included 9 
RCTS with 603 CF patients and lasted between 1 day (single dose phase 1 trial) and 48 weeks.  
4.1 CFTR potentiators  
4.1.1 Findings of the review  
Appraisal and synthesis of the evidence on CFTR potentiators demonstrated that Ivacaftor had a 
clinically relevant impact on outcomes at 24 and 48 weeks in adults and children with the G551D 
mutation (class III mutation) but not in patients with the ΔF508 mutation (class II mutation). These 
results were in accordance with increased chloride conductance seen in cell studies, recently 
published systematic review on Ivacaftor by Whiting, and the current recommendations for the use 
of Ivacaftor for patients with the G551D mutation in the UK.43, 109, 206 
4.1.2 Strengths and limitations of the included studies  
The included studies in this review had a number of strengths. All included studies were RCTs of 
parallel design representing the best form of clinical trial design for establishing the evidence for an 
intervention. These trials also reported on a number of key clinical outcomes included in our review; 
quality of life, lung function, adverse effects of therapy, hospitalisations, extra courses of antibiotics, 
weight gain, BMI and sweat chloride concentration. Reporting of these outcomes are important to 
both clinicians and patients to inform clinical decision making.  
In addition to this, all trials in this review were conducted at multiple sites demonstrating a more 
precise effect of Ivacaftor on outcomes. Two studies in this review (phase 3 G551D studies) 
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demonstrated homogeneity with regards to patient characteristics (i.e. genotype but not age), trial 
settings, treatment regimens and end-points and also demonstrated consistency in the effect of 
Ivacaftor on lung function (FEV1), weight gain and sweat chloride reduction. These trials also 
reported data in a form that permitted inclusion into a meta-analysis and by combining the data; we 
were able to demonstrate a more precise estimate of the benefits and harms of Ivacaftor on 
patients with G551D.  
Trials in this review also had number of limitations. With regards to methodological quality, the 
included studies in this review demonstrated adequate random sequence generation, allocation 
concealment (low selection bias) and blinding of study personnel (low performance bias). The trials 
however, were limited by high risks of attrition bias and selective outcome reporting bias. High risks 
of these biases are associated with over-estimation of the treatment effect through; 1) exclusion of 
unfavourable participant outcome data (attrition bias) 2) disruption of matching between groups in 
baseline characteristics (attrition bias) and 3) having bias towards reporting of significant results 
over non-significant results (selective outcome reporting bias).177, 182 Attrition and selective outcome 
reporting bias therefore limit the overall methodological quality of the included studies and the 
internal validity of the evidence. To demonstrate the impact of these biases on the overall treatment 
effect estimate we planned to conduct a sensitivity analysis but this was not possible with the small 
number of included trials.  
This assessment of methodological quality was not in line with the assessment of quality in the 
systematic review by Whiting.206 Both reviews employed the Cochrane risk of bias tool but in the 
Whiting review, the judgements of risks of biases gave the trials a higher overall methodological 
quality. For more details regarding the differences, refer to the discussion section of full review. In 
both reviews, the review authors have provided a written description to support their risk of bias 
judgements, and differences between reviews highlight the subjective nature of risk of bias 
assessments when using the Cochrane risk of bias tool. 
The trials were further limited by length, which precluded proper assessment of the long-term 
impact of Ivacaftor on survival and other outcomes (beyond 48 weeks), and missing data for other 
outcomes we considered clinically important. There was insufficient data for the outcomes school or 
work attendance; radiological measures of lung disease; acquisition of respiratory pathogens; and 
cost of treatment.  
4.1.3 Applicability of the evidence  
In this review, three trials recruited 238 patients with the G551D mutation representing a significant 
proportion of patients with this mutation in the countries they were recruited. Also, 140 patients 
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with the ΔF508 mutations were recruited also representing a significant proportion of patients with 
this mutation above the age of 12. We can therefore assume that the results of this review are 
applicable to patients with these mutations not included in these studies, although CF patients less 
than 6 years of age or in pregnancy were not enrolled. In addition, all trials were conducted at 
multiple sites in a number of continents accounting for the differences on healthcare systems and 
environment on clinical outcomes, providing greater generalizability of the results.     
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4.2 CFTR correctors  
4.2.1 Findings of the review  
The review on CFTR correctors demonstrated that there is no evidence for the use of CFTR 
correctors as monotherapy or combination therapy, in patients with ΔF508 (class II mutations) in the 
short term. As we are aware, this is the first systematic review to be conducted on CFTR correctors. 
This is not surprising given the modernity of RCTs included in this review.   
4.2.2 Strengths and limitations of the included studies  
The included studies in this review had a number of strengths and limitations. All included studies 
were RCTs of parallel design representing the best form of clinical trial design for establishing the 
evidence for an intervention. One study (Lumacaftor-Ivacaftor study by Boyle) examined the impact 
of Lumacaftor and Ivacaftor combination therapy. This study was of high methodological quality, 
demonstrating low risks of biases for all but one domain (incomplete outcome data domain), which 
was judged to be unclear. Therefore the quality of the evidence for combination therapy was high. 
The Lumacaftor-Ivacaftor study also examined Lumacaftor monotherapy in addition to the 
Lumacaftor study by Clancy. The overall methodological quality of the evidence for Lumacaftor 
however was limited by high risks of attrition bias and selective outcome reporting bias found in the 
Lumacaftor study. These studies reported data for Lumacaftor monotherapy at different time-points 
so we were unable to combine data in a meta-analysis despite the studies demonstrating 
homogeneity with regards to patients (age and genotype), trial settings, treatment regimens and 
end-points.   
Two studies examined the impact of 4PBA and one trial examined the impact of CPX. These trials 
were of moderate methodological quality, because risks of bias for the majority of domains were 
unclear. All three studies stated they were double-blinded RCTs, but did not describe the method of 
randomisation, allocation concealment or blinding. The phase 2 4PBA study by Zeitlin was judged to 
have a high risk of performance bias and attrition bias, which further limited the quality of the 
evidence for 4PBA. With regards to consistency, adverse events demonstrated by the 4PBA studies 
were variable, with more participants in the 20g group of the phase 2 4PBA study reporting mild 
adverse events than participants given 19g 4PBA in the pilot study. Both 4PBA trials demonstrated 
no significant impact on sweat chloride concentration on patients treated with 4PBA, but the 
precision of the overall treatment effect were limited by unstandardized and inconsistent reporting 
of data precluding combination of data in a meta-analysis.  
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All trials included in this review were further limited by length (range 1 day – 28 days), which 
precluded proper assessment of 1) the longer-term impact of CFTR correctors on outcomes (e.g. 
survival) and 2) the longer term safety profile of CFTR correctors. In addition to this, there were 
missing data for key clinical outcomes; FVC, hospitalisations, school or work attendance, extra 
courses of antibiotics, radiological measures of lung disease, acquisition and eradication of 
respiratory pathogens, weight gain, BMI and growth. Only one trial reported on QoL,125 relative 
change from baseline in FEV1,125 and absolute change from baseline in FEV1.127  
4.2.3 Applicability of the evidence  
In this review, five studies recruited 225 patients homozygous for the ΔF508 mutation (class II) and 
examined the impact of four different CFTR corrector therapies. A total of 151 patients were 
recruited to examine Lumacaftor monotherapy and 62 patients were recruited to examine 
Lumacaftor in combination with Ivacaftor; representing significant portions of patients aged 18 years 
upwards with this mutation. We can therefore assume that the limited results with regards to 
Lumacaftor monotherapy and combination therapy with Ivacaftor can be applied to CF patients not 
included in these trials. 37 patients were recruited and to assess the impact of CPX and a further 37 
patients were recruited to examine 4PBA; again demonstrating representative proportions of 
patients with this mutation. In light of the adverse safety profile of 4PBA, further clinical trials 
examining this therapy may not be appropriate. 
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4.3 Limitations in research on CFTR potentiators and CFTR correctors for 
Cystic Fibrosis  
The research of the effects of CFTR potentiators and CFTR correctors are further limited by several 
factors; the lack of uniform reporting of adverse events, the lack of shared definitions for pulmonary 
exacerbations, ambiguity about why participants were excluded from the analysis and inappropriate 
selection of design and choice of analysis.  
4.3.1 Reporting of adverse effects 
Trialists are recommended to adhere to the CONSORT statement for harms when reporting adverse 
events in clinical trials.207 This statement encourages trialists to list adverse effects, to provide a 
definition of the adverse effect and to provide definitions for headings used when grading severity. 
For example, if trialists labelled adverse effects as mild, they should provide a definition of mild. In 
the included studies, trialists failed to report definitions for headings used in grading severity and 
this limited the ability of the reviewer to interpret these adverse effects and to potentially combine 
these adverse effects for a more precise estimate of harms of the interventions.  
In addition, studies included in this review reported on withdrawals, discontinuations and dose 
reductions but often failed to report all clinically relevant data associate with this. In a number of 
trials it was unclear what adverse effect lead to withdrawal/discontinuations/dose reduction, whose 
decision it was, what group the participant was assigned to and whether blinding was maintained 
during the process .  
4.3.2 Lack of definition for pulmonary exacerbations 
Pulmonary exacerbations are an important clinical outcome and are being used as primary and 
secondary outcomes in CF clinical trials.98 However to date, there is no established definition for a 
pulmonary exacerbation meaning trialists can identify events using either pre-defined criteria 
(protocol defined) or their own clinical judgement (physician defined). As physician defined 
exacerbations can include exacerbations identified using different criteria, it is inappropriate to 
combine data for protocol and physician defined exacerbation in the same meta-analysis. The review 
author can identify studies that share similar definitions (only if protocol-defined) to include in a 
meta-analysis, but without a well-established definition, data from studies will continue to be 
excluded, limiting the precision of the treatment effect estimate for this important outcome.  
4.3.3 Exclusion of participants from the analysis 
In order to assess attrition bias, the review authors need to know 1) the number of withdrawals from 
the study and reasons for withdrawals and 2) the number of participants excluded from the analysis 
 
  
99 
 
and reasons for exclusions. Review authors require information on why participants were excluded 
from the analysis to judge whether intervention assigned participants who had unfavourable results, 
were more likely to be excluded from the analysis leading to an over-estimation of the treatment 
effect. In 6 out of the 9 included studies in this review, participant data were excluded from the 
analysis. Only in 2 studies was information provided on the reasons for exclusions. In one study, 
insufficient data were acquired for analysis. This was judged to have an unclear risk of bias because 
it was unknown how incomplete participant data would affect the balance between randomised 
groups in baseline characteristics. In the other study a modified ITT approach had been employed, 
whereby participant data were excluded for participants who withdrew, so was judged to have a 
high risk of attrition bias. In the remaining 4 studies, participants appeared to have been excluded 
from the analysis for no apparent reason and these trials were judged to have a high risk of bias. 
Attrition bias in these studies limited the internal validity of the evidence of the reviews they were 
included in.  
4.3.4 Inappropriate selection of design and choice of analysis   
Trials of cross over design did not seem appropriate for examining CFTR potentiators and CFTR 
correctors given that these interventions target the underlying defect of CF. However, from our 
literature searches we found a number of trials that were of cross over design which would have 
otherwise been eligible for inclusion in our reviews.187-189, 202, 204, 205 This limited the amount of data 
for the examined therapies.  
 In addition to this, the evidence on Lumacaftor monotherapy and combination therapy was limited 
because in the Lumacaftor-Ivacaftor study, data for placebo participants in cohorts 2 and 3 were 
inappropriately combined, undoing the effects of randomisation.127 This is a shame given the large 
number of participants enrolled in these cohorts and the number of clinically relevant outcomes 
reported. The primary author was approached for separate placebo assigned participant data.   
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4.4 Strengths and limitations of the review process  
4.4.1 The protocol stage  
The systematic review process has a number of strengths starting with review protocol. Both 
systematic reviews in this thesis were conducted in accordance with peer reviewed and published 
protocol.141, 142 This is in line with Cochrane systematic review guidelines, and offers advantages over 
reviews conducted without protocol. The protocol stage allows authors to pre-determine the review 
methodology before the review stage is started so the review authors have a clear idea of how it is 
to be conducted and can use it as guidance. Also, the protocol stage helps reduce introducing bias 
during the review stage; pre-planned search strategy helps reduce bias from being introduced during 
the selection of studies and pre-defined outcome measures ensure selective outcome reporting bias, 
which limits the validity of many systematic reviews, is minimised.208 The main advantage of the 
protocol stage, however, is the improvement in methodological transparency it offers to the review 
process. It allows readers of the review to determine how results and conclusions in the review stage 
were formed, so they can use this information to form their own judgements on the evidence.  
4.4.2 The review stage  
There are also many advantages to the review process. For each review, we conducted a thorough 
literature search. This included searching relevant online databases and registries, hand searching 
conference abstracts and contacting relevant leaders and pharmaceutical companies investigating 
mutation-specific therapies. This comprehensive approach to literature searching ensured that all 
relevant data (published and unpublished) contributed to the evidence base. In addition to this, by 
conducting regular searches of databases and journals and indexing the relevant studies with 
appropriate keywords in the group’s Cystic Fibrosis registry, the review authors could easily ensure 
the most up-to-date evidence was provided.  
Two individual assessors applied the pre-defined inclusion criteria to the results of the literature 
search to identify studies eligible for inclusion. 4 studies were included in the CFTR potentiators 
review and 5 studies were included in the CFTR correctors review. Given the modernity of the 
examined interventions assessed in these reviews, in particular Ivacaftor and Lumacaftor, we were 
not surprised with the small number of identified trials and the large number of on-going studies. 
Two authors extracted relevant data from included studies, reducing the risk of inaccurate 
extraction.  
The methodological quality (risk of bias) of the included studies was assessed using the Cochrane risk 
of bias tool. This tool permitted the review authors to provide both a written description and an 
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overall judgement on the risk of bias for each domain (high risk, low risk or unclear risk). Given this is 
a subjective assessment, it was important that review authors were transparent about how 
judgements were derived so that readers of the reviews could form their own verdicts on the 
internal validity of the evidence. As per Cochrane protocol, two authors were recruited to reduce the 
risk of inaccurate methodological assessments.  
In these systematic reviews, we only combined data for studies that demonstrated homogeneity, 
increasing the precision of the treatment effect estimate.198, 200 Data were combined with the 
appropriate method for synthesis (random effects or fixed effect model) and checked for 
appropriateness by the review statistician.  
This methodological and transparent approach to the review process ensured bias was kept low and 
meant the highest quality of evidence was provided. It also meant that methods can be easily 
replicated for future updates of this review. This is particularly important for the included reviews 
given then that the assessed therapies were new, and that there are a number of on-going studies.  
There are also a number of limitations to the review process. It is well known that studies with 
statistically significant results are more likely to be published with faster time to publication and 
when studies are published, there is selective reporting towards significant results.182 This omission 
of data can deprive review authors of essential data for meta-analyses and can lead to over-
estimation of the treatment effect; whereby patients may be recommended interventions that have 
serious adverse events or be deprived of cheaper or more effective medication.178 In our systematic 
reviews, we approached trialists and relevant pharmaceutical companies for unpublished data but 
these were not made available. Therefore these systematic reviews are at risk of unavoidable 
publication bias. We have highlighted selective reporting of outcomes in our studies. 
 The issue of over-estimation of treatment effect due to selective outcome reporting can be further 
emphasised by selective outcome reporting in systematic reviews.208, 209 However, in these reviews 
the review authors ensured that all data for pre-defined outcomes were included.  
In these reviews, we reported on adverse effects of therapy as mild (therapy does not need to be 
discontinued), moderate (therapy is discontinued and the adverse effect deceases) and severe (life 
threatening or debilitating or persists after treatment is discontinued). This method of reporting 
adverse effects is clinically relevant and is recommended by the Cochrane Handbook of systematic 
reviews.159 It is also advocated by the CONSORT statement for harms for the reporting of adverse 
effects by RCTs, as it reflects the participant’s and/or clinician’s ultimate decision to withdraw or 
discontinue study medication.207 Despite this, there were a number of limitations in employing this 
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approach to reporting adverse effects. We first extracted the number of participants from each trial 
who required study drug interruption due to an to adverse effect (moderate adverse effect) and the 
number of participants experiencing life threatening or debilitating adverse events or adverse events 
that require the patient to discontinue the allocated treatment (severe adverse effect) as per 
protocol. With this classification however, all other adverse effects were considered under the 
heading mild, even though they may have reflected more severe adverse effects. In addition to this 
the reasons for study drug interruption or withdrawals in the included studies varied. This meant 
that participants who required study drug interruption or discontinuation due to mild adverse 
effects, for example a mild case of cough, were considered moderate or severe adverse effects in 
the review.  
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4.5 Conclusion  
In conclusion, the two systematic reviews demonstrate that there is evidence for the use of Ivacaftor 
in patients with G551D mutation but no evidence to support the short-term use of CFTR correctors 
or CFTR potentiators, or both as combination therapy in patients with the ΔF508 mutation. Readers 
of these systematic reviews should be aware of the limitations in methodological quality in the 
included studies of both reviews.   
4.6 Priorities for future research  
Ivacaftor is the first intervention that corrects the underlying molecular defect in CF. It has 
demonstrated effectiveness in patients with a class III mutation (G551D) and has the potential to be 
used for other class III/IV mutations because both mutation classes are characterised by ion gating 
defects. This has been demonstrated by cell studies.210 Trials examining the use of Ivacaftor in class 
III – IV mutations (e.g. R117H) are on-going, and we will update the findings of these reviews when 
they are available.193-196  
As patients with class II mutations comprise a significant proportion of all CF patients, identifying an 
efficacious CFTR corrector (or CFTR corrector and CFTR potentiator combination) will have a 
profound impact on the field. Researchers have been investigating drugs that can correct the 
underlying intracellular processing defect of class II mutations (mainly ΔF508 mutation) for many 
years. These therapies have come under increased limelight after Lumacaftor and Ivacaftor 
combination therapy partially restored chloride ion conductance in ΔF508 cell studies, and the 
progression of these therapies into human clinical trials. This review however demonstrated that 
short term therapy with Lumacaftor monotherapy or combination therapy with Ivacaftor did not 
demonstrate a clinically relevant impact on patients with class II mutations. There is a need for 
larger, well-designed clinical trials to assess the long term benefits and harms of CFTR corrector 
monotherapy and combination therapy with CFTR potentiators in people with class II mutations. 
Given the on-going clinical trials on Lumacaftor128-130 and VX-661,123, 124 both in combination with 
Ivacaftor, we expect this data to be available soon, and to update the findings of this review when 
this data are available.  
4.6.1 Study design  
As new clinical trials on mutation-specific-therapies emerge, it is important that the lessons learnt 
from these reviews are taken on board, in particular with regards to study design. Future studies 
should be well powered and of sufficient length to demonstrate 1) the long term impact of therapies 
on key outcomes and 2) the long term safety profile of this intervention and its effect on survival. 
This is particularly relevant for Ivacaftor given its association with the formation of cataracts in 
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juvenile rats treated with 10mg/kg/day of Ivacaftor.211 The mechanism of how this occurs is 
currently unknown. Post-market surveillance of this intervention will be equally as important.  
In addition, trialists should ensure the appropriate RCT study design is employed (parallel and not 
cross-over) and that all participants are properly randomised.  
4.6.2 Bias within included studies  
It is also important that lessons are learnt about minimising risk of bias in particular with regards to 
selective outcome reporting and incomplete outcome data (attrition bias). To reduce selective 
outcome reporting, there must be greater emphasis on improving the methodological transparency 
of these trials, starting with publically available published protocol containing pre-defined outcomes. 
Trialists should then report on all data for pre-defined outcomes, regardless of whether or not they 
demonstrated statistical significance or were consistent with other findings. Data that cannot be 
included in the full report due to limitation in the word count can be reported in the supplementary 
appendix or on online trials registries (for example ClinicalTrials.gov).  
In the USA and Europe, initiatives have been set up to reduce the burden of publication bias and 
selective outcome reporting. In the USA, trialists are required to publish all study protocols on online 
trials registries (www.clinicaltrials.gov).212 In Europe, the ‘ALLTRIALS’ campaign (www.alltrials.net), 
which is supported by the Cochrane Collaboration, aims to make the reporting of data more 
transparent. One recommendation is for all results of all trials to be publically available within 1 year 
of completion.213  
With regards to incomplete outcome data, future studies need to report on the number of 
participants included or excluded from the analysis and why participants were excluded. This will 
enable review authors to properly assess the risk of attrition bias.  
4.6.3 Outcomes  
With novel therapies and approaches, such as Ivacaftor, the reporting of adverse events is critical 
and this should be undertaken in a robust and consistent manner. Reporting the number of cases of 
temporary discontinuations and withdrawals is clinically relevant way of demonstrating the safety 
profile of an intervention. In order for adverse effect to be reported in this way, trialists must ensure 
that these data are reported with the following information 1) why participants were excluded 2)  
whose decision it was to discontinue or withdraw the patient and 3) whether blinding was 
maintained during this process. Only with this amount of detail can systematic reviews properly 
report on the safety profile of an intervention. This is particularly crucial to systematic reviews of 
novel therapies where the long-term safety profile of the intervention is mainly unknown. In 
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addition to this, there should be a more uniform and consistent reporting of pulmonary 
exacerbations by trialists, so that data from all relevant trials can be pooled.   
It is also important that these trials examine all valid outcomes that are relevant to patients with CF 
and their families. At present, these outcomes can be found in systematic reviews of Cystic Fibrosis, 
but both review authors and trialists would benefit from a core outcome set for systematic review of 
CF.208 Trialists would be aware of key outcomes expected to be reported during trials and this would 
increase the amount of data for synthesis in systematic reviews.  
Furthermore, there should be continued research into end-points in clinical trials that demonstrate 
improvements in clinical status of patients with different disease severities (discriminant validity). 
This is particularly relevant given the existing limitations of current end-points, such as survival rates 
and FEV1 in patients with mild lung disease, as patients with CF live longer and display better 
respiratory function.  
4.6.4 Precision of the treatment effect 
As more clinical trials are conducted on these interventions, more data will be available for inclusion 
in a meta-analysis providing a more precise estimate of the treatment effect. However, this is 
dependent on trials being homogenous and trialists reporting data in a standardised and consistent 
manner for pooling of the results. Therefore, before conducting new trials, trialists should also 
incorporate features of previously conducted trials, so that when data from these trials are 
combined they express minimal heterogeneity. Furthermore, trialists should continue to conduct 
multi-centre studies to demonstrate increased precision of the effect of mutation-specific-therapies 
on outcomes.   
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Appendix 
I. Interaction with primary authors of studies included in the CFTR 
potentiators review  
A. Evidence of interaction with primary author of the ΔF508 study  
E-mail 1: Request for additional outcome data for the ΔF508 study by Flume and response from 
Vertex.  
From: Flume, Patrick A. [mailto:flumepa@musc.edu]  
Sent: 07 January 2014 17:00 
To: Patel, Sanjay [md0u92cd] 
Cc: Southern, Kevin 
Subject: RE: Cochrane systematic review of a mutation specific therapy in Cystic Fibrosis 
Forgive the lengthy delay.  I finally heard back from Vertex.  The message is copied below. 
pf 
Patrick 
Sorry this email got lost in my system (probably reflects a lack of system!). 
I am not sure that there is much value to a Cochrane systematic review of the Kalydeco data since 
there is really only data from STRIVE and ENVISION. 
Many of the data points that he is requesting are not available or were not collected in the study. 
My suggestion is that you let him know that we are unable to supply these data at this time. 
Thanks and a Happy New Year. 
Best 
CJ 
From: Patel, Sanjay [md0u92cd] [mailto:S.Patel7@liverpool.ac.uk]  
Sent: Thursday, December 05, 2013 11:40 AM 
To: Flume, Patrick A. 
Cc: Southern, Kevin 
Subject: Cochrane systematic review of a mutation specific therapy in Cystic Fibrosis 
Dear Professor Flume, 
I am a postgraduate researcher at the University of Liverpool, UK. My research topic is on the novel 
Cystic Fibrosis mutation specific therapies that target the underlying CFTR defect. As part of my 
research, I am working with the Cochrane Cystic Fibrosis Group to conduct a Cochrane systematic 
review on CFTR potentiators. 
We would like to include the study “Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous 
for the F508del-CFTR Mutation” (ClinicalTrials.gov Identifier: NCT00953706) in our review. Many of 
 
  
118 
 
the endpoints reported in this study match the outcomes of interest we would like to investigate in 
the review. However for some of the endpoints no numerical data is presented and for others no 
confidence Interval or standard deviation has been given, so we are unable to include them in the 
meta analysis. 
The Mean Absolute change in CFQ-R respiratory domain scores are presented for both the placebo 
and the intervention group, however, no standard deviation or confidence intervals have been 
reported. Results have been reported in a similar way for absolute change in weight, absolute 
change in BMI, absolute change in weight-for-age-z-score and absolute change in BMI-for-age Z 
score. We would appreciate any standard deviation or confidence interval values for these means. 
In addition to this, the full paper reported hospitalisations and extra courses of antibiotics as 
clinically relevant events. We understand that the results obtained for these outcomes were not 
clinically significant; however we would like to view any numerical data on these outcomes. 
Finally, did you measure and would you be able to provide any information regarding 
· cost of treatment,  
· radiological measures of lung disease,  
· acquisition of respiratory pathogens or eradication of respiratory pathogens.  
These are other outcomes in our study that would like to comment on.  
Thank you for taking the time to read this e-mail. Any information you can provide will help shape 
the results of the systematic review and will be highly appreciated. 
Regards, 
Sanjay Patel.   
E-mail 2: Request for information on missing data in the ΔF508 study by Flume  
From: Patel, Sanjay [md0u92cd] 
Sent: 23 January 2014 11:05 
To: flumepa@musc.edu 
Cc: Southern, Kevin 
Subject: FW: Cochrane systematic review of a mutation specific therapy in Cystic Fibrosis 
Dear Professor Flume,  
 
Whilst assessing whether an intention to treat analysis was employed, I noticed that in table 3 of the 
full paper, the number of participants in the ivacaftor group is displayed as 112. However, In the 
results section on clinicaltrials.gov, the number of participants in the ivacaftor group is shown to be 
111. Could you provide an explanation for this discrepancy? I have attached both the full paper and 
a screenshot from clinical trials.gov. The following web address is a link to the results of the study on 
clincaltrials.gov:  
 
http://clinicaltrials.gov/ct2/show/results/NCT00953706?term=Ivacaftor+AND+cystic+Fibrosis&rank=
7§=X6015 
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In addition to this, one of the participants from the ivacaftor group was removed from the trial due 
to 'early termination per sponsor decision' as shown on clinicaltrials.gov. Could you provide further 
information as to why this participant was discontinued from the study.  
 
I appreciate the time you have taken to read this e-mail and look forward to hearing from you.  
 
Regards, 
  
Sanjay Patel.  
 
E-mail 3 : Request for trial protocol and key outcome data measured in the trial but not reported 
in the published text. 
From: Patel, Sanjay [md0u92cd] 
Sent: 02 February 2014 12:10 
To: flumepa@musc.edu 
Cc: Southern, Kevin 
Subject: FW: Cochrane systematic review of a mutation specific therapy in Cystic Fibrosis 
Dear Professor Flume,  
 
Thank you for taking the time to contact Vertex regarding outcomes of interest. We appreciate the 
time taken to do so.  
 
There are however, a couple more points I would like to ask about. I apologise for not requesting this 
information, and the information regarding intention to treat analysis, in the initial e-mail.  
 
I would like to request the study protocol for the study “Ivacaftor in Subjects With Cystic Fibrosis 
Who Are Homozygous for the F508del-CFTR Mutation."  Currently, only the full paper and the 
supplementary appendix are available online. In addition, would you be able to provide any 
numerical data for the outcome change from baseline in Forced Vital Capacity (FVC). In the full 
paper, you have mentioned that no statistically significant differences were seen in this outcome; 
however no numerical data has been reported.  
 
Thank you again, for your time and we look forward to hearing from you,  
 
Sanjay Patel.  
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B. Evidence of Interaction with primary author of the child phase 3 G551D study  
 
E-mail 4: Request for additional outcome data for the child phase 3 G551D study by Davies  
From: Davies, Jane C [j.c.davies@imperial.ac.uk] 
Sent: 06 December 2013 11:49 
To: Patel, Sanjay [md0u92cd] 
Cc: Southern, Kevin 
Subject: RE: Cochrane systematic review of mutation specific therapy in Cystic Fibrosis 
Dear Sanjay 
None of those items were included in that study, which I agree is a shame. 
Good luck with your review 
Warm regards, Jane 
From: Sanjay Patel [mailto:s.patel7@liverpool.ac.uk]  
Sent: 05 December 2013 16:07 
To: Davies, Jane C 
Cc: Kevin Southern 
Subject: Cochrane systematic review of mutation specific therapy in Cystic Fibrosis 
Dear Dr Jane Davies,  
I am a postgraduate researcher at the University of Liverpool, UK. My research topic is on the novel 
Cystic Fibrosis mutation specific therapies that target the underlying CFTR defect. As part of my 
research, I am working with the Cochrane Cystic Fibrosis Group to conduct a Cochrane systematic 
review on CFTR potentiators. 
We would like to include “Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the 
G551D Mutation” (ClinicalTrials.gov Identifier: NCT00909727) in our systematic review. Many of the 
outcomes reported on in this study match the outcomes of interest that we would like to investigate 
in the review.  However I am contacting you to ask whether you measured or have data on any of 
the following outcomes. 
· cost of treatment, 
· hospitalisation, 
· school work attendance, 
· radiological measures of lung function, 
· Acquisition of respiratory pathogens and 
· Eradication of respiratory pathogens and height 
Any additional information would go towards shaping the results of the review and would be highly 
appreciated.  
Regards,  
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Sanjay Patel  
E-mail 5: Interaction between review author, Professor Jane Davies and Vertex regarding 
incomplete outcome data in the child phase 3 G551D study.  
Hi Jane,  
Please find Haihong’s response below.  Essentially, the requester is correct in that not all patients 
had measurements available at every timepoint. This is addressed by the footnote in the table that 
reads, “*Least squares mean and mixed-effects model for repeated measures. Adjusted for all 
available”.   
Let me know if any additional information would be helpful. 
Best,  
Elizabeth 
From: Haihong Li  
Sent: Friday, May 17, 2013 10:22 AM 
To: Elizabeth Dorn 
Subject: RE: Cochrane review about Ivacaftor - request for information please 
Hi Elizabeth, 
In the supplement, the “N” represents number of subjects in the Full Analysis Set in respective arms, 
defined as all randomized subjects who took at one dose of study drug.  (To address the last 
question, this represents modified ITT, and is not per-protocol.)  For Study 770-103 N=26 for both 
ivacaftor and placebo.   
Among these, not all subjects completed all assessments.  Therefore, for a particular endpoint, the 
available subjects could be less than 26 per arm. 
I went to clinicaltrial.gov and found that the number of subjects reported: 
  Placebo Ivacaftor 
Percent Predicted FEV1 25 26 
CFQ-R 25 26 
Sweat Chloride 23 23 
Weight 26 26 
 
Since the numbers in the supplement and at clinicaltrials.gov carry different interpretations, there is 
no real discrepancy, especially since the results are identical between these 2 places.  However, if 
the editors insist, we can add the numbers of subjects with available assessments (i.e., numbers 
from CT.gov) to the table in the supplement. 
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Thanks, 
Haihong 
From: Elizabeth Dorn  
Sent: Friday, May 17, 2013 8:46 AM 
To: Haihong Li 
Subject: FW: Cochrane review about Ivacaftor - request for information please 
Hi Haihong,  
Request from Jane Davies to clarify the following questions. Can you help? 
iii) I noticed a few differences between the number of patients included in analyses for some 
outcomes when your data were presented on clinicaltrials.gov, and the number in the 
Supplementary file in your paper. In the paper, it is stated that n=52 (26/group) for all outcomes at 
24 and 48 weeks, but on clinicaltrials.gov, this is different (although the results are identical) - in 
particular, there is a discrepancy for sweat chloride (46 on clinical trials.gov), FEV1 (1 excluded from 
placebo group), and CFQR (1 excluded from placebo group). Weight appears to have included all 
patients in the analysis, both on clinicaltrials.gov, and in the paper. I would be grateful if you may 
clarify the discrepancies here, and whether the analysis was ITT or per-protocol.  
E-mail 6: Request for trial protocol and key outcome data measured in the trial but not reported in 
the published text for the child phase 3 G551D study.  
 Dear Sanjay and Kevin 
I’ve heard back from Vertex and I’m sorry to say that they are not willing to share these data; I’m 
disappointed in that decision and will discuss it with senior members of staff whom I’ll be seeing 
soon at a forthcoming meeting but apologise that I can’t help further at the moment 
Warm regards, Jane 
From: Patel, Sanjay [md0u92cd] [mailto:S.Patel7@liverpool.ac.uk]  
Sent: 02 February 2014 12:56 
To: Davies, Jane C 
Cc: Southern, Kevin 
Subject: RE: Cochrane systematic review of mutation specific therapy in Cystic Fibrosis 
Dear Dr Jane Davies ,   
Thank you for taking the time to respond to us regarding outcomes of interest.  
There are however, a couple more points I would like to ask about. I apologise for not requesting this 
information, and the information regarding intention to treat analysis, in the initial e-mail.  
Would I be able to request the study protocol for the study: “Study of Ivacaftor in Cystic Fibrosis 
Subjects Aged 6 to 11 Years With the G551D Mutation (ENVISION).”  Currently, only the full paper 
and the supplementary appendix are available online. In addition, the supplementary appendix 
states that FVC was measured at visits scheduled on day 1, day 15 and week 8, then every week 
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through week 48, however results have not been reported. Would you be able to provide any 
numerical data for the outcome change from baseline in Forced Vital Capacity (FVC).  
Thank you for your time and we look forward to hearing from you,  
Sanjay Patel.  
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C. Evidence of Interaction with primary author of the adult phase 3 G551D study  
 
E-mail 7: Request for additional outcome data for the adult phase 3 G551D study by Ramsey  
From: Sanjay Patel [s.patel7@liv.ac.uk] 
Sent: 05 December 2013 16:23 
To: bonnie.ramsey@seattlechildrens.org 
Cc: Southern, Kevin 
Subject: Cochrane systematic review of a mutation specific therapy in Cystic Fibrosis 
Dear Professor Ramsey, 
I am a postgraduate researcher at the University of Liverpool, UK. My research topic is on the novel 
Cystic Fibrosis mutation specific therapies that target the underlying CFTR defect. As part of my 
research, I am working with the Cochrane Cystic Fibrosis Group to conduct a Cochrane systematic 
review on CFTR potentiators. 
We would like to include the study “A CFTR Potentiator in Patients with Cystic Fibrosis and the 
G551D Mutation” (ClinicalTrials.gov number NCT00909532). I am writing to request additional 
results you may have of the study. 
Firstly, confidence intervals or the standard deviation have not been given for the mean difference 
between groups in the Cystic Fibrosis Questionnaire Revised domain score (CFQ-R). A treatment 
difference of +8.1 with a P value of P<0.0001 is given, however a standard deviation or confidence 
interval is required to include this result into the meta-analysis. Also, this is the result given for the 
pooled result from the adult and child questionnaires. Would it be possible to obtain the non-pooled 
results? 
In addition to this, we would like to request any addition data you may have on the following 
endpoints of interest; 
· Cost of treatment, 
· school work attendance, 
· radiological measures of lung function, 
· Acquisition of respiratory pathogens, 
· Eradication of respiratory pathogens and  
· Height. 
These are endpoints we have included in our review that we hope to comment on. 
Any information that you are able to provide will help shape this review and would be highly 
appreciated. 
Regards, 
Sanjay Patel  
E-mail 8: Request for information on incomplete outcome data in the adult phase 3 G551D study 
by Ramsey  
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From: Patel, Sanjay [md0u92cd]  
Sent: 27 January 2014 13:14 
To: bonnie.ramsey@seattlechildrens.org 
Cc: Southern, Kevin 
Subject: Cochrane systematic review of mutation specific therapy in Cystic Fibrosis 
Dear Dr Ramsey, 
I am a postgraduate researcher at the University of Liverpool, UK. My research topic is on the novel 
Cystic Fibrosis mutation specific therapies that target the underlying CFTR defect. As part of my 
research, I am working with the Cochrane Cystic Fibrosis Group to conduct a Cochrane systematic 
review on CFTR potentiators. I have attached the protocol.   
We would like to include the study “Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and 
Older with the G551D Mutation (STRIVE)” (ClinicalTrials.gov number NCT00909532) in our review. 
When assessing whether an intention to treat analysis was employed, according to the 
supplementary appendix table 1, the number of participants analysed in the placebo group is 78 and 
in the Ivacaftor group is 83. However, according to the results presented on clinicaltrials.gov, 71 
participants in the placebo group and 80 in the Ivacaftor group were analysed for the CFQ-R 
respiratory domain scores. In addition to this, 74 participants in the placebo group and 78 in the 
Ivacaftor group were analysed for the outcome; change from baseline in sweat chloride 
concentration. Could you provide an explanation for this discrepancy? I have attached both the 
supplementary appendix and a screenshots from clinical trials.gov.  
I appreciate the time you have taken to read this e-mail and look forward to hearing from you.  
Regards, 
 Sanjay Patel. 
E-mail 9: Request for data on outcomes pre-specified in the protocol but not reported in published 
text in the adult phase 3 G551D study by Ramsey.  
This e-mail was sent but cannot be located. It was sent by a different review author.       
E-mail 10: Request for clarification on discrepancy between full text and supplementary data in 
the relative change from baseline in FEV1 at 24 weeks in the adult phase 3 G551D study by 
Ramsey. 
From: Sanjay Patel [s.patel7@liv.ac.uk] 
Sent: 20 January 2014 16:08 
To: bonnie.ramsey@seattlechildrens.org 
Cc: Southern, Kevin 
Subject: Cochrane Systematic Review of CFTR Potentiators for Cystic Fibrosis  
Dear Dr Ramsey   
 
I am a Masters student at the University Of Liverpool, UK. I am currently conducting a Cochrane 
Systematic Review of CFTR potentiators and the study titled “A CFTR potentiator in Patients with 
Cystic Fibrosis and the G551D Mutation” is suitable for inclusion.  
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When reading the paper, I noticed a discrepancy. Under the subheading “Clinical Efficacy” in the 
Results section of the paper, you have reported a relative change from baseline of 17.2% in the 
Ivacaftor group and 0.1% in the placebo group at 24 weeks. This gives a treatment effect of 17.1%. In 
supplementary table 1 of the supplementary appendix however, you have reported a relative 
change from baseline of 17.6% in the Ivacaftor group and 0.7% in the placebo group at the same 24 
week time point. These values give a treatment effect of 16.9%. Could you clarify this discrepancy.  
 
I appreciate the time taken to read this e-mail and any information you are able to provide.  
 
Regards,  
 
Sanjay Patel.  
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D. Evidence of Interaction with primary author of the phase 2 G551D study  
 
E-mail 11: Request for additional outcome data and key data that were measured during the trial 
but not reported in the full text in the phase 2 G551D study by Accurso.  
From: Patel, Sanjay [md0u92cd]  
Sent: 27 December 2013 13:38 
To: accurso.frank@tchden.org 
Cc: Southern, Kevin 
Subject: Cochrane systematic review of mutation specific therapy in Cystic Fibrosis  
Dear Dr Accurso, 
I am a postgraduate researcher at the University of Liverpool, UK. My research topic is on the novel 
Cystic Fibrosis mutation specific therapies that target the underlying CFTR defect. As part of my 
research, I am working with the Cochrane Cystic Fibrosis Group to conduct a Cochrane systematic 
review on CFTR potentiators. The following web address is a link to the protocol:  
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009841/abstract 
We would like to include Part 2 of the study “Effect of VX-770 in Persons with Cystic Fibrosis and the 
G551D-CFTR Mutation” (ClinicalTrials.gov number, NCT00457821) in our review. Many of the 
outcomes reported on in this study match the outcomes of interest that we would like to investigate 
in the review. However I am contacting you to ask whether you measured or have data on any of the 
following outcomes: 
· survival,  
· cost of treatment,  
· hospitalisation,  
· extra courses of antibiotics,  
· radiological measures of lung function,  
· Acquisition of respiratory pathogens,  
· Eradication of respiratory pathogens,  
· nutrition and growth (weight, height and BMI).  
For any continuous data outcomes (e.g. measures of lung function) we would appreciate it if you 
were able to send us values for the mean and standard deviation for each group (treatment and 
control). For binary data, we need the number of patients experiencing an event (not the actual 
number of events) per group (treatment and control) in order to be able to analyse these correctly.  
Any additional information would go towards shaping the results of the review and would be highly 
appreciated. We will, of course, acknowledge your assistance in the published version of the review 
Regards, 
Sanjay Patel. 
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2. Data extraction forms for studies included in the CFTR potentiators review.  
Data Extraction Table 1 Phase 2 G551D study by Accurso (2010)  
TRIAL ID ACCURSO 2010 
MAIN REFERENCE  N Engl J Med 2010;363:1991-2003. 
OTHER REFERENCES     
FUNDING (delete) Pharma Non-pharma  DETAILS:  VERTEX, NIH, CFF, OTHER NON-PHARMA 
POPULATION AGE: >18 YO Median (Range): 21 (18-42)  
10 MALES (53%) 9 FEMALES (47%) 
GENETICS: AT LEST ONE G551D-CFTR 
allele 
OTHER (EG FEV1): FEV1>40% PRED 
INTERVENTION (EXPERIMENTAL ARMS) AND CONTROL ARM (N RANDOMISED) 
DRUG VX 770 
DRUG DOSE ARM 1 150 MG BD (N=8) 
DRUG DOSE ARM 2 250 MG BD (N=7) 
LENGTH OF TREATMENT 28 DAYS  
DESCRIPTION OF CONTROL MATCHED PLACEBO (N=4) 
PRIMARY OUTCOME 
PRIMARY OUTCOME 1 SAFETY 
SAMPLE SIZE  REQUIRED: NOT CALCULATED. ASSUMED 38 SUFFICIENT RANDOMISED: 19 IN PART 2 (AND 19 IN PART 1) 
PRIMARY TIMEPOINT  CONTINUOUS THROUGHOUT 1 MONTH PERIOD AND 1 WEEK FOLLOW UP 
SECONDARY OUTCOMES (Y/N)  , COMMENTS ,  TIMEPOINT(S) , WHO WAS BLINDED (IF REVLEVANT) 
MORTALITY  NO 
REL FEV1  Days 1, 3, 14, 21, and 28 
QOL  Days 1, 14, and 28 ; CFQ-R  
OTHER PFT (SPECIFY)  FVC, FEV1, FEV1/FVC, and FEF25-75  ;  Days 1, 3, 14, 21, and 28 
HOSPITAL ADMISSION  NO 
SCHOOL/WORK DAYS MISSED  INCLUDED UNDER ‘ROLE’ DOMAIN OF CFQ-R  
EXTRA ANTIBIOTICS  NO 
RADIOLOGICAL OUTCOMES  NO 
NUTRITIONAL OUTCOMES  WEIGHT : Days 1, 3, 14, 21, 28, and at follow-up = MEASURED BUT NOT REPORTED AS AN OUTCOME 
SWEAT CHLORIDE  Days 1, 3, 14, 21 and 28 
MICROBIOLOGICAL OUTCOME  NO 
ERADICATION OF RESPIRATORY 
PATHOGENS  
 No  
SAFETY  YES 
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OUTCOME TIME COMPARISON HOW 
EXPRESSED 
RESULTS      NOTES EG TYPE OF OUTCOME 
ETC 
  ARM 1 
(N) 
ARM 2 
(N) 
EG Δ BL, 
TIME TO  
RESULT 
ARM 1 
RESULT 
ARM 2 
DIFF VARIANCE 
(SPECIFY) 
P CI 
SWEAT CHLORIDE D14 150 (8) PLAC (4) MEDIAN Δ 
BL 
    0.03  1. SWEAT CHLORIDE ALSO 
MEASURED ON D3 AND D21, 
BUT RESULTS NOT REPORTED 
2. UNITS = MMOL/L 
SWEAT CHLORIDE D14 250 (7) PLAC (4) MEDIAN Δ 
BL 
    0.05  
SWEAT CHLORIDE D28 150 (8) PLAC (4) MEDIAN Δ  
BL  
-59.5 +5.0   0.02  
SWEAT CHLORIDE D28 250 (7) PLAC (4) MEDIAN Δ 
BL 
-38.0 +5.0   0.03  
FEV1 (% predicted relative to 
baseline) 
D14 150 (8) PLAC (4) MEDIAN REL 
Δ BL 
    0.46  1. FEV1 ALSO MEASURED ON 
D3 AND D21, BUT RESULTS 
SHOWN ON FIGURE 3 – NOT 
STATISTICALLY SIGNIFICANT 
 
  250 (7) PLAC (4) MEDIAN REL 
Δ BL 
    1.0  
FEV1 (L) D14 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
    0.46  
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
    0.07  
FEV1 (% predicted relative to 
baseline) 
D28 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
+ 8.7% 
(2.3 TO 
31.3) 
+7.3% 
(5.2 TO 
8.2) 
  0.56  
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
+4.4% (0 
TO 18.3) 
+7.3% 
(5.2 TO 
8.2) 
  0.78  
FEV1 (L) D28 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
+0.25 L 
(0.05 TO 
0.75) 
+0.20 L 
(0.12 TO 
0.33) 
  1.0  
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
+.017 L (0 
TO 0.37)  
+ 0.20 L 
(0.12 TO 
0.33)  
  0.65  
FVC D28 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
+0.18 +0.10      
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
+ 0.09 L +0.10     
FEF25-75 D14 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
+0.06 
L/SEC 
+0.09   0.56   
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
+0.44 +0.09   0.05  
 D28 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
+0.05 +0.27     
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
+0.17 +0.27     
QOL – RESP DOMAIN OF CFQR D14 150 (8) PLAC (4) MEDIAN +5.6 (0 +2.8 (-   0.61   
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VALUE Δ BL 
(RANGE) 
TO 16.7) 5.6 TO 
11.1)  
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
+5.6 (-
11.1 TO 
11.1)  
+2.8 (-
5.6 TO 
11.1) 
  0.71  
 D28 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
+8.3 (0 
TO 16.7) 
+2.8 (-
5.6 TO 
11.1) 
  0.45  
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
+11.1 (-
5.6 TO 
33.3) 
+2.8 (-
5.6 TO 
11.1) 
  0.47  
QOL – BODY IMAGE  D14 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-22.2 
TO 0) 
0 (-11.1 
TO 22.2) 
     
  250 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-11.1 
TO 22.2) 
0 (-11.1 
TO 22.2) 
     
 D28 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-22.2 
TO 11.1) 
-5.6 (-
11.1 TO 
22.2) 
     
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-11.1 
TO 44.4)  
-5.6 (-
11.1 TO 
22.2) 
     
QOL – DIGESTIVE SYMPTOMS  D14 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (0 TO 
22.2)  
-5.6 (-
22.2 TO 
0) 
     
  250 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-11.1 
TO 22.2)  
-5.6 (-
22.2 TO 
0) 
     
 D28 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
5.6 (0 TO 
22.2) 
0 (-22.0 
TO 0) 
     
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-11.1 
TO 33.3) 
0 (-22.0 
TO 0) 
     
QOL – EATING DISTURBANCES  D14 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (0 TO 
11.1) 
0 (-11.1 
TO 11.1) 
     
  250 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-11.1 
TO 0) 
0 (-11.1 
TO 11.1) 
     
 D28 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (0 TO 0) -5.6 (-
11.1 TO 
0) 
     
  250 (7) PLAC (4) MEDIAN 0 (-11.1 -5.6 (-      
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VALUE Δ BL 
(RANGE) 
TO 0)  11.1 TO 
0) 
QOL – EMOTIONAL 
FUNCTIONING  
D14 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-26.7 
TO 0) 
13.3 (-
6.7 TO 
20.0) 
     
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-20.0 
TO 26.7) 
13.3 (-
6.7 TO 
20.0) 
     
 D28 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-6.7, 
6.7) 
3.3  
(0, 20.0) 
     
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
6.7 (-6.7, 
20.0) 
3.3  
(0, 20.0) 
     
QOL – HEALTH PERCEPTIONS  D14 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-22.2 
to 22.2) 
5.6 (-
11.1 to 
11.1) 
     
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
(-33.3 to 
11.1) 
5.6 (-
11.1 to 
11.1) 
     
 D28 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-22.2 
to 22.2) 
0 (-11.1 
to 11.1) 
     
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-11.1 
to 11.1) 
0 (-11.1 
to 11.1) 
     
QOL – PHYSICAL FUNCTIONING  D14 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
2.1 (-4.2 
to 16.7) 
0 (0 to 
4.2) 
     
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
4.2 (0 to 
8.3) 
0 (0 to 
4.2) 
     
 D28 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
4.2 (-8.3 
to 25.0) 
2.1 ( 0 to 
4.2) 
     
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (0 to 
12.5)  
2.1 ( 0 to 
4.2) 
     
QOL – ROLE  D14 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-8.3 to 
8.3) 
0 (0 to 
8.3) 
     
  150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (0 to 
8.3)  
0 (0 to 
8.3) 
     
 D28 150 (8) PLAC (4) MEDIAN 0 (-8.3 to 0 (0 to 0)      
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VALUE Δ BL 
(RANGE) 
8.3)  
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-8.3 to 
8.3)  
0 (0 to 0)      
QOL – SOCIAL  D14 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-44.4 
to 11.1) 
2.8 (-5.6 
to 5.6) 
     
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
-5.6 (-
16.7 to 
5.6) 
2.8 (-5.6 
to 5.6) 
     
 D28 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-11.1 
to 5.6) 
2.8 (-
11.1 to 
5.6) 
     
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-16.7 
to 11.1) 
2.8 (-
11.1 to 
5.6) 
     
QOL – TREATMENT BURDEN   D14 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
-5.6 (-
22.2 to 
11.1) 
0 (-11.1 
to 11.1)  
     
  150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-22.2 
to 22.2) 
0 (-11.1 
to 11.1) 
     
 D28 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
-5.6 (-
22.2 to 
11.1) 
0 (0 to 0)      
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-22.2 
to 11.1) 
0 (0 to 0)      
QOL – VITALITY  D14 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
4.2 (-8.3 
to 16.7) 
4.2 (-
16.7 to 
8.3) 
     
  150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-8.3 to 
16.7) 
4.2 (-
16.7 to 
8.3) 
     
 D28 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-16.7 
to 25.0) 
-8.3 (-
16.7 to 
0) 
     
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (0 to 
16.7) 
-8.3 (-
16.7 to 
0) 
     
QOL – WEIGHT  D14 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (0 to 
33.3) 
0 (0 to 
33.3) 
     
  150 (8) PLAC (4) MEDIAN 0 (-33.3 0 (0 to      
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OUTCOME TIME COMPARISON HOW 
EXPRESSED 
RESULTS      NOTES EG TYPE OF OUTCOME 
ETC 
  ARM 1 
(N) 
ARM 2 
(N) 
EG Δ BL, 
TIME TO  
RESULT 
ARM 1 
RESULT 
ARM 2 
DIFF VARIANCE 
(SPECIFY) 
P CI 
WEIGHT           MEASURED BUT NOT 
REPORTED IN PUBLICATION 
SWEAT CHLORIDE (MMOL/L)  D28 150 PLAC MEDIAN 
VALUE Δ BL 
(RANGE) 
-59.5 (-
66.0 TO -
19.0)  
+5.0 (-
2.0 TO 
+11.0) 
  0.02  D1, D3 , D14, D21 REPORTED 
BUT NOT EXTRACTED AS TOO 
SHORT TERM FOR THIS 
REVIEW?    250 PLAC MEAN 
CHANGE BL 
-38.0 (-
47.0 TO -
10.5)  
+5.0 (-
2.0 TO 
+11.0) 
  0.03  
 
 
             
 
SEVERITY OF ADVERSE EVENTS, AS GRADED BY TRIAL AUTHORS  
 PLACEBO N=4 VX770 ANY 
DOSE N=15 
VX770 150MG  
N=8 
VX770 250 
MG N=7 
MILD 3 (75) 10 5 (63) 5 (71) 
MODERATE 1 (25) 2 1 (13) 1 (14) 
SEVERE 0 0 0 0 
 
DISCONTINUATION OF STUDY DRUG : NONE IN ANY GROUP 
ADVERSE EVENT/ EFFECT REQUIRING STUDY DRUG INTERRUPTION : NOT REPORTED 
VALUE Δ BL 
(RANGE) 
to 33.3) 33.3) 
 D28 150 (8) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (0 to 
33.3) 
0 (0 to 
33.3) 
     
  250 (7) PLAC (4) MEDIAN 
VALUE Δ BL 
(RANGE) 
0 (-33.3 
to 33.3)  
0 (0 to 
33.3) 
     
 
  
134 
 
Data Extraction Table  2 Adult Phase 3 G551D study by Ramsey (2011)   
TRIAL ID RAMSEY 2011 – “STRIVE” 
MAIN REFERENCE N Engl J Med 2011;365:1663-72. 
FUNDING (delete) Pharma Non-pharma Unclear DETAILS: VERTEX AND OTHERS (NON-PROFIT EG NIH) 
POPULATION AGE: >12 YO 
GENETICS: AT LEAST ONE G551D ALLELE 
OTHER (EG FEV1): FEV1>40%PRED 
INTERVENTION (EXPERIMENTAL ARMS) AND CONTROL ARM 
DRUG Ivacaftor  
DRUG DOSE ARM  150 MG BD 
LENGTH OF TREATMENT 48 WEEKS 
DESCRIPTION OF CONTROL MATCHED PLACEBO 
PRIMARY OUTCOME 
PRIMARY OUTCOME 1 ABSOLUTE CHANGE FROM BASELINE IN FEV1  
PRIMARY OUTCOME 2  
SAMPLE SIZE  REQUIRED: 80 RANDOMISED: 160 
PRIMARY TIMEPOINT  48 WEEKS 
SECONDARY OUTCOMES (Y/N)  , COMMENTS ,  TIMEPOINT(S) , WHO WAS BLINDED (IF REVLEVANT) 
MORTALITY   
FEV1 Y Spirometry (FEV1,) measured D1, D15, W4, W8, W12, W16, W20 W24, W28, W32, W36, W44, W48 
QOL Y CFQ-R resp domain only measured D1, D15, W4, W8, W12, W16, W20 W24, W28, W32, W36, W44, W48 
OTHER CFQ-R DOMAIN presented in abstract form - significant results only 
EQ-5D Measured D1, D15, W8, W16, W24, W32, W40, W48 – NOT REPORTED IN PUBLICATION  
OTHER PFT (SPECIFY)  FVC, FEV1/FVC/FEF MEASURED ACCORDING TO PROTOCOL measured D1, D15, W4, W8, W12, W16, W20 W24, W28, 
W32, W36, W44, W48 
HOSPITAL ADMISSION Y  
SCHOOL/WORK DAYS MISSED N  
EXTRA ANTIBIOTICS Y  
RADIOLOGICAL OUTCOMES N  
NUTRITIONAL OUTCOMES Y WEIGHT Measured D1, D15, W8, W16, W24, W32, W40, W48 
HEIGHT Measured D1, D15, W8, W16, W24, W32, W40, W48 – NOT REPORTED IN PUBLICATION 
SWEAT CHLORIDE Y Measured D1, D15, W8, W16, W24, W32, W40, W48 
MICROBIOLOGICAL OUTCOME N  
SAFETY Y Adverse effects of therapy – measured D1, D15, W4, W8, W12, W16, W20 W24, W28, W32, W36, W44, W48  
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OUTCOME TIME 
(wks) 
COMPARISON HOW 
EXPRESSED 
RESULTS      NOTES EG TYPE OF OUTCOME 
ETC 
  ARM 1 
(N) 
ARM 2 
(N) 
EG Δ BL, 
TIME TO  
RESULT 
ARM 1 
RESULT 
ARM 2 
MEAN 
DIFF 
VARIANCE 
(SPECIFY) 
P CI 
FEV1 %PRED 24 83 78 MEAN 
CHANGE BL 
%PRED +/- 
SE 
10.4 +/- 
0.7 
-0.2 +/- 
0.7 
10.6 SEM +/-1.0  <0.000
1 
8.6-
12.6 
 
FEV1 %PRED 48 83 78 MEAN 
CHANGE BL 
%PRED 
10.1+/- 
0.7 
-0.4 +/- 
0.7 
10.5  SEM +/-1.0 <0.000
1 
8.5-
12.5 
FEV1 LITRES 24 83 78 MEAN 
CHANGE BL, 
LITRES 
0.4 0.0 0.4  <0.000
1 
0.3-0.4 
FEV1 LITRES 48 83 78 MEAN 
CHANGE BL 
LITRES 
0.4 0.0 0.4  <0.000
1 
0.3-0.4 
FEV1 RELATIVE 24 83 78 MEAN 
CHANGE BL 
RELATIVE 
17.6 0.7 16.9  <0.000
1 
13.6-
20.2 
FEV1 RELATIVE 48 83 78 MEAN 
CHANGE BL 
RELATIVE 
17.5 0.8 16.8  <0.000
1 
13.5-
20.1 
 
QOL – pooled child and adult 
respiratory domain  
24 80 71 MEAN 
CHANGE BL 
+/- SE 
6.0 +/- 
1.2 
-2.1 +/- 
1.3 
8.1   SEM +/-1.7 <0.000
1 
4.7-
11.4 
 
QOL – pooled child and adult 
respiratory domain  
48 80 71 MEAN 
CHANGE BL 
+/- SE 
6.0 +/- 
1.1 
-2.7 +/- 
1.2 
8.6  SEM +/-1.7 <0.000
1 
5.3-
11.9 
 
HOSPITALISATION 48/52 83 78 NUMBER OF 
EXACERBATI
ONS 
REQUIRING 
21 33  *   0.1948  *NOTE – 33 REPORTED IN 
SUPPLEMENTARY DATA, BUT 
31 REPORTED IN PUBLICATION 
HOSPITALISATION 48/52 83 78 DAYS 
HOSPITALISE
D FOR 
EXACERBATI
ONS 
3.92 4.15   0.0275     
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PULMONARY EXACERBATION – 
REQUIRING IV ANTIBIOTICS  
48 83 78 RATE OF 
EVENT 
47 99   0.0003  NOTE, THIS IS NOT 
PRESPECIFIED AS AN 
OUTCOME IN OUR PROTOCOL 
EXTRA IV ANTIBIOTIC 
(PULMONARY EXACERBATION) 
48 83 78 RATE OF 
EVENT 
28 47   0.0776     
DAYS WITH IV ABX 
ADMINISTERED FOR 
PULMONARY EXACERBATIONS  
48 83 78 DAYS WITH 
IV ABX FOR 
PULMONARY 
EXACERBATI
ONS 
6.68 
(19.43) 
11.03 
(20.36) 
  0.0183     
EXTRA IV ANTIBIOTIC 
(PULMONARY EXACERBATION) 
   TIME TO – 
REPORTED 
AS 
PROPORTIO
N-FREE 
       
 
WEIGHT 24 83 78 MEAN 
CHANGE 
FROM BL, IN 
KG +/- SEM 
3.0 +/- 
0.4 
0.2 +/- 
0.2 
2.8 SEM +/- 0.5 <0.000
1 
1.8 TO 
3.7 
IN SUPPLEMENTARY APPENDIX 
P VALUE FOR DIFFERENCE IS 
<0.0001 BUT IN BOROWITZ 
ABSTRACT P=0.0001 AT 48 
WKS.  WEIGHT 48 83 78 MEAN 
CHANGE 
FROM BL, IN 
KG +/- SEM 
3.1 +/- 
0.5 
0.4 +/- 
0.5  
2.7 SEM +/- 0.7 <0.000
1 
1.3-4.1 
BMI 24/52   MEASURED 
BUT NOT 
REPORTED 
         
 48/52   MEASURED 
BUT NOT 
REPORTED 
         
NOTE – BMI AND HEIGHT, 
REPORTED FOR 12-20 YO WERE 
PRESENTED IN BOROWITZ 
ABSTRACT BUT NOT IN STUDY 
REPORT 
             
              
SWEAT CHLORIDE 24 78 74 MEAN 
CHANGE BL 
MMOL/L +/- 
SEM 
-48.7 +/- 
1.2 
-0.8 +/- 
1.3 
-47.9 SEM +/- 1.7 <0.000
1 
-51.3 
TO -
44.5 
   
SWEAT CHLORIDE 48 78 74 MEAN 
CHANGE BL 
MMOL/L +/- 
SEM 
-48.7 +/- 
1.2 
-0.6 +/- 
1.3 
-48.1 SEM +/- 1.7 <0.000
1 
-51.5 
TO -
44.7 
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WEIGHT Z SCORE  48   MEAN 
CHANGE BL  
  0.33  0.0260   ONLY 47 PARTICIPANTS OF 161 
WERE INCLUDED IN Z SCORE 
ANALYSIS. (BORROWITZ 
ABSTRACT)  
BMI (KG/M2) 48 83 78 MEAN 
CHANGE BL 
  0.93  <0.000
1 
 (BORROWITZ ABSTRACT) 
BMI Z SCORE (AGED 12-20)  48    MEAN 
CHANGE BL 
  0.33  0.0490  ONLY 47 PARTICIPANTS OF 161 
WERE INCLUDED IN Z SCORE 
ANALYSIS. (BORROWITZ 
ABSTRACT) 
HEIGHT Z SCORE (AGED 12-20)  24   MEAN 
CHANGE BL 
  +0.05    ONLY 47 PARTICIPANTS OF 161 
WERE INCLUDED IN Z SCORE 
ANALYSIS. (BORROWITZ 
ABSTRACT) 
“NOT SIGNIFICANT’ NO P 
VALUE PUBLISHED 
HEIGHT Z SCORE (AGED 12-20)  48   MEAN 
CHANGE BL 
  +0.06    ONLY 47 PARTICIPANTS OF 161 
WERE INCLUDED IN Z SCORE 
ANALYSIS. (BORROWITZ 
ABSTRACT) 
“NOT SIGNIFICANT’ NO P 
VALUE PUBLISHED 
              
QOL – pooled child and adult 
physical functioning scale  
domain (points) 
48 ? ? MEAN 
CHANGE BL  
  4.4  0.0055  Quittner abstract 2012 
European CF conference  
QOL – pooled child and adult 
social functioning scale domain 
(points) 
48 ? ? MEAN 
CHANGE BL  
  4.3  0.0026  
QOL – pooled child and adult 
eating disturbances scale 
domain (points) 
48 ? ? MEAN 
CHANGE BL  
  3.3  0.0021  
QOL – pooled child and adult 
treatment burden scale domain 
(points) 
48 ? ? MEAN 
CHANGE BL  
  3.3  0.0419  
              
% PRED FEV1 in subgroup: Mean 
change in FEV1 % PRED <5%  
48 22 64 MEAN 
CHANGE BL 
  4.2  <0.000
1 
 B.J Plant abstract only not in 
full text 
Sweat chloride (mMol/L) in 
subgroup: Mean change in FEV1 
% PRED <5% 
48 20 64 MEAN 
CHANGE BL 
  -46.1  <0.000
1 
 
Body weight (kg) in subgroup: 
Mean change in FEV1 % PRED 
<5% 
48 22 64 MEAN 
CHANGE BL 
  3.3  <0.000
1 
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% PRED FEV1 in subgroup: Mean 
change in FEV1 % PRED >5%  
48 61 12 MEAN 
CHANGE BL 
  6.2  0.0023  B.J Plant abstract only not in 
full text 
Sweat chloride (mMol/L) in 
subgroup: Mean change in FEV1 
% PRED >5% 
48 58 11 MEAN 
CHANGE BL 
  -49.7  <0.000
1 
 
Body weight (kg) in subgroup: 
Mean change in FEV1 % PRED 
>5% 
48 61 12 MEAN 
CHANGE BL 
  1.7  0.3313  
 
SAFETY PROFILE 
SEVERITY OF ADVERSE EVENTS, WITH REGARDS WHETHER STUDY DRUG WAS INTERRUPTED OR WITHDRAWN – SHOWN AS NUMBER (%) OF PATIENTS IN 
WHOM STUDY DRUG WAS INTERRUPTED OR DISCONTINUED 
 PLACEBO N= 78 VX770 150 MG N=83 
INTERRUPTED 5 (6%) 11 (13%) 
DISCONTINUED 4 (5%) 1 (1%) 
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 Data Extraction Table  3 Child Phase 3 G551D study by Davies (2013)   
TRIAL ID DAVIES 2013 – ‘ENVISION’-   
MAIN REFERENCE AM J RESPIR CRIT CARE MED. 2013 JUN 1;187(11):1219-25. DOI: 10.1164/RCCM.201301-0153OC 
CONFERENCE ABSTRACTS, ALSO INFORMATION TAKEN FROM CLINICALTRIALS.GOV 
FUNDING (delete) Pharma   DETAILS:  SUPPORTED BY VERTEX  
POPULATION AGE: 6-11 
GENETICS: At least one G551D-CFTR allele   
OTHER (EG FEV1): FEV1 40-105% PRED (AGE, SEX, HEIGHT), WEIGHT => 15KG.  
INTERVENTION (EXPERIMENTAL ARMS) AND CONTROL ARM 
DRUG  
DRUG DOSE ARM 1 150 MG VX 700 BD 
DRUG DOSE ARM 2  
DRUG DOSE ARM 3  
DRUG DOSE ARM 4  
LENGTH OF TREATMENT 48 WEEKS 
DESCRIPTION OF CONTROL PLACEBO 
PRIMARY OUTCOME 
PRIMARY OUTCOME 1 Absolute change from baseline in percent predicted forced expiratory volume in 1 second (% predicted FEV1) 
PRIMARY OUTCOME 2  
SAMPLE SIZE  REQUIRED: Minimum of 30 based on anticipated available 
population NOT power calculations  
RANDOMISED: 52 (26 EACH ARM) – NOTE 1 PLACEBO 
WITHDRAWN AS WRONG GENETICS 
PRIMARY TIMEPOINT  WEEK 24 
SECONDARY OUTCOMES (Y/N)  , COMMENTS ,  TIMEPOINT(S) , WHO WAS BLINDED (IF REVLEVANT) 
MORTALITY Y IN TEXT  
REL FEV1 Y  
QOL (Total/domain SPECIFY)  Y RESPIRATORY DOMAIN ONLY - Measured at days 1, 15 and weeks 8, 16, 24, 32, 40 and 48  
DATA WEEK 24 AND 48, Other data plotted on graph  
OTHER PFT (SPECIFY) Y ABS FEV1, FVC, FEV1/FVC, FEF25%-75% Measured at days 1, 15 and weeks 8, 16, 24, 32, 40 and 48  
ABS FEV1 – DATA FOR W24, W48, other data plotted on graph  
HOSPITAL ADMISSION N  
SCHOOL/WORK DAYS MISSED N  
EXTRA ANTIBIOTICS N  
RADIOLOGICAL OUTCOMES N  
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OUTCOME TIME COMPARISON HOW 
EXPRESSED 
RESULTS      NOTES EG TYPE OF OUTCOME 
ETC 
  ARM 1 
(N) 
ARM 2 
(N) 
EG Δ BL, 
TIME TO  
RESULT 
ARM 1 
RESULT 
ARM 2 
MEAN 
DIFF 
VARIANCE 
(SPECIFY) 
P 95%CI 
FEV1 (% PRED) 
  
WEEK 
24 
150 
GM 
(26) 
PLAC 
(25) 
MEAN 
ABSOLUTE Δ 
BL %PRED 
+/-SE 
12.6 +/- 
2.1  
0.1 +/= 
2.1 
12.5 SEM 2.9 <0.000
1 
6.6 to 
18.3  
 
FEV1 (% PRED) WEEK 
48 
150 
GM 
(26) 
PLAC 
(25) 
MEAN 
ABSOLUTE Δ 
BL %PRED 
+/-SE 
10.7 +/- 
1.9 
0.7 +/- 
2.0 
10.0 2.7 0.0006 4.4 to 
15.5 
FEV1 (L) WEEK 
24 
150 
GM 
(26) 
PLAC 
(25) 
MEAN 
ABSOLUTE Δ 
BL (L) 
0.303 0.067 0.0236  0.0001 0.123 
to 
0.349 
FEV1 (L) WEEK 
48 
150 
GM 
(26) 
PLAC 
(25) 
MEAN 
ABSOLUTE Δ 
BL (L) 
0.325 0.125 0.200  0.0007 0.089 
to 
0.311 
FEV1 (% PRED) – BASELINE FEV1 < 
90% 
WEEK 
24 
150 
GM 
(16) 
PLAC 
(14) 
MEAN 
ABSOLUTE Δ 
BL (L) 
  14.9   7.3 TO 
22.5 
Subgroup analysis  
FEV1 (% PRED) – BASELINE FEV1 > 
90% 
WEEK 
24 
150 
GM 
(10) 
PLAC 
(11) 
MEAN 
ABSOLUTE Δ 
BL (L) 
  6.9   -3.8 TO 
17.6 
FEV1 (% PRED) – N. AMERICA  WEEK 
24 
150 
GM 
(12) 
PLAC 
(14) 
MEAN 
ABSOLUTE Δ 
BL (L) 
  5.8   -2.6 TO 
14.1 
FEV1 (% PRED) – EUROPE  WEEK 
24 
150 
GM (6) 
PLAC (5) MEAN 
ABSOLUTE Δ 
BL (L) 
  24.6   6.4 TO 
42.9 
FEV1 (% PRED) – AUSTRALIA  WEEK 
24 
150 
GM (6) 
PLAC (8) MEAN 
ABSOLUTE Δ 
  4.2   -3.7 TO 
12.0 
NUTRITIONAL OUTCOMES 
(SPECIFY)  
 WEIGHT Measured at days 1, 15 and weeks 8, 16, 24, 32, 40 and 48  
DATA WEEK 24 AND 48 other data plotted on graph 
HEIGHT – measured BMI but no data for height published except in Borrowitz abstact which reported height z 
scores (protocol not available for schedule of assessments) 
SWEAT CHLORIDE Y Measured at days 1, 15 and weeks 8, 16, 24, 32, 40 and 48  
DATA WEEK 24 AND 48 - other data plotted on graph 
MICROBIOLOGICAL OUTCOME N  
ADVERSE EVENTS  Y Measured at days 1, 15 and weeks 8, 16, 24, 32, 40 and 48 
PULMONARY EXACERBATION Measured at days 1, 15 and weeks 8, 16, 24, 32, 40 and 48 
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BL (L) 
FEV1 (% PRED) – MALE  WEEK 
24 
150 
GM (9) 
PLAC 
(15) 
MEAN 
ABSOLUTE Δ 
BL (L) 
  5.2   -2.2 TO 
12.5 
FEV1 (% PRED) – FEMALE  WEEK 
24 
150 
GM 
(17) 
PLAC 
(10) 
MEAN 
ABSOLUTE Δ 
BL (L) 
  13.8   4.2 TO 
23.4 
QOL – CFQ-R Respiratory domain 
CHILD VERSION (<=12) 
WEEK 
24 
150 
GM 
(26) 
PLAC 
(25) 
MEAN 
ABSOLUTE Δ 
BL +/-SE 
6.3 +/- 
2.5 
0.3 +/- 
2.6 
6.1 +/- 2.7 0.1092 -1.4 to 
13.5 
 
QOL – CFQ-R Respiratory domain 
CHILD VERSION (<=12) 
WEEK 
48 
150 
GM 
(26) 
PLAC 
(25) 
MEAN 
ABSOLUTE Δ 
BL +/-SE 
6.1 +/- 
2.2 
1.0 +/- 
2.3 
5.1 3.3 0.1354 -1.6 TO 
11.8 
QOL – CFQ-R Respiratory domain 
PARENT/CAREGIVER VERSION  
WEEK 
24 
150 
GM 
(26) 
PLAC 
(25) 
MEAN 
ABSOLUTE Δ 
BL 
4.9 -1.1 5.9  0.0330 0.5 to 
11.4 
QOL – CFQ-R Respiratory domain 
PARENT/CAREGIVER VERSION 
WEEK 
48 
150 
GM 
(26) 
PLAC 
(25) 
MEAN 
ABSOLUTE Δ 
BL 
3.7 -1.2 4.9  0.1354 -0.4 TO 
10.2 
 
SWEAT CHLORIDE (mmol/l)  WEEK 
24 
150 
GM 
(23) 
PLAC 
(23) 
MEAN 
ABSOLUTE Δ 
BL +/-SE 
-55.5 +/- 
2.6 
-1.2 +/- 
2.6 
-54.3 3.7 <0.000
1 
-61.8 
TO -
46.8 
 
 WEEK 
48 
150 
GM 
(23) 
PLAC 
(23) 
MEAN 
ABSOLUTE Δ 
BL +/-SE 
-56.0 +/- 
2.5 
-2.6 +/- 
2.6 
-53.5 3.7 <0.000
1 
-60.9 
TO -
46.0 
 
WEIGHT (KG) WEEK 
24 
150 
GM 
(26) 
PLAC 
(26) 
MEAN 
ABSOLUTE Δ 
BL +/-SE 
3.7 +/- 
0.4 
1.8 +/- 
0.4 
1.9  0.5 0.0004 0.9 TO 
2.9 
 
 WEEK 
48 
150 
GM 
(26) 
PLAC 
(26) 
MEAN 
ABSOLUTE Δ 
BL +/-SE 
5.9 +/- 
0.5 
3.1 +/- 
0.5 
2.8 0.7 0.0002 1.3 TO 
4.2 
 
FEF25%-75% WEEK 
24 
150 
GM 
(26) 
PLAC 
(24) 
MEAN 
ABSOLUTE Δ 
BL 
20.7 -1.6 22.3  0.0002 (11.1 
to 
33.5) 
 
 WEEK 
48 
150 
GM 
(26) 
PLAC 
(24) 
MEAN 
ABSOLUTE Δ 
BL 
18.5 -0.7 19.2  0.0011 (8.1 to 
30.2)  
 
BMI for age Z SCORES WEEK 
24 
     0.34  P<0.00
1 
 Limited information precluding 
inclusion into the meta-
analysis.   WEEK 
48 
     0.45  P>0.00
1 
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FEV1 (RELATIVE)  WEEK 
24 
150 
GM 
(26) 
PLAC 
(24) 
MEAN 
RELATIVEΔ 
BL 
21.7% 4.3% 17.4%  P<0.00
01 
  
            
WEIGHT Z SCORES  WEEK 
24 
150 
GM 
(26) 
PLAC 
(26) 
MEAN Δ BL   0.39  <0.000
1 
  
BMI (KG/M2) 48 26 26 MEAN Δ BL   1.09  0.0003  (BORROWITZ ABSTRACT) 
BMI Z SCORE   48  26 26 MEAN 
CHANGE BL 
  0.45  <0.000
1 
  (BORROWITZ ABSTRACT) 
HEIGHT Z SCORE  24   MEAN 
CHANGE BL 
  +0.06     (BORROWITZ ABSTRACT) 
“NOT SIGNIFICANT’ NO P 
VALUE PUBLISHED 
HEIGHT Z SCORE  48   MEAN 
CHANGE BL 
  +0.12     (BORROWITZ ABSTRACT) 
“NOT SIGNIFICANT’ NO P 
VALUE PUBLISHED 
            
QOL – POOLED SCORE 48 26 26 MEAN 
CHANGE BL 
  5.1  0.1354  Quittner abstract 2012 
European CF conference   
            
% PRED FEV1 in subgroup: Mean 
change in FEV1% PRED <5%  
48 10 18 MEAN 
CHANGE BL 
  1.6  0.5093  B.J Plant abstract only not in 
full text 
Sweat chloride (mMol/L) in 
subgroup: Mean change in 
FEV1% PRED <5% 
48 9 17 MEAN 
CHANGE BL 
  -55.8  <0.000
1 
 
Body weight (kg) in subgroup: 
Mean change in FEV1% PRED 
<5% 
48 10 18 MEAN 
CHANGE BL 
  2.0  0.0582  
            
% PRED FEV1 in subgroup: Mean 
change in FEV1% PRED >5%  
48 16 6 MEAN 
CHANGE BL 
  9.8  0.0522  B.J Plant abstract only not in 
full text 
Sweat chloride (mMol/L) in 
subgroup: Mean change in 
FEV1% PRED >5% 
48 16 6 MEAN 
CHANGE BL 
  -53.9  <0.000
1 
 
Body weight (kg) in subgroup: 
Mean change in FEV1% PRED 
>5% 
48 16 6 MEAN 
CHANGE BL 
  3.4  0.0094  
SEVERITY OF ADVERSE EVENTS, WITH REGARDS WHETHER STUDY DRUG WAS INTERRUPTED OR WITHDRAWN – SHOWN AS NUMBER (%) OF PATIENTS  
 PLACEBO N= 26 VX770 150 MG N=26 
INTERRUPTED 3 (11%) 1 (4%) 
DISCONTINUED 1 (4%) 0 
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Data Extraction Table 4 ΔF508 study by Flume (2011)     
TRIAL ID  FLUME 2011 – “DISCOVER” 
MAIN REFERENCE FLUME 2011 CONFERENCE ABSTRACTS + METHODS AND RESULTS INFO FROM CLINICALTRIALS.GOV 
FUNDING (delete) Pharma Non-pharma Unclear DETAILS:  
POPULATION AGE: >12 YEARS GENETICS: HOMOZYGOUS FOR DF 508 OTHER (EG FEV1): >40% 
INTERVENTION (EXPERIMENTAL ARMS) AND CONTROL ARM 
DRUG VX770 
DRUG DOSE ARM 1 150 MG VX770 BD 
DRUG DOSE ARM 2  
DRUG DOSE ARM 3  
DRUG DOSE ARM 4  
LENGTH OF TREATMENT 16 WEEKS 
DESCRIPTION OF CONTROL PLACEBO 
PRIMARY OUTCOME 
PRIMARY OUTCOME 1 ABSOLUTE CHANGE IN %PRED FEV1  
PRIMARY OUTCOME 2  
SAMPLE SIZE  REQUIRED: RANDOMISED: 140 (112 VX770, 28 PLAC) 
PRIMARY TIMEPOINT  16 WEEKS 
SECONDARY OUTCOMES (Y/N)  , COMMENTS ,  TIMEPOINT(S) , WHO WAS BLINDED (IF REVLEVANT) 
MORTALITY   
FEV1 Y D15, W8, W16 
QOL Y CFQ-R respiratory domain score  
OTHER PFT (SPECIFY)  ABS Δ FEV1 D15, W8, W16 – NO DATA FOR WEEK 8  
FVC, FEF 
HOSPITAL ADMISSION   
SCHOOL/WORK DAYS MISSED   
EXTRA ANTIBIOTICS Y ABX Rx FOR SINOPULOMNARY SIGNS OR Sx 
RADIOLOGICAL OUTCOMES   
NUTRITIONAL OUTCOMES Y WEIGHT 
BMI  
WEIGHT FOR AGE SCORE 
SWEAT CHLORIDE Y  
MICROBIOLOGICAL OUTCOME   
SAFETY Y ADVERSE EVENTS  
NO PULMONARY EXACERBATIONS  
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SAFETY PROFILE  
SEVERITY OF ADVERSE EVENTS, WITH REGARDS WHETHER STUDY DRUG WAS INTERRUPTED OR WITHDRAWN – SHOWN AS NUMBER (%) OF PATIENTS  
 PLACEBO N= 28 VX770 150 MG N=112 
INTERRUPTED 0 2 (1.8%) 
DISCONTINUED 2 (7.1%) 3 (2.7%) 
 
 
OUTCOME TIME COMPARISON HOW 
EXPRESSED 
RESULTS      NOTES EG TYPE OF OUTCOME 
ETC 
  ARM 1 
(N) 
ARM 2 
(N) 
EG Δ BL, 
TIME TO  
RESULT 
ARM 1 
RESULT 
ARM 2 
MEAN 
DIFF 
VARIANCE 
(SEM) 
P CI 
FEV1 16 
WEEK 
VX770 
(111) 
PLAC 
(28) 
ABSOLUTE 
CHANGE BL 
% PRED 
1.5 +/- 
0.5 
-0.2 +/-
1.1 
1.7 1.2 0.15 -0.6 TO 
4.1 
   
QOL – CFQ-R RESP DOMAIN 16 
WEEK 
VX770 
(111) 
PLAC 
(28) 
ABSOLUTE 
CHANGE BL 
-0.1 +/- 
1.0 
-1.4 +/- 
1.9 
1.3 2.1 0.54 -2.9 TO 
5.6 
   
SWEAT CHLORIDE 16 
WEEK 
VX770 
(111) 
PLAC 
(28) 
ABSOLUTE 
CHANGE BL 
-2.7 +/- 
0.6 
0.1 +/- 
1.2 
-2.9 1.4 0.04 -5.6 TO 
0.2 
   
WEIGHT 16 
WEEK 
VX770 
(111) 
PLAC 
(28) 
ABSOLUTE 
CHANGE BL 
0.8 +/- 
0.2 
0.9 +/- 
0.4 
-0.2 0.5 0.727 -1.1 TO 
0.7 
   
BMI (kg/m2) 16 
WEEK 
VX770 
(112) 
PLAC 
(28) 
ABSOLUTE 
CHANGE BL 
0.21 00.25 0.04       
WEIGHT-FOR-AGE-Z-SCORE 16 
WEEK 
VX770 
(56) 
PLAC (7) ABSOLUTE 
CHANGE BL 
0.43 0.0007        
BMI-FOR-AGE-Z-SCORE 16 
WEEK 
VX770 
(56) 
PLAC (7) ABSOLUTE 
CHANGE BL 
0.73 -0.002        
PULMONARY EXACERBATION 16 
WEEK 
VX770 
(112) 
PLAC 
(28) 
NO (%)  25 (21) 10 (32)        
ABX Rx FOR SINOPULOMNARY 
SIGNS OR Sx 
16 
WEEK 
VX770 
(112) 
PLAC 
(28) 
NO (%)  48 (43)  16 (56)         
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3. Interaction with primary authors of studies included in the CFTR 
correctors review  
Evidence of interaction with primary author of the pilot 4PBA study  
 
E-mail 12: Interaction with primary author of the pilot 4PBA study  
From: Ron Rubenstein [mailto:rrubenst@mail.med.upenn.edu]  
Sent: 21 April 2014 11:57 
To: Patel, Sanjay [md0u92cd] 
Cc: Southern, Kevin 
Subject: Re: Cochrane Systematic Review of CFTR correctors - request for information 
Hi Sanjay 
In response to your queries: 
I cannot find the trial protocol.  Dr Pam Zeitlin may have it. 
The change from baseline sweat Cl concentration was presented in a figure in the publication 
As this was a one week trial, pulmonary function, QOL (for which there was no validated instrument 
at the time), admissions, work/school missed, extra antibiotics, radiology and respiratory pathogens 
were not assessed. 
Good luck with your review, 
Ron Rubenstein 
Ron Rubenstein, MD, PhD 
Associate Professor of Pediatrics 
Perelman School of Medicine at the University of Pennsylvania 
Director, Cystic Fibrosis Center 
Richard B. Johnston, Jr. Endowed Chair in Pediatrics 
Division of Pulmonary Medicine and Cystic Fibrosis Center 
The Children's Hospital of Philadelphia 
Email: rrubenst@mail.med.upenn.edu 
From: "Patel, Sanjay [md0u92cd]" <S.Patel7@liverpool.ac.uk> 
Date: Wednesday, April 16, 2014 5:52 AM 
To: "'rrubenst@welchlink.welch.jhu.edu'" <rrubenst@welchlink.welch.jhu.edu>, Ronald Rubenstein 
<rrubenst@mail.med.upenn.edu> 
Cc: "Southern, Kevin" <K.W.Southern@liverpool.ac.uk> 
Subject: Cochrane Systematic Review of CFTR correctors - request for information 
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Dear Professor Rubenstein,  
I am a postgraduate researcher at the University of Liverpool, UK. My research topic is on the novel 
cystic fibrosis mutation specific therapies that target the underlying CFTR defect. As part of my 
research, I am working with the Cochrane Cystic Fibrosis & Genetic Disorders Group to conduct a 
Cochrane systematic review on CFTR correctors. I have attached a copy of the protocol for this 
systematic review for your information. 
We would like to include the study “A Pilot Clinical Trial of Oral Sodium 4-Phenylbutyrate 
(Buphenyl) in DF508-Homozygous Cystic Fibrosis Patients”. I am contacting you to request  
1) Additional data for the outcomes measured during the trial  
2) Data for other outcomes important to our review  
3) The trial protocol  
4) Information on any additional clinical trials of CFTR corrects that you may be aware of.  
  
1. Additional data required from outcomes measured during the trial:  
a. Change from baseline sweat chloride concentration  
  
2. There are outcomes in our review, that do not correspond to outcomes measured in your trial 
however we feel it is important to request this information in case information is available. The 
additional outcomes are  
a. pulmonary function (relative change of FEV1, FVC)  
b. quality of life  
c. hospital admissions,  
d. school/work days missed, 
e. extra antibiotics  
f. radiological outcomes  
g. acquisition and eradication of respiratory pathogens  
  
For continuous data outcomes (e.g. measures of lung function) we would appreciate it if you were 
able to send us values for the mean and standard deviation for each group (all treatment groups and 
control).  
3. We would also like to request the trial protocol. 
4. So far we have retrieved the following additional studies through our electronic and manual 
literature searches.   
1. Boyle 2011: “Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) 
Patients Homozygous or Heterozygous for the F508del-CFTR Mutation” (Clinical trial number 
NCT01225211) 
2. Clancy 2012: “Results of a phase IIa study of VX-809, an investigational CFTR corrector 
compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation” 
(Clinical trial number NCT00865904) 
3. Donaldson 2013: “VX-661, an investigational CFTR corrector, in combination with ivacaftor, a 
CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation” 
(Clinical trial number NCT01531673) 
4. McCarty 2002: “A Phase 1 Randomized, Multicenter Trial of CPX in Adult Subjects With Mild 
Cystic Fibrosis” (Clinical trial number NCT00004428) 
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5. Zeitlin 2002: “Evidence of CFTR Function in Cystic Fibrosis after Systemic Administration of 4-
Phenylbutyrate” 
As a leader in the field of cystic fibrosis, I would also like to ask if you know about any additional 
clinical trials on CFTR Correctors (with published or unpublished results) that we may have missed 
out.  
Thank you for taking the time out to read this e-mail. Any additional information would go towards 
shaping the results of the review and would be highly appreciated. We will, of course, acknowledge 
your assistance in the published version of the review.  
Sanjay Patel 
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Evidence of interaction with primary author of the phase 2 4PBA study  
 
E-mail 13: interaction with primary author of the phase 2 4PBA study 
From: Pamela Zeitlin [mailto:pzeitlin@jhmi.edu]  
Sent: 28 April 2014 15:45 
To: Patel, Sanjay [md0u92cd] 
Cc: Southern, Kevin 
Subject: RE: Cochrane Systematic Review of CFTR correctors - request for information 
Dear Sanjay 
Thank you for your interest in your trial.  I may not be able to get everything you request given how 
“ancient” our trials seem now, 
But I will take a look.  What sort of time frame are you working in? 
Pam 
Pamela L. Zeitlin, M.D. Ph.D. 
Professor of Pediatrics 
Director, Eudowood Division of Pediatric Respiratory Sciences 
Deputy Director, Institute for Clinical and Translational Research 
Phone: 410 955 2035 
Fax: 410 955 103  
WARNING: E-mail sent over the Internet is not secure.  Information sent by e-mail may not remain 
confidential. 
 
DISCLAIMER: This e-mail is intended only for the individual to whom it is addressed. It may be used 
only in accordance with applicable laws. If you received this e-mail by mistake, notify the sender 
and destroy the e-mail. 
From: Patel, Sanjay [md0u92cd] [mailto:S.Patel7@liverpool.ac.uk]  
Sent: Wednesday, April 16, 2014 6:05 AM 
To: Pamela Zeitlin 
Cc: Southern, Kevin 
Subject: Cochrane Systematic Review of CFTR correctors - request for information 
Dear Professor Zeitlin,  
I am a postgraduate researcher at the University of Liverpool, UK. My research topic is on the novel 
cystic fibrosis mutation specific therapies that target the underlying CFTR defect. As part of my 
research, I am working with the Cochrane Cystic Fibrosis & Genetic Disorders Group to conduct a 
Cochrane systematic review on CFTR correctors. I have attached a copy of the protocol for this 
systematic review for your information. 
We would like to include the study “Evidence of CFTR Function in Cystic Fibrosis after Systemic 
Administration of 4-Phenylbutyrate”. I am contacting you to request for  
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1) additional data for the outcomes measured during the trial  
2) data for other outcomes important to our review  
3) information on missing data  
4) information on any additional clinical trials of CFTR corrects that you may be aware of.  
 
1. Additional data required from outcomes measured during the trial  
a. Change from baseline in sweat chloride concentration at day 2, day 3, day 4 and day 7 
b. Change from baseline in pulmonary function test results at day 3, day 4 and day 7 
c. respiratory pathogens scores at day 7 
 
2. There are outcomes in our review, that do not correspond to outcomes measured in your trial 
however we feel it is important to request this information in case information is available. The 
additional outcomes are  
a. survival,  
b. pulmonary function (relative change of FEV1, FVC)  
c. quality of life  
d. hospital admissions for adverse events 
e. extra antibiotics  
f. radiological outcomes  
g. nutritional outcomes (weight, height, BMI)  
 
For continuous data outcomes (e.g. measures of lung function) we would appreciate it if you were 
able to send us values for the mean and standard deviation for each group (all treatment groups and 
control).  
3. We would appreciate any clarification on the following issues:  
a. A sample size of 6 participants per group was planned, but only 4 participants were 
randomised to the placebo group. Why weren’t six participants randomised to the 
placebo group?  
b. In Table 1 showing baseline NPD parameters, the total number of participants enrolled 
in the study appears to be 35.  
c. It is unclear how many participants were used in the analysis of each outcome measure, 
so it is unclear whether an ITT approach was taken.  
4. So far we have retrieved the following additional studies through our electronic and manual 
literature searches.   
1. Boyle 2011: “Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) 
Patients Homozygous or Heterozygous for the F508del-CFTR Mutation” (Clinical trial number 
NCT01225211) 
2. Clancy 2012: “Results of a phase IIa study of VX-809, an investigational CFTR corrector 
compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation” 
(Clinical trial number NCT00865904) 
3. Donaldson 2013: “VX-661, an investigational CFTR corrector, in combination with ivacaftor, a 
CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation” 
(Clinical trial number NCT01531673) 
4. McCarty 2002: “A Phase 1 Randomized, Multicenter Trial of CPX in Adult Subjects With Mild 
Cystic Fibrosis” (Clinical trial number NCT00004428) 
5. Rubenstein 1998 “A Pilot Clinical Trial of Oral Sodium 4-Phenylbutyrate (Buphenyl) in DF508-
Homozygous Cystic Fibrosis Patients” 
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As a leader in the field of cystic fibrosis, I would also like to ask if you know about any additional 
clinical trials on CFTR correctors that we may have missed out during literature search.   
Thank you for taking the time out to read this e-mail. Any additional information would go towards 
shaping the results of the review and would be highly appreciated. We will, of course, acknowledge 
your assistance in the published version of the review.  
Sanjay Patel 
  
 
  
151 
 
Evidence of interaction with primary author of CPX study  
 
E-mail 14: interaction with primary author of CPX study  
 
From: McCarty, Nael [mailto:namccar@emory.edu]  
Sent: 16 April 2014 13:46 
To: Patel, Sanjay [md0u92cd]; 'nael.mccarty@biology.gatech.edu' 
Cc: Southern, Kevin 
Subject: RE: Cochrane Systematic Review of CFTR correctors - request for information 
 
There are literally hundreds of clinical trials on correctors and potentiators that have taken place 
since the CPX trial.  These are readily found with judicious searches in PubMed. 
NM 
From: Patel, Sanjay [md0u92cd] [mailto:S.Patel7@liverpool.ac.uk]  
Sent: Wednesday, April 16, 2014 5:40 AM 
To: McCarty, Nael; 'nael.mccarty@biology.gatech.edu' 
Cc: Southern, Kevin 
Subject: Cochrane Systematic Review of CFTR correctors - request for information 
Dear Professor McCarty 
I am a postgraduate researcher at the University of Liverpool, UK. My research topic is on the novel 
cystic fibrosis mutation specific therapies that target the underlying CFTR defect. As part of my 
research, I am working with the Cochrane Cystic Fibrosis & Genetic Disorders Group to conduct a 
Cochrane systematic review on CFTR correctors. I have attached a copy of the protocol for this 
systematic review for your information. 
We would like to include the study “A Phase 1 Randomized, Multicenter Trial of CPX in Adult 
Subjects With Mild Cystic Fibrosis” (Clinical trial number NCT00004428). I am contacting you to 
request for  
1) additional data for the outcomes measured during the trial  
2) data for other outcomes important to our review  
3) the trial protocol  
4) information on any additional clinical trials of CFTR corrects that you may be aware of.  
 
1. Additional data required from outcomes measured during the trial:  
a. Pulmonary function test results (measured at day 1 and day 2)  
 
2. There are outcomes in our review, that do not correspond to outcomes measured in your trial 
however we feel it is important to request this information in case information is available. The 
additional outcomes are 
a. extra antibiotics  
b. radiological outcomes  
c. acquisition and eradication of respiratory pathogens  
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For continuous data outcomes (e.g. measures of lung function) we would appreciate it if you were 
able to send us values for the mean and standard deviation for each group (all treatment groups and 
control).  
3. We would also like to request the trial protocol. 
4. So far we have retrieved the following additional studies through our electronic and manual 
literature searches.   
1. Boyle 2011: “Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) 
Patients Homozygous or Heterozygous for the F508del-CFTR Mutation” (Clinical trial number 
NCT01225211) 
2. Clancy 2012: “Results of a phase IIa study of VX-809, an investigational CFTR corrector 
compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation” 
(Clinical trial number NCT00865904) 
3. Donaldson 2013: “VX-661, an investigational CFTR corrector, in combination with ivacaftor, a 
CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation” 
(Clinical trial number NCT01531673) 
4. Rubenstein 1998 “A Pilot Clinical Trial of Oral Sodium 4-Phenylbutyrate (Buphenyl) in DF508-
Homozygous Cystic Fibrosis Patients” 
5. Zeitlin 2002 “Evidence of CFTR Function in Cystic Fibrosis after Systemic Administration of 4-
Phenylbutyrate” 
As a leader in the field of cystic fibrosis, I would also like to ask if you know about any additional 
clinical trials on CFTR Correctors (with published or unpublished results) that we may have missed 
out.  
Thank you for taking the time out to read this e-mail. Any additional information would go towards 
shaping the results of the review and would be highly appreciated. We will, of course, acknowledge 
your assistance in the published version of the review.  
Sanjay Patel 
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Evidence of interaction with primary author of the Lumacaftor study  
 
E-mail 15: Interaction with primary author of the Lumacaftor study  
From: Clancy, John [mailto:John.Clancy@cchmc.org]  
Sent: 18 April 2014 16:02 
To: Patel, Sanjay [md0u92cd] 
Cc: Southern, Kevin 
Subject: RE: Cochrane Systematic Review of CFTR correctors - request for information 
thank you for the note, Sanjay.  I'll need to ask vertex for the data/information that you request.  I 
do not have the data personally 
best, jpc 
From: Patel, Sanjay [md0u92cd] [S.Patel7@liverpool.ac.uk] 
Sent: Wednesday, April 16, 2014 5:26 AM 
To: Clancy, John 
Cc: Southern, Kevin 
Subject: Cochrane Systematic Review of CFTR correctors - request for information 
Dear Professor Clancy, 
I am a postgraduate researcher at the University of Liverpool, UK. My research topic is on the novel 
cystic fibrosis mutation specific therapies that target the underlying CFTR defect. As part of my 
research, I am working with the Cochrane Cystic Fibrosis & Genetic Disorders Group to conduct a 
Cochrane systematic review on CFTR correctors. I have attached a copy of the protocol for this 
systematic review for your information. 
We would like to include the study “Results of a phase IIa study of VX-809, an investigational CFTR 
corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation” 
(Clinical trial number NCT00865904). I am contacting you to request for: 
1) additional data for the outcomes measured during the trial; 
2) data for other outcomes important to our review;  
3) information on missing data;  
4) the trial protocol;  
5) information on any additional clinical trials of CFTR corrects that you may be aware of.  
 
1. For the following continuous data outcomes we would appreciate it if you were able to send us 
values for the mean and standard deviation for each group (all treatment groups and control).  
a) Relative change from baseline in FEV1 
b) Change from baseline in FVC and FEF25-75  
c) Change from baseline in sweat chloride concentration  
 
In addition we would like to know what respiratory adverse events caused study drug termination in 
the 4 discontinued participants and how many subjects required study interruption and the reason 
for this.  
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Some of this information has been provided in the publications. However the table below shows 
exactly what information is required.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. There are outcomes in our review, that do not correspond to outcomes measured in your trial 
however we feel it is important to request this information, in case the information available. 
The additional outcomes we would like data for are  
a. Survival  
b. Hospital admissions  
c. School/work days missed 
d.  Extra antibiotics  
e. Radiological outcomes  
f. Nutritional outcomes (weight, height, BMI)  
g. Acquisition and eradication of respiratory pathogens  
 
3. Issues on missing data that require clarification:  
a. In Table 2 (Frequency of occurrence of adverse events occurring in more than one subject in any 
VX-809 treatment group), the total number of subjects in the trial is shown to be 45, yet the 
total number of randomised participants is 89.  
b. In Figure 1b (Sweat chloride change from baseline to day 28) the total number of participants in 
the treatment arms adds up to 63 (16+16+15+16). However, a total of 72 participants were 
randomised to the intervention arms.  
Outcome measure  Data required  
Relative change from baseline in FEV1 
through day 28 
1. Standard deviation values for the mean 
change from baseline results in all 
treatment arms 
Change from baseline in FVC and FEF25 75 
through day 28 
1. Mean change from baseline in each arm. 
2. Standard deviation for the change from 
baseline results in all treatment arms  
Change from baseline in sweat chloride 
concentration through day 28 
1. Mean change from baseline in each arm. 
2. Standard deviation for the change from 
baseline results in all treatment arms.  
NB: We understand that data has been 
plotted on a graph, but we cannot estimate 
the values from the graph with accuracy.  
Safety  1. Number of participants who required 
study drug interruption and why  
2. What respiratory adverse events caused 
study drug termination in the 4 
discontinued participants?  
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c. In Supplementary appendix, the CFQ-R domain scores have been reported. The number of 
participants analysed (n = 85) excludes 4 recruited participants.  
 
4. We would also like to request the trial protocol. 
5. So far we have retrieved the following additional studies through our electronic and manual 
literature searches.   
1. Boyle 2011: “Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) 
Patients Homozygous or Heterozygous for the F508del-CFTR Mutation” (Clinical trial number 
NCT01225211) 
2. Donaldson 2013: “VX-661, an investigational CFTR corrector, in combination with ivacaftor, a 
CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation” 
(Clinical trial number NCT01531673) 
3. McCarty 2002: “A Phase 1 Randomized, Multicenter Trial of CPX in Adult Subjects With Mild 
Cystic Fibrosis” (Clinical trial number NCT00004428) 
4. Rubenstein 1998 “A Pilot Clinical Trial of Oral Sodium 4-Phenylbutyrate (Buphenyl) in DF508-
Homozygous Cystic Fibrosis Patients” 
5. Zeitlin 2002 “Evidence of CFTR Function in Cystic Fibrosis after Systemic Administration of 4-
Phenylbutyrate” 
As a leader in the field of cystic fibrosis, I would also like to ask if you know about any additional 
clinical trials on CFTR correctors (with published or unpublished results) that we may have missed 
out.  
Thank you for taking the time out to read this e-mail. Any additional information would go towards 
shaping the results of the review and would be highly appreciated. We will, of course, acknowledge 
your assistance in the published version of the review.  
Sanjay Patel  
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Evidence of contact with primary author of the Lumacaftor-Ivacaftor study  
 
E-mail 16: Interaction with primary author of the Lumacaftor-Ivacaftor study before publication of 
full report 
From: Patel, Sanjay [md0u92cd]  
Sent: 16 April 2014 10:16 
To: 'mboyle@jhmi.edu' 
Cc: Southern, Kevin 
Subject: Cochrane Systematic Review of CFTR correctors - request for information  
 
Dear Professor Boyle, 
I am a postgraduate researcher at the University of Liverpool, UK. My research topic is on the novel 
cystic fibrosis mutation specific therapies that target the underlying CFTR defect. As part of my 
research, I am working with the Cochrane Cystic Fibrosis & Genetic Disorders Group to conduct a 
Cochrane systematic review on CFTR correctors. I have attached a copy of the protocol for this 
systematic review for your information. 
We would like to include the study titled “Study of VX-809 Alone and in Combination With VX-770 
in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation” 
(Clinical trial number NCT01225211). Through our literature search we identified three abstracts 
(2011, 2012 and 2013 conference abstracts) for this study. I am contacting you to request for: 
1) additional data for the outcomes measured during the trial; 
2) data for cohorts 3 and 4; 
3) data for other outcomes important to our review; 
4) the trial protocol; 
5) information on any additional clinical trials of CFTR corrects that you may be aware of.  
 
1. Additional data required for outcomes measured during the trial 
 
COHORT 1 
1. How many participants have been randomised to each of the three arms?  
2. For the following continuous data outcomes we would appreciate it if you were able to send us 
values for the mean and standard deviation for each group (all treatment groups and control);  
a. Change from baseline to day 14 (after VX-809 therapy alone), in sweat chloride 
concentration,  
b. Change from day 15 to day 21 (after VX-809 +VX-770 therapy) in sweat chloride 
concentration   
c. Change from baseline to day 14 (after VX-809 therapy alone) in FEV1 
d. Change from day 15 to day 21 (after VX-809 +VX-770 therapy) in FEV1 
3. The number of participants included in the analysis of each outcomes measure  
4. Steps taken to minimising risk in the trial   
 
COHORT 2 
1. For the following continuous data outcomes we would appreciate it if you were able to send us 
values for the mean and standard deviation for each group (all treatment groups and control);  
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a. Change from baseline to day 28 (after VX-809 therapy alone) in sweat chloride 
concentration, 
b. Change from baseline to day 56 (after VX-809 + VX-770 therapy) in sweat chloride 
concentration, 
c. Change from baseline to day 28 (after VX-809 therapy alone) in FEV1 
d. Change from baseline to day 56 (after VX-809 + VX-770 therapy) in FEV1 
e. Change from baseline in CFQ-R scores through day 56  
 
2. According to our literature search conducted in February 2014, no results for Cohorts 3 and 4 have 
yet been published. We would like to request any available data for these cohorts.    
 
3. There are outcomes in our review, that do not correspond to outcomes measured in your trial 
however we feel it is important to request this information, in case information is available. The 
additional outcomes are 
a. Survival 
b. Hospital admissions 
c. School/work days missed 
d. Extra antibiotics  
e. Radiological outcomes  
f. Nutritional outcomes (weight, height, BMI)  
g. Acquisition and eradication of respiratory pathogens  
 
4. We would also like to request the study protocol.  
5. So far we have retrieved the following additional studies through our electronic and manual 
literature searches.   
1. Clancy 2012: “Results of a phase IIa study of VX-809, an investigational CFTR corrector 
compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation” 
(Clinical trial number NCT00865904) 
2. Donaldson 2013: “VX-661, an investigational CFTR corrector, in combination with ivacaftor, a 
CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation” 
(Clinical trial number NCT01531673) 
3. McCarty 2002: “A Phase 1 Randomized, Multicenter Trial of CPX in Adult Subjects With Mild 
Cystic Fibrosis” (Clinical trial number NCT00004428) 
4. Rubenstein 1998 “A Pilot Clinical Trial of Oral Sodium 4-Phenylbutyrate (Buphenyl) in DF508-
Homozygous Cystic Fibrosis Patients” 
5. Zeitlin 2002 “Evidence of CFTR Function in Cystic Fibrosis after Systemic Administration of 4-
Phenylbutyrate” 
As a leader in the field of cystic fibrosis, I would also like to ask if you know about any additional 
clinical trials on CFTR correctors (with published or unpublished results) that we may have missed 
out.  
Thank you for taking the time out to read this e-mail. Any additional information would go towards 
shaping the results of the review and would be highly appreciated. We will, of course, acknowledge 
your assistance in the published version of the review.  
Regards,  
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Sanjay Patel  
E-mail 17: Interaction with primary author of the Lumacaftor-Ivacaftor study after publication of 
full report 
From: Patel, Sanjay [md0u92cd]  
Sent: 24 July 2014 13:19 
To: mboyle@jhmi.edu 
Cc: Southern, Kevin 
Subject: Cochrane Systematic Review of CFTR correctors - request for information  
Dear Professor Boyle,  
Further to my previous e-mail (see thread), we would like to include data from the recently 
published, full report of the study: “A CFTR corrector (Lumacaftor) and a CFTR potentiator 
(Ivacaftor) for treatment of patients with Cystic Fibrosis who have a phe508del CFTR mutation; a 
phase 2 randomised controlled trial” (Clinical trial number NCT01225211) into our Cochrane 
Systematic review on CFTR correctors.  I am contacting you to request for: 
1) Separate data for the placebo groups randomised in cohort 2 and 3  
2) Data for pre-specified outcomes   
3) Data for other outcomes important to our review; 
4) The trial protocol 
1. Separate data for the placebo groups randomised in cohort 2 and 3    
In this study, data for placebo participants in cohorts 2 and 3 were combined. As randomisation for 
cohorts 2 and 3 were conducted separately, combining the data undoes the effects of 
randomisation. Therefore, in order to include the data for cohorts 2 and 3 into the meta-analysis, I 
would like to request the following separate data for placebo participants randomised in cohort 2 
and cohort 3: 
·       Mean (SD) change from baseline in sweat chloride concentration at day 28 (Lumacaftor 
monotherapy) and day 56 (Lumacaftor and Ivacaftor combination therapy).  
·       Mean (SD) change from baseline in CFQ-R scores at day 14 and 28 (Lumacaftor monotherapy) 
and day 42 and 56 (Lumacaftor and Ivacaftor combination therapy). 
·       Mean (SD) relative change from baseline in FEV1 at day 14 and 28 (Lumacaftor monotherapy) 
and day 42 and 56 (Lumacaftor and Ivacaftor combination therapy).Mean (SD) absolute change from 
baseline in FEV1 at day 14 and 28 (Lumacaftor monotherapy) and day 42 and 56 (Lumacaftor and 
Ivacaftor combination therapy). 
·       Safety assessment of Lumacaftor monotherapy and Lumacaftor and Ivacaftor combination 
therapy, including adverse effects of therapy.  
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2. To assess for selective outcome reporting in this study, we compared outcomes presented on the 
US National Institute of Health trials registry (http://clinicaltrials.gov/), to the results in the full 
report. We identified that in the full report there were no data for the pre-specified outcomes; 
absolute change in BMI or absolute change in body weight for the patients heterozygous for the 
phe508del mutation. We would like to request this data if they are available.  
3. There are outcomes in our review, that do not correspond to outcomes measured in your trial 
however we feel it is important to request this information, in case data are available. The additional 
outcomes are 
a.       Survival 
b.       Hospital admissions 
c.        School/work days missed 
d.       Extra antibiotics 
e.        Radiological outcomes 
f.        Nutritional outcomes (weight, height, BMI) 
g.        Acquisition and eradication of respiratory pathogens 
4. We would also like to request the study protocol. 
 
Thank you for taking the time out to read this e-mail. Any additional information would go towards 
shaping the results of the review and would be highly appreciated. We will, of course, acknowledge 
your assistance in the published version of the review. 
Regards, 
Sanjay Patel  
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Evidence of interaction with the primary author of the on-going study examining the 
impact of VX-661 on patients homozygous for the F508del-mutation. 
 
E-mail 18: interaction with the primary author of the on-going study examining the impact of VX-
661 on patients homozygous for the F508del-mutation. 
 
From: Patel, Sanjay [md0u92cd]  
Sent: 16 April 2014 10:33 
To: 'scott_donaldson@med.unc.edu' 
Cc: Southern, Kevin 
Subject: Cochrane Systematic Review of CFTR correctors - request for information 
 
Dear Professor Donaldson  
I am a postgraduate researcher at the University of Liverpool, UK. My research topic is on the novel 
cystic fibrosis mutation specific therapies that target the underlying CFTR defect. As part of my 
research, I am working with the Cochrane Cystic Fibrosis & Genetic Disorders Group to conduct a 
Cochrane systematic review on CFTR correctors. I have attached a copy of the protocol for this 
systematic review for your information. 
We would like to include the study “VX-661, an investigational CFTR corrector, in combination with 
Ivacaftor, a CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation” 
(Clinical trial number NCT01531673). So far, we have access to one reference for this trial (2013 
conference abstract taken from the Journal of Cystic Fibrosis). There are no results in the abstract 
and therefore we cannot yet include this trial in our review. I am writing to request any data that 
you are willing to make available for this trial.  
For continuous data outcomes (e.g. measures of lung function), we would appreciate it if you were 
able to send us values for the mean and standard deviation for each group (all treatment groups and 
control). For binary data, we need the number of patients experiencing the event (not the actual 
number of events) per group (treatment and control) in order to be able to analyse these correctly.  
Outcomes that we would like to report on in our trial are  
a. survival 
b. pulmonary function (Relative change of FEV1, FVC)  
c. quality of life  
d. adverse effects of therapy  
e. hospital admissions,  
f. school/work days missed, 
g. extra antibiotics  
h. radiological outcomes  
i. nutritional outcomes (weight, height, BMI)  
j. acquisition and eradication of respiratory pathogens  
k. sweat chloride concentration  
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In addition, so far we have retrieved the following additional studies through our electronic and 
manual literature searches.   
1. Boyle 2011: “Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) 
Patients Homozygous or Heterozygous for the F508del-CFTR Mutation” (Clinical trial number 
NCT01225211) 
2. Clancy 2012: “Results of a phase IIa study of VX-809, an investigational CFTR corrector 
compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation” 
(Clinical trial number NCT00865904) 
3. McCarty 2002: “A Phase 1 Randomized, Multicenter Trial of CPX in Adult Subjects With Mild 
Cystic Fibrosis” (Clinical trial number NCT00004428) 
4. Rubenstein 1998 “A Pilot Clinical Trial of Oral Sodium 4-Phenylbutyrate (Buphenyl) in DF508-
Homozygous Cystic Fibrosis Patients” 
5. Zeitlin 2002 “Evidence of CFTR Function in Cystic Fibrosis after Systemic Administration of 4-
Phenylbutyrate” 
As a leader in the field of cystic fibrosis, I would also like to ask if you know about any additional 
clinical trials on CFTR Correctors (with published or unpublished results) that we may have missed 
out.  
Thank you for taking the time out to read this e-mail. Any additional information would go towards 
shaping the results of the review and would be highly appreciated. We will, of course, acknowledge 
your assistance in the published version of the review.  
Sanjay Pate
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4. Data extraction forms for studies included in the CFTR potentiators review. 
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Data Extraction Table 5 Pilot 4PBA study by Rubenstein (1998)   
TRIAL ID Rubenstein 1998  
MAIN REFERENCE AM J RESPIR CRIT CARE MED 1998;157:484–490. 
FUNDING (delete) Pharma Non-pharma Unclear DETAILS: ?? 
POPULATION AGE: >=14 years 
Placebo: 24.8 (4.9)  
4PBA: 22.3 (5.9) 
GENETICS: 
Homozygous  ΔF508 -CFTR 
OTHER (EG FEV1): 
Mean FVC, % PRED (SD): 
Placebo: 65.5 (18.6)  
4PBA: 73.4 (20.3) 
Mean FEV1, % PRED (SD): 
Placebo: 47.5 (22.1)  
4PBA: 57.8 (27.2) 
INTERVENTION (EXPERIMENTAL ARMS) AND CONTROL ARM 
DRUG Sodium 4-phenylbutyrate (Buphenyl, 4BPA)  
DRUG DOSE ARM 1 19 grams daily PO divided into three doses of 6, 6 and 7 grams. 
DRUG DOSE ARM 2  
DRUG DOSE ARM 3  
DRUG DOSE ARM 4  
LENGTH OF TREATMENT 1 week 
DESCRIPTION OF CONTROL Placebo  
PRIMARY OUTCOME 
PRIMARY OUTCOME 1  
PRIMARY OUTCOME 2  
SAMPLE SIZE  REQUIRED: RANDOMISED: 18 
PRIMARY TIMEPOINT   
SECONDARY OUTCOMES (Y/N)  , COMMENTS ,  TIMEPOINT(S) , WHO WAS BLINDED (IF REVLEVANT) 
MORTALITY N  
FEV1 N  
QOL N  
OTHER PFT (SPECIFY) N  
HOSPITAL ADMISSION N  
SCHOOL/WORK DAYS MISSED N  
EXTRA ANTIBIOTICS N  
RADIOLOGICAL OUTCOMES N  
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SWEAT CHLORIDE VALUES    
Values for sweat chloride concentration were presented in a graph and could not be extracted with accuracy. Primary author reported that there was no 
significant difference in sweat chloride concentration between 4PBA and placebo assigned subjects (P = 0.387 
ADVERSE EVENT PROFILE  
SEVERITY OF ADVERSE EVENTS, WITH REGARDS WHETHER STUDY DRUG WAS INTERRUPTED OR WITHDRAWN – SHOWN AS NUMBER (%) OF PATIENTS IN 
WHOM STUDY DRUG WAS INTERRUPTED OR DISCONTINUED 
 PLACEBO N=9 19G 4PBA N=9 
INTERRUPTED 0 0 
DISCONTINUED 0 0 
 
NUTRITIONAL OUTCOMES N  
SWEAT CHLORIDE Y YES (18/18)  
MICROBIOLOGICAL OUTCOME N  
SAFE Y ADVERSE EVENTS  
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Data Extraction Table 6 Phase 2 4PBA Study by Zeitlin (2002) 
TRIAL ID Zeitlin 2002 
MAIN REFERENCE  
FUNDING (delete) Pharma Non-pharma Unclear DETAILS:  
POPULATION AGE: 
Mean (SD) 28.5 (7.1) 
GENETICS: 
Homozygous ΔF508 mutation 
OTHER (EG FEV1): 
Mean weight (SD) – 62.6 (17.0) 
Mean FEV1(% predicted) (SD) – 63.7 
(17.0) 
INTERVENTION (EXPERIMENTAL ARMS) AND CONTROL ARM 
DRUG 4-Phenylbutyrate (Buphenyl) 
DRUG DOSE ARM 1 20G (n = 6) 
DRUG DOSE ARM 2 30G (n = 6) 
DRUG DOSE ARM 3 40G (n = 6) 
DRUG DOSE ARM 4  
LENGTH OF TREATMENT  
DESCRIPTION OF CONTROL PLACEBO  
PRIMARY OUTCOME 
PRIMARY OUTCOME 1 Change in NPD 
PRIMARY OUTCOME 2  
SAMPLE SIZE  REQUIRED: 6 PER GROUP = 24 based on NPD RANDOMISED: 22 
PRIMARY TIMEPOINT   
SECONDARY OUTCOMES (Y/N)  , COMMENTS ,  TIMEPOINT(S) , WHO WAS BLINDED (IF REVLEVANT) 
MORTALITY   
FEV1   
QOL   
OTHER PFT (SPECIFY) Y ABSOL Δ BL D0, D3, D4, D7 – NO RESULTS REPORTED IN TRIAL 
HOSPITAL ADMISSION   
SCHOOL/WORK DAYS MISSED   
EXTRA ANTIBIOTICS   
RADIOLOGICAL OUTCOMES   
NUTRITIONAL OUTCOMES   
SWEAT CHLORIDE Y ABSOLUTE CALUES NOT CHANGE FROM BASELINE BL, D2, D3, D4, D7 – CHANGE FROM BASELINE 
REQUESTED 
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MICROBIOLOGICAL 
OUTCOME 
  
SAFETY Y ADVERSE EVENTS, HEPATIC ENZYMES  
OUTCOME TIME COMPARISON HOW 
EXPRESSED 
RESULTS      NOTES EG TYPE OF OUTCOME 
ETC 
  ARM 1 
(N) 
ARM 2 
(N) 
EG Δ BL, 
TIME TO  
RESULT 
ARM 1 
RESULT 
ARM 2 
MEAN 
DIFF 
VARIANCE 
(SPECIFY) 
P CI 
Sweat chloride  BL 20g (6) PLAC (4) ABSOL 
VALUE, 
MEAN (SD) 
119.2 
(12.7) 
110.1 
(16.6) 
       
  30g (6)  PLAC (4) ABSOL 
VALUE, 
MEAN (SD) 
116.8 
(16.8) 
110.1 
(16.6) 
       
 D2 20g (6) PLAC (4) ABSOL 
VALUE, 
MEAN (SD) 
119.8 
(10.4) 
119.2 
(7.4) 
       
  30g (6)  PLAC (4) ABSOL 
VALUE, 
MEAN (SD) 
96.2 
(45.3) 
119.2 
(7.4) 
     
 D3 20g (6) PLAC (4) ABSOL 
VALUE, 
MEAN (SD) 
117.2 
(9.0) 
113.6 
(13.6) 
       
  30g (6)  PLAC (4) ABSOL 
VALUE, 
MEAN (SD) 
121.1 
(13.5) 
113.6 
(13.6) 
       
 D4 20g (6) PLAC (4) ABSOL 
VALUE, 
MEAN (SD) 
116.2 
(9.9) 
111.0 
(8.7) 
       
  30g (6)  PLAC (4) ABSOL 
VALUE, 
MEAN (SD) 
110.3 
(16.2) 
111.0 
(8.7) 
       
 D7 20g (6) PLAC (4) ABSOL 
VALUE, 
MEAN (SD) 
116.5 
(10.7) 
117.2 
(10.3) 
       
  30g (6)  PLAC (4) ABSOL 
VALUE, 
MEAN (SD) 
119.8 
(4.4) 
117.2 
(10.3) 
       
 
P. aeurginosa  
(likert scale 0 (light)-6 (heavy))  
BL 20g (6) PLAC (4) MEDIAN  2 4.5        
  30g (6)  PLAC (4) MEDIAN 5 4.6        
 D7 20g (6) PLAC (4) MEDIAN  NS NS        
  30g (6)  PLAC (4) MEDIAN NS NS        
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Sweat chloride  BL 20g (6) PLAC (4) ABSOL 
VALUE, 
MEAN (SD) 
119.2 
(12.7) 
110.1 
(16.6) 
    Author reported ‘great inter-
subject variability’  
  30g (6)  PLAC (4) ABSOL 
VALUE, 
MEAN (SD) 
116.8 
(16.8) 
110.1 
(16.6) 
    
 D2 20g (6) PLAC (4) CHANGE 
FROM BL 
0.6  9.1 -8.5    
  30g (6)  PLAC (4) CHANGE 
FROM BL 
-20.6 9.1 -29.7    
 D3 20g (6) PLAC (4) CHANGE 
FROM BL 
-2.0  3.5 -5.5    
  30g (6)  PLAC (4) CHANGE 
FROM BL 
4.3 3.5 0.8    
 D4 20g (6) PLAC (4) CHANGE 
FROM BL 
-3.0 0.9 -3.9    
  30g (6)  PLAC (4) CHANGE 
FROM BL 
-6.5 0.9 -7.4    
 D7 20g (6) PLAC (4) CHANGE 
FROM BL 
-2.7 7.1 -9.8    
  30g (6)  PLAC (4) CHANGE 
FROM BL 
3 7.1 -4.1     
 
 D2 20g (6) PLAC (4) REL CHANGE 
FROM BL 
0.5% 
 
8.3% 
 
 
-7.8% 
 
      
  30g (6)  PLAC (4) REL CHANGE 
FROM BL 
-17.6% 8.3% 
 
 
-25.9% 
 
      
 D3 20g (6) PLAC (4) REL CHANGE 
FROM BL 
-1.7% 
 
 
3.2% -4.9%       
  30g (6)  PLAC (4) REL CHANGE 
FROM BL 
3.7% 3.2% 0.5%       
 D4 20g (6) PLAC (4) REL CHANGE 
FROM BL 
-2.5% 0.8% -3.3%       
  30g (6)  PLAC (4) REL CHANGE 
FROM BL 
-5.6% 0.8% -6.4%       
 D7 20g (6) PLAC (4) REL CHANGE 
FROM BL 
-2.3% 6.4% -8.7%       
  30g (6)  PLAC (4) REL CHANGE 
FROM BL 
2.6% 6.4% -3.9%       
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ADVERSE EVENT PROFILE  
SEVERITY OF ADVERSE EVENTS, WITH REGARDS WHETHER STUDY DRUG WAS INTERRUPTED OR WITHDRAWN – SHOWN AS NUMBER (%) OF PATIENTS IN 
WHOM STUDY DRUG WAS INTERRUPTED OR DISCONTINUED 
 PLACEBO N=4 20G 4PBA N=6 
INTERRUPTED 0 0 
DISCONTINUED / DOSE REDUCTION 0 0 
 
 PLACEBO N=4 30G 4PBA N=6 
INTERRUPTED 0 0 
DISCONTINUED / DOSE REDUCTION  0 2 
 
 PLACEBO N=4 40G 4PBA N=3 
INTERRUPTED 0 0 
DISCONTINUED / DOSE REDUCTION 0 2 
 
The 40 g cohort was terminated early following analysis of the data by the safety monitoring committee  
 
 
Data Extraction Table 7 CPX study by McCarty (2002) 
TRIAL ID McCarty 2002 
MAIN REFERENCE Pediatric Pulmonology 33:90-98 (2002)  
FUNDING (delete) Pharma Non-pharma Unclear DETAILS: Funded by NIH  
POPULATION AGE: >18  
RANGE 18-38 
GENETICS:  
HOMOZYGOUS  ΔF508 
OTHER (EG FEV1): 
MILD CF (FEV1>60%) 
21 MALES AND 16 FEMALES  
INTERVENTION (EXPERIMENTAL ARMS) AND CONTROL ARM 
DRUG CPX (8-cyclopentyl-1,3-dipropylxanthine) 
DRUG DOSE ARM 1 1MG (n = 4) 
DRUG DOSE ARM 2 3MG (n = 4) 
DRUG DOSE ARM 3 10 MG (n = 4) 
DRUG DOSE ARM 4 30 MG (n = 4) 
DRUG DOSE ARM 5 100 MG (n = 5) 
DRUG DOSE ARM 6 300 MG (n = 4) 
DRUG DOSE ARM 7 1, 000 MG (n = 4) 
LENGTH OF TREATMENT 1 DOSE  
DESCRIPTION OF CONTROL PLACEBO (n = 8) 
PRIMARY OUTCOME 
PRIMARY OUTCOME 1 SAFETY  
PRIMARY OUTCOME 2  
SAMPLE SIZE  REQUIRED: UNCLEAR  RANDOMISED: 37 
PRIMARY TIMEPOINT  D1 – SINGLE DOSE ASSESSMENT  
SECONDARY OUTCOMES (Y/N)  , COMMENTS ,  TIMEPOINT(S) , WHO WAS BLINDED (IF REVLEVANT) 
MORTALITY   
FEV1   
QOL   
OTHER PFT (SPECIFY)   
HOSPITAL ADMISSION   
SCHOOL/WORK DAYS MISSED   
EXTRA ANTIBIOTICS   
RADIOLOGICAL OUTCOMES   
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NUTRITIONAL OUTCOMES   
SWEAT CHLORIDE Y D0, D1 
MICROBIOLOGICAL 
OUTCOME 
  
SAFETY Y ADVERSE EVENTS D1, D2, FOLOW UP 
OUTCOME TIME COMPARISON HOW 
EXPRESSED 
RESULTS      NOTES EG TYPE OF OUTCOME 
ETC 
  ARM 1 
(N) 
ARM 2 
(N) 
EG Δ BL, 
TIME TO  
RESULT 
ARM 1 
(SD) 
RESULT 
ARM 2 
(SD) 
MEAN 
DIFF 
VARIANCE 
(SPECIFY) 
P CI 
SWEAT CHLORIDE 
CONCENTRATION (mEq/L) 
D1 1MG 
(4) 
PLAC (8) MEAN (SD) 113.6 
(19.8) 
100.0 
(18.2) 
       
SWEAT CHLORIDE 
CONCENTRATION 
D1 3MG 
(4) 
PLAC (8) MEAN (SD) 107.9 
(15.9) 
100.0 
(18.2) 
       
SWEAT CHLORIDE 
CONCENTRATION 
D1 10MG 
(4) 
PLAC (8) MEAN (SD) 112.0 
(8.0) 
100.0 
(18.2) 
       
SWEAT CHLORIDE 
CONCENTRATION 
D1 30MG 
(4) 
PLAC (8) MEAN (SD) 105.7 
(22.8) 
100.0 
(18.2) 
       
SWEAT CHLORIDE 
CONCENTRATION 
D1 100M
G (5) 
PLAC (8) MEAN (SD) 105.4 
(16.0) 
100.0 
(18.2) 
       
SWEAT CHLORIDE 
CONCENTRATION 
D1 300M
G (4) 
PLAC (8) MEAN (SD) 115.6 
(22.6) 
 
100.0 
(18.2) 
       
SWEAT CHLORIDE 
CONCENTRATION 
D1 1000M
G (4) 
PLAC (8) MEAN (SD) 91.3 
(9.8) 
100.0 
(18.2) 
       
SWEAT CHLORIDE 
CONCENTRATION 
D1 ALL 
CPX 
(29) 
PLAC (8) MEAN (SD) 107.9 
(18.2) 
100.0 
(18.2) 
       
              
PRE-CPX/PLACEBO  D1    MEAN 106.0 
(13.1) 
106.0 
(13.1) 
       
SWEAT CHLORIDE 
CONCENTRATION (mEq/L) 
D1 1MG 
(4) 
PLAC (8) MEAN 
CHANGE 
FROM BL 
7.6 -6.0 13.6        
SWEAT CHLORIDE 
CONCENTRATION 
D1 3MG 
(4) 
PLAC (8) MEAN 
CHANGE 
FROM BL 
1.9 -6.0 7.9       
SWEAT CHLORIDE 
CONCENTRATION 
D1 10MG 
(4) 
PLAC (8) MEAN 
CHANGE 
FROM BL 
6 -6.0 12       
SWEAT CHLORIDE 
CONCENTRATION 
D1 30MG 
(4) 
PLAC (8) MEAN 
CHANGE 
FROM BL 
-0.3 -6.0 5.7       
SWEAT CHLORIDE 
CONCENTRATION 
D1 100M
G (5) 
PLAC (8) MEAN 
CHANGE 
FROM BL 
-0.6 -6.0 5.4       
SWEAT CHLORIDE 
CONCENTRATION 
D1 300M
G (4) 
PLAC (8) MEAN 
CHANGE 
FROM BL 
9.6 
 
-6.0 15.6       
    
  
172 
 
 
 
 
 
 
 
 
 
 
 
ADVERSE EVENT PROFILE  
SEVERITY OF ADVERSE EVENTS, WITH REGARDS WHETHER STUDY DRUG WAS INTERRUPTED OR WITHDRAWN – SHOWN AS NUMBER (%) OF PATIENTS IN 
WHOM STUDY DRUG WAS INTERRUPTED OR DISCONTINUED 
 PLACEBO N=8 CPX (combined) n=29 
INTERRUPTED 0 0 
DISCONTINUED / DOSE REDUCTION 0 0 
 
 
  
SWEAT CHLORIDE 
CONCENTRATION 
D1 1000M
G (4) 
PLAC (8) MEAN 
CHANGE 
FROM BL 
-14.7 -6.0 -8.7       
SWEAT CHLORIDE 
CONCENTRATION 
D1 ALL 
CPX 
(29) 
PLAC (8) MEAN 
CHANGE 
FROM BL 
1.9 -6.0 7.9       
              
SWEAT CHLORIDE 
CONCENTRATION (mEq/L) 
D1 1MG 
(4) 
PLAC (8) REL CHANGE 
FROM BL 
7.2% -5.7% 12.8%       
SWEAT CHLORIDE 
CONCENTRATION 
D1 3MG 
(4) 
PLAC (8) REL CHANGE 
FROM BL 
1.8% -5.7% 7.5%       
SWEAT CHLORIDE 
CONCENTRATION 
D1 10MG 
(4) 
PLAC (8) REL CHANGE 
FROM BL 
5.7% -5.7% 11.3%       
SWEAT CHLORIDE 
CONCENTRATION 
D1 30MG 
(4) 
PLAC (8) REL CHANGE 
FROM BL 
-0.3% -5.7% 5.4%       
SWEAT CHLORIDE 
CONCENTRATION 
D1 100M
G (5) 
PLAC (8) REL CHANGE 
FROM BL 
-0.6% -5.7% 5.1%       
SWEAT CHLORIDE 
CONCENTRATION 
D1 300M
G (4) 
PLAC (8) REL CHANGE 
FROM BL 
9.1% -5.7% 14.7%       
SWEAT CHLORIDE 
CONCENTRATION 
D1 1000M
G (4) 
PLAC (8) REL CHANGE 
FROM BL 
-13.9% -5.7% -8.2%       
SWEAT CHLORIDE 
CONCENTRATION 
D1 ALL 
CPX 
(29) 
PLAC (8) REL CHANGE 
FROM BL 
1.8% -5.7% 7.5%       
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Data Extraction Table 8 Lumacaftor study by Clancy (2012) 
TRIAL ID CLANCY 2012 
MAIN REFERENCE Thorax 2012;67:12e18 
FUNDING (delete) Pharma Non-pharma Unclear DETAILS:  SUPPORTED BY VERTEX, AND OTHER FUNDING EG NIH 
POPULATION AGE: >18 years GENETICS: homozygous for df508 OTHER (EG FEV1): 
FEV1 (% PRED)  
Median: 71 
Range: 34.2-128.3  
BMI, mg/m2 
median: 22 
Range: 16-34 
Sweat chloride (mmol/L)  
median; 103.5 
Range: 66.0 – 129.0 
INTERVENTION (EXPERIMENTAL ARMS) AND CONTROL ARM 
DRUG VX809 
DRUG DOSE ARM 1 25 MG OD (n = 18) 
DRUG DOSE ARM 2 50 MG OD (n = 18) 
DRUG DOSE ARM 3 100 MG OD (n = 17) 
DRUG DOSE ARM 4 200 MG 0D (n = 19) 
LENGTH OF TREATMENT 28 DAYS 
DESCRIPTION OF CONTROL PLACEBO (n = 17) 
PRIMARY OUTCOME 
PRIMARY OUTCOME 1 SAFETY AND TOLERABILITY 
PRIMARY OUTCOME 2 SWEAT CL – NOTE THIS IS INFERRED FROM SAMPLE SIZE CALCULATION AS CO-PRIMARY. IT IS NOT STATED AS SUCH. 
SAMPLE SIZE  REQUIRED: 90 RANDOMISED: 89 (25 = 18, 50=18, 100=17, 200=19, PLAC 
= 19) 
PRIMARY TIMEPOINT  28 DAYS 
SECONDARY OUTCOMES (Y/N)  , COMMENTS ,  TIMEPOINT(S) , WHO WAS BLINDED (IF REVLEVANT) 
MORTALITY   
REL FEV1 Y  
QOL Y CFQR 
OTHER PFT (SPECIFY) Y FEV1, FVC, FEF25 75 – FVC and FEF NOT REPORTED IN PUBLICATION 
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HOSPITAL ADMISSION   
SCHOOL/WORK DAYS MISSED   
EXTRA ANTIBIOTICS   
RADIOLOGICAL OUTCOMES   
NUTRITIONAL OUTCOMES   
SWEAT CHLORIDE Y MEAN CHANGE FROM BASELINE AT DAY 7 AND 28 
MICROBIOLOGICAL 
OUTCOME 
  
SAFETY Y ADVERSE EFFECTS  
 
OUTCOME TIME COMPARISON HOW 
EXPRESSED 
RESULTS      NOTES EG TYPE OF OUTCOME 
ETC 
  ARM 1 
(N) 
ARM 2 
(N) 
EG Δ BL, 
TIME TO  
RESULT 
ARM 1 
RESULT 
ARM 2 
MEAN 
DIFF 
VARIANCE 
(SPECIFY) 
P CI 
SWEAT CHLORIDE D28 25 mg  PLAC  MEAN 
CHANGE 
FROM BL 
  +0.1  NS  DATA ALSO PRESENTED AT 
EARLIER TIMEPOINTS – NOT 
INCLUDED IN REVIEW 
 
UNCLEAR OF NUMBERS IN EACH 
GROUP 
SWEAT CHLORIDE D28 50 mg  PLAC     -4.61  NS  
SWEAT CHLORIDE D28 100 mg  PLAC     -6.13  <0.05 -12.25 
TO -0.01 
SWEAT CHLORIDE D28 200 mg PLAC     -8.21  <0.01 -14.33 
TO -2.10 
            
FEV1 D28 25 mg  PLAC  MEAN REL 
CHANGE 
FROM BL 
%PRED 
-2.46 +0.07   NS  DATA ALSO PRESENTED AT 
EARLIER TIMEPOINTS – NOT 
INCLUDED IN REVIEW 
 
UNCLEAR OF NUMBERS IN EACH 
GROUP 
FEV1 D28 50 mg  PLAC  MEAN REL 
CHANGE 
FROM BL 
%PRED 
-2.15 +0.07   NS  
FEV1 D28 100 mg  PLAC  MEAN REL 
CHANGE 
FROM BL 
%PRED 
+0.32 +0.07    NS   
FEV1 D28 200 mg PLAC  MEAN REL 
CHANGE 
FROM BL 
+0.47 +0.07   NS  
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%PRED 
              
FEF 25 – 75            JUST REPORTED AS NS 
FVC            JUST REPORTED AS NS 
              
CFQR D28 25 (17) PLAC (17) MEAN 
CHANGE 
FROM BL 
-5.2 +4.5   NS  THESE DATA RELATE TO 
RESPIRATORY DOMAIN. TOTAL 
SCORES, AND SCORES FROM 
OTHER DOMAINS REPORTED IN 
THE SA.   
 
 
 D28 50 (17) PLAC (17) MEAN 
CHANGE 
FROM BL 
-6.3 +4.5   <0.05  
 D28 100 
(16) 
PLAC (17) MEAN 
CHANGE 
FROM BL 
-1.3 +4.5   NS  
 D28 200 
(18) 
PLAC (17) MEAN 
CHANGE 
FROM BL 
+2.2 +4.5   NS  
              
SWEAT CHLORIDE  D7 25 mg  PLAC  MEAN 
CHANGE 
FROM BL 
-0.5 +2.2        
 D7 50 mg  PLAC  MEAN 
CHANGE 
FROM BL 
-3.7    P = 
0.03 
-7.1 to -
0.28 
   
 D7 100 mg  PLAC  MEAN 
CHANGE 
FROM BL 
-2.3         
 D7 200 mg PLAC  MEAN 
CHANGE 
FROM BL 
-6.6    P = 
0.0008 
-10.27 
to -2.83 
   
 
MEAN CHANGE FROM BASELINE IN CFQ-R DOMAIN SCORES AT DAY 28 IN PARTICIPANTS TREATED WITH LUMACAFTOR  
 Lumacaftor Placebo 
Domain 25 mg (n = 17) 50 mg (n = 17) 100 mg (n = 16) 200 mg (n =18) (n = 17) 
Body -0.21 -1.63 2.61 0.06 -1.34 
Digestion 2.28 -0.72 0.25 2.58 4.62 
Eating -3.66 -7.27* 3.24 -2.58 2.11 
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Emotion -3.22 -1.36 3.49 -2.62 4.86 
Health Perceptions -2.84 -6.97* -0.44 -1.9 5.03 
Physical -5.97 -7.38* -3.46 -0.98 1.23 
Respiratory -5.22 -6.32* -1.29 2.22 4.53 
Role -5.94* -4.6 1.1 -6.53* 2.21 
Social 0 -1.01 0.47 -2.64 -0.55 
Treatment Burden 4.19 -5.96* 1.42 -0.68 2.46 
Vitality -4.65 -7.23* -1.52 0.73 -2.18 
Weight 5.41 2.18 8.83 -4.19 0.3 
 
* demonstrated significance when compared to placebo  
ADVERSE EVENT PROFILE  
SEVERITY OF ADVERSE EVENTS, WITH REGARDS WHETHER STUDY DRUG WAS INTERRUPTED OR WITHDRAWN – SHOWN AS NUMBER (%) OF PATIENTS IN 
WHOM STUDY DRUG WAS INTERRUPTED OR DISCONTINUED 
 Placebo (n=17) Lumacaftor (n=72) 
INTERRUPTED 0 0 
DISCONTINUED  0 4 (6%) participants withdrew due to 
respiratory adverse effects, one 
from each of the Lumacaftor groups.   
 
   
    
  
177 
 
Data Extraction Table 9  Lumacaftor-Ivacaftor study by Boyle (2014) 
TRIAL ID BOYLE 2014 – COHORT 1 
MAIN REFERENCE BOYLE 2014 
FUNDING (delete) Pharma Non-pharma Unclear DETAILS: VERTEX  
POPULATION AGE: > 18 YEARS 
MEAN AGE 29.1 years  
 
GENETICS: DF 508 HOMOZYGOTE 
ALL PARTICIPANTS DF 508 HOMOZYGOTE 
OTHER (EG FEV1): >40% 
MEAN FEV1 PRED 66.9% (range 32.8-
117.1) 
MEAN SWEAT CL 101.9 mmol/L (range 
87.5-121.0) 
INTERVENTION (EXPERIMENTAL ARMS) AND CONTROL ARM 
DRUG 2 PERIODS : PART 1 = VX809 ALONE (D1 – D14) PART 2 = VX 809 + VX770 (D15-D28) 
DRUG DOSE ARM 1 (N=20) VX 809 200MG OD D1 - D14, FOLLOWED BY VX 809 200 MG OD+ VX 770 150 MG BD  D15-D21 
DRUG DOSE ARM 2 (N=21) VX 809 200MG OD D 1 -14, FOLLOWED BY VX 809 200 MG  OD+ VX 770 250 MG BD  D15-21 
DRUG DOSE ARM 3  
DRUG DOSE ARM 4  
LENGTH OF TREATMENT  3 WEEKS 
DESCRIPTION OF CONTROL MATCHED PLACEBO D 1 – D 21 (N=21) 
PRIMARY OUTCOME 
PRIMARY OUTCOME 1 CHANGE IN SWEAT CHLORIDE BETWEEN DAY 15 AND DAY 21 
PRIMARY OUTCOME 2 SAFETY AND TOLERABILITY OF STUDY THERAPY  
SAMPLE SIZE  REQUIRED: HOPED FOR 60 (20/GROUP)  RANDOMISED: 62 
PRIMARY TIMEPOINT   1) D 14-21 2) D35 
SECONDARY OUTCOMES (Y/N)  , COMMENTS ,  TIMEPOINT(S) , WHO WAS BLINDED (IF REVLEVANT) 
MORTALITY   
FEV1 Y  CHANGE IN ABSOLUTE % PRED FEV1 AT D 7, 14 & 21 
QOL  CFQ-R RESP DOMAIN SCORES D1, 14, 28, 42 AND 56 
OTHER PFT (SPECIFY)   
HOSPITAL ADMISSION   
SCHOOL/WORK DAYS MISSED   
EXTRA ANTIBIOTICS   
RADIOLOGICAL OUTCOMES   
NUTRITIONAL OUTCOMES   
SWEAT CHLORIDE Y  AFTER VX-809 ALONE D14 
MICROBIOLOGICAL OUTCOME   
SAFETY   
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OUTCOME TIME COMPARISON HOW 
EXPRESSE
D 
RESULTS      NOTES EG TYPE OF OUTCOME 
ETC 
  ARM 1 (N) ARM 2 
(N) 
EG Δ 
BL, TIME 
TO  
RESULT 
ARM 1 
RESULT 
ARM 2 
MEAN DIFF VARIANC
E 
(SPECIFY) 
P CI 
CHANGE IN FEV1 D0 – D14 D14 VX 809 (?N) PLACEB
O (?N) 
MEAN 
CHANGE 
-0.2 +1.7      
CHANGE IN FEV1 D14 – D21 D21 VX 809 + VX 770 
150MG (?N) 
PLACEB
O (?N) 
MEAN 
CHANGE 
+3.5 -1.4     
CHANGE IN FEV1 D14 – D21 D21 VX 809 + VX 770 
250MG (17) 
PLACEB
O (?N) 
MEAN 
CHANGE 
+0.6 -1.4     
CHANGE IN FEV1 D14 – D21 D21 VX 809 + VX 770 
150MG (?N) 
VX 809 
+ VX 
770 
250MG 
(17) 
MEAN 
CHANGE 
+3.5 +0.6     
 
CHANGE IN SWEAT CHLORIDE D0 – 
D14 
D14 VX 809 (?N) PLACEB
O (?N) 
MEAN 
CHANGE 
-4.2 -2.9     
 
CHANGE IN SWEAT CHLORIDE D15 
– D21 
D21 VX 809 + VX 770 
150MG (?N) 
PLACEB
O (?N) 
MEAN 
CHANGE 
-2.2 +1.3     
CHANGE IN SWEAT CHLORIDE D15 
– D21 
D21 VX 809 + VX 770 
250MG (?N) 
PLACEB
O (?N) 
MEAN 
CHANGE 
-9.1 +1.3     
CHANGE IN SWEAT CHLORIDE D15 
– D21 
D21 VX 809 + VX 770 
150MG (?N) 
VX 809 
+ VX 
770 
250MG 
(17) 
MEAN 
CHANGE 
-2.2 -9.1     
CHANGE IN SWEAT CHLORIDE D0 – 
D21 
D21 VX 809 + VX 770 
150MG (?N) 
PLACEB
O (?N) 
MEAN 
CHANGE 
-6.4 1.6      
CHANGE IN SWEAT CHLORIDE D0 – 
D21 
D21 VX 809 + VX 770 
250MG (?N) 
PLACEB
O (?N) 
MEAN 
CHANGE 
-13.2 1.6      
DATA EXTRACTED FROM THE FULL TEXT  
            
CHANGE IN SWEAT CHLORIDE 
DURING LUMACAFTOR 
MONOTHERAPY  
D14 200MG VX 809 
OD(+150MG 
LUMACAFTOR)(1
9) 
PLACEB
O (21) 
MEAN 
CHANGE 
-4.8 
(95% CI 
-8.6 TO 
-1.0) 
-1.7 
(95%CI -
5.6 to 2.3) 
-3.1 (95%CI -8.7, 
2.4) 
P=0.264   
CHANGE IN SWEAT CHLORIDE 
DURING LUMACAFTOR 
D14 200MG VX 809 
OD(+250MG 
PLACEB
O (21) 
MEAN 
CHANGE 
-4.1 (-
8.1 to -
-1.7 
(95%CI -
-2.4 (95% CI -8.0 
TO 3.2) 
P=0.393   
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MONOTHERAPY  VX770)(21) 0.1) 5.6 to 2.3) 
CHANGE IN SWEAT CHLORIDE 
DURING LUMACAFTOR 
IVACAFTOR COMBINATION 
THERAPY  
D14-
D21 
200MG VX 809 
OD +150MG 
LUMACAFTOR 
BD(19) 
PLACEB
O (17) 
MEAN 
CHANGE 
-2.1 
(95%CI -
5.4, 0.9)  
0.5 
(95%CI -
3.0, 4.1) 
-2.7 (95%CI -7.5, 
2.1) 
P=0.267   
CHANGE IN SWEAT CHLORIDE 
DURING LUMACAFTOR 
IVACAFTOR COMBINATION 
THERAPY 
D14-
D21 
200MG VX 809 
OD +250MG 
VX770BD(14) 
PLACEB
O (17) 
MEAN 
CHANGE 
-9.1 
(95%Ci -
12.9, -
5.4)  
0.5 
(95%CI -
3.0, 4.1) 
-9.7 (95% CI -
14.8 TO -4.6) 
P=<0.001   
CHANGE IN SWEAT CHLORIDE 
DURING LUMACAFTOR 
IVACAFTOR COMBINATION 
THERAPY  
D1-D21 200MG VX 809 
OD +150MG 
LUMACAFTOR 
BD(20) 
PLACEB
O (16) 
MEAN 
CHANGE 
-6.7 
(95%CI -
11.1, -
2.4) 
-1.7 
(95%CI -
6.5, 3.1)  
-5.0  (-11.6, 1.5)  0.126   
CHANGE IN SWEAT CHLORIDE 
DURING LUMACAFTOR 
IVACAFTOR COMBINATION 
THERAPY 
D1-D21 200MG VX 809 
OD +250MG 
VX770BD(17) 
PLACEB
O (16) 
MEAN 
CHANGE 
-12.6 
(95%CI -
17.2, -
7.9)  
-1.7 
(95%CI -
6.5, 3.1) 
-10.9 (95% CI -
17.6 TO -4.2) 
P=0.02   
CHANGE IN SWEAT DURING 
LUMACAFTOR MONOTHERAPY  
D14 200MG VX 809 
OD(+150MG 
LUMACAFTOR)(2
0) 
PLACEB
O (21) 
MEAN 
CHANGE 
-0.3 
(95%CI -
2.4, 1.7) 
1.7 
(95%CI -
0.2, 3.6) 
-2.1 95%CI -4.8, 
1.7 
0.137   
CHANGE IN SWEAT CHLORIDE 
DURING LUMACAFTOR 
MONOTHERAPY  
D14 200MG VX 809 
OD(+250MG 
VX770)(20) 
PLACEB
O (21) 
MEAN 
CHANGE 
-0.1 
(95%CI -
2.1, 2.0) 
1.7 
(95%CI -
0.2, 3.6) 
-2.2 95%CI -4.7, 
1.1 
0.123   
CHANGE IN FEV1 DURING 
LUMACAFTOR IVACAFTOR 
COMBINATION THERAPY  
D14-
D21 
200MG VX 809 
OD +150MG 
LUMACAFTOR 
BD(20) 
PLACEB
O (21) 
MEAN 
CHANGE 
3.5 
(95%CI 
0.9, 6.1) 
-1.4 
(95%CI -
3.9, 1.1)  
4.9 95%CI 1.4, 
8.4  
0.007   
CHANGE IN FEV1DURING 
LUMACAFTOR IVACAFTOR 
COMBINATION THERAPY 
D14-
D21 
200MG VX 809 
OD +250MG 
VX770BD(18) 
PLACEB
O (21) 
MEAN 
CHANGE 
0.6 
(95%CI -
2.2, 3.5) 
-1.4 
(95%CI -
3.9, 1.1)  
2.1  95%CI -1.8, 
5.9 
0.282   
CHANGE IN FEV1DURING 
LUMACAFTOR IVACAFTOR 
COMBINATION THERAPY  
D1-D21 200MG VX 809 
OD +150MG 
LUMACAFTOR 
BD(20) 
PLACEB
O (21) 
MEAN 
CHANGE 
3.1 
(95%CI 
0.1, 6.1)  
0.3 
(95%CI -
2.6, 3.1) 
2.8 (95%CI -1.3, 
7.0)  
0.176   
CHANGE IN FEV1DURING 
LUMACAFTOR IVACAFTOR 
COMBINATION THERAPY 
D1-D21 200MG VX 809 
OD +250MG 
VX770BD(18) 
PLACEB
O (21) 
MEAN 
CHANGE 
0.5 
(95%CI -
2.8, 3.8) 
0.3 
(95%CI -
2.6, 3.1) 
0.3 (-4.2, 4.7) 0.908   
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ADVERSE EVENT PROFILE  
SEVERITY OF ADVERSE EVENTS, WITH REGARDS WHETHER STUDY DRUG WAS INTERRUPTED OR WITHDRAWN – SHOWN AS NUMBER (%) OF PATIENTS IN 
WHOM STUDY DRUG WAS INTERRUPTED OR DISCONTINUED 
 Placebo (n=21) Lumacaftor (n=41) 
INTERRUPTED 0 0 
DISCONTINUED  0 1 (2.4%) (chest tightness) during the 
200mg Lumacaftor once daily 
period. 
 
 Placebo (n=21) Lumacaftor + Ivacaftor (combined 
from both 150mg and 250mg 
Ivacaftor groups) (n=41) 
INTERRUPTED 0 0 
DISCONTINUED  0 0 
 
